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The increasing cost of randomised controlled trials is hindering the rate at which new,
effective therapies reach patients. To accelerate drug development, more efficient clinical
trial designs are needed. One such design which has had success in speeding up the evalu-
ation of therapies in cancer is the multi-arm multi-stage (MAMS) design. This particular
design compares multiple new treatments against a control in a single trial, obviating
the need for multiple two-arm studies, and ceases recruitment to poorly performing arms
during the study. To further increase efficiency, interim assessments can be based on an
intermediate outcome which is on the causal pathway to the primary outcome of the trial,
thus allowing phases 2 and 3 of evaluation to be incorporated into a single, seamless design.
The MAMS design was initially developed for trials in cancer where time to event outcomes
are commonly used. To make it more widely applicable to other disease areas, we first
extend the design to other types of outcome measure such as binary. The new designs
are then applied to trials in tuberculosis — a disease area with many new treatments
currently in the clinical pipeline and which may therefore benefit from using more efficient
trial designs.
We then consider more general design issues such as familywise error rate and expected
sample size and present calculations of both measures using simulation. Methods are
developed for finding designs which have the desired overall operating characteristics and
which are the most efficient under particular optimality criteria, known as admissible
designs. Guidance is provided for choosing the number of stages and allocation ratio for a
particular number of arms and we apply the methods developed in the thesis to existing
and hypothetical MAMS trials. Throughout, Stata programs are created and updated to
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1.1 Context of the research
Recent advances in basic biomedical science, such as the sequencing of the human genome,
have broadened our understanding of many disease areas and have raised the prospect of
new, more effective and safer therapies for patients. However, in 2004 the US Food and
Drug Administration (FDA) reported a slowdown rather than an expected increase in
the number of new therapies reaching patients over the preceding ten years, despite an
increase in drug research and development spending [1]. A major barrier to research is
the escalating cost of bringing a drug to market which is estimated to have increased from
an average of US$802 million in 2003 to US$1.3–1.7 billion in 2009 [2]. Such high costs
limit the number of drugs that can be evaluated at any time and in particular discourage
investment in therapies for uncommon diseases or diseases of poverty because the costs
are not likely to be recouped [1].
A major cause of the slowdown in drug approval is what Scannell et al. [3] refer to as the
‘better than the Beatles’ problem. This states that because existing therapies for many
conditions are already highly effective, new therapies do not gain market approval as they
only carry a small or no additional benefit. In order to detect the small effects that new
treatments might have over existing therapies, the size of clinical trials has to increase,
thus escalating the cost of treatment evaluation. Another cause is that regulators are more
cautious now than in the past and are therefore increasing the number of hurdles that have
to be passed for a drug to reach the market [3]. As a result, new medical compounds in
phase I have only an 8% chance of reaching the market compared to a 14% chance 15
years ago [4].
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The cost of drug development is exacerbated by the inefficiency of conventional clinical trial
designs whereby each new treatment is compared to a control in a separate fixed-sample
trial. This inefficient process means that new drugs cannot be assessed as quickly as they
are created and delays the time between trial design and market approval. To combat
this, the FDA introduced the Critical Path Initiative in 2004 which seeks to improve and
accelerate the drug development process through the use of new scientific tools [5, 6].
O’Neill [4] has outlined the areas where, in his view, biostatistics can contribute to the
FDA’s goal. One of these areas is adaptive study designs, defined as a “multistage study
design that uses accumulating data to decide how to modify aspects of the study without
undermining the validity and integrity of the trial” [7]. Such designs are more flexible
than conventional fixed-sample designs and can help to streamline and increase the success
rate of clinical trials. One way they achieve this is by allowing recruitment to arms to
be stopped prematurely at interim analyses if an experimental treatment is performing
significantly worse or no better than control, thus saving time and resources for evaluating
more promising therapies. Such an approach is particularly useful when there are several
new therapies to evaluate in a single trial, so that only the most promising treatments are
selected for further evaluation.
There are a vast number of modifications other than treatment selection that could be
made in an adaptive design. These include but are not constrained to: adaptive randomi-
sation, whereby the allocation ratio adapts to favour the most promising treatment as
the trial progresses; sample size re-estimation, which allows the sample size of the trial
to be altered at an interim analysis based on observed results to increase power; enrich-
ment designs which allow the patient population to change; and designs which allow the
hypothesis or primary endpoint to change during the course of the trial [8, 9].
In this introductory chapter, a range of clinical trial designs which aim to improve the
efficiency of drug development are reviewed. We begin with multi-arm trial designs which
obviate the need for separate trials of each new treatment by assessing them all in a
single trial. Next, we touch upon seamless designs which reduce sample size requirements
by combining two consecutive phases of testing into a single trial, thus allowing patients
from the first phase to also be included in the analysis of the final phase should the trial
reach that point. In the main section of this chapter, various adaptive treatment selection
designs, which can combine the advantages of multi-arm and seamless designs in a single
trial, are discussed. Such designs operate by selecting a subset of treatment arms at
an interim analysis to continue for further assessment in the trial and can stop the trial
prematurely if no arms are effective or if an arm shows overwhelming benefit over the
control. Designs in which treatment selection is based on the primary outcome of the
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trial, some short-term outcome measure or both are considered.
An area which might benefit from such designs in the future is tuberculosis (TB) [10]
— a disease which is still highly prevalent in many developing countries and for which
many new treatments are currently in the clinical pipeline [11]. The current TB clinical
development programme is outlined and reasons why a new approach to TB treatment
evaluation is needed are given. A particular adaptive design has been suggested as an
ideal candidate for use in TB following its success in cancer trials and we briefly review
the challenges in applying this design to this area. Lastly, the objectives for this thesis
are given.
1.2 Conventional trial designs
New drugs which are shown to be safe in phase 1 trials are often continued to phase 2
testing where they may be assessed alone, against a standard treatment or a placebo on a
short-term outcome. Promising treatments are then evaluated in larger phase 3 trials, often
on a longer-term outcome which has direct relevance to the patient. In the conventional
approach to treatment evaluation, phase 2 and 3 trials are conducted separately with no
overlap in the patients recruited and analysed in each study. This process is inefficient for
several reasons:
1. By not continuing follow-up of the participants in the phase 2 trial and excluding
them from the analysis of the phase 3 trial, one has to recruit the required number
of patients for the phase 3 trial from scratch. Thus the total sample size over both
phases will be larger than might otherwise be required. The most efficient use of
resources is therefore not made.
2. Conducting separate trials means that an often lengthy pause is required between
phases to allow the phase 2 data to be analysed and interpreted and for the phase
3 trial to be designed, thus prolonging treatment evaluation. Furthermore, separate
protocols and approvals are required for each study which increases the administra-
tive burden. Although this interval is often important to allow the phase 3 trial to
be designed more appropriately with the hindsight of the phase 2 results, in some
cases it might not be necessary [12].
3. When several treatments are simultaneously available for testing, they are often
evaluated in separate trials each with its own control arm. Thus several control
arms are required which can increase the demand on patient resources.
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1.3 Multi-arm designs
In some disease areas there are often several new treatments available for testing at any
point in time. For example, in TB there are currently at least ten new or repurposed
drugs in clinical development [13] while in cancer there are over 1500 [14]. Testing each
new treatment in its own trial is inefficient as it requires the use of multiple control arms.
To reduce sample size requirements and decrease the administrative burden associated
with multiple trials, all new treatments could instead be compared to a common control
arm in a single, multi-arm trial (see Figure 1.1). For example, comparing four experimental
arms in parallel to a single control (five-arm trial) reduces the required sample size by 37%
compared to four separate two-arm trials if no adjustments for multiple testing are made.
In general, comparing K experimental arms to a single control reduces the overall sample
size by a factor of (K − 1)/2K compared to K separate two-arm trials [15].
Figure 1.1: Increased efficiency of a multi-arm design compared to separate two-arm trials
for each experimental arm (Ei) against the control treatment (C).
1.3.1 Multiplicity issues
Despite the benefits of increased efficiency, multi-arm trials bring about several challenges
including the issue of multiplicity [16]. By making several treatment comparisons in a sin-
gle trial, the chance of finding at least one false-positive result, known as the familywise
error rate (FWER), is likely to be higher than the significance level at which each compar-
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ison is made [17]. For instance, if several arms are each compared at the 5% significance
level against a common control then the maximum probability of finding at least one false
positive result will be higher than 5% with the inflation being greater for a larger number
of comparisons.
There is much disagreement in the literature about whether the FWER should be con-
trolled in a multi-arm study at some conventional level or whether it suffices to control
the type I error rate for each pairwise comparison (PWER). A common argument against
adjustment is that if each experimental arm was compared to a control in its own two-arm
study then no adjustment for multiple testing would be made across studies [18]. Wason
et al. [19] give an interesting analogy to this for multiple primary outcomes: one could test
each outcome in its own trial without requiring a correction for multiple testing, however,
if they were all evaluated in a single trial then such a correction would be encouraged
by regulatory bodies. As a general rule, the European Medicines Agency state that a
‘minimal prerequisite’ in confirmatory trials is to control the FWER in the ‘strong sense’,
that is, limiting the maximum probability of making at least one false positive [20]. In
addition, control is mandatory in dose response studies that are aimed at recommending
the dose of a drug for future trials. FWER control is not required for exploratory multi-
arm studies such as phase 2 trials, however, Wason et al. [19] suggest that the FWER is a
more important quantity to control than the PWER as it limits the maximum probability
of continuing an ineffective treatment to a potentially resource-intensive phase 3 trial.
Freidlin et al. [15] argue that the decision to control the FWER depends on the relatedness
of the questions that the study is attempting to answer. For instance, if the evaluation
of each treatment arm can be viewed as separate experiments and a multi-arm trial was
used purely for reasons of efficiency, then not controlling the FWER may be justified.
Alternatively, the same might apply for a trial in which the results of one arm will have
no direct influence on the results of other arms, or if one positive result will not mean a
positive result for the trial as a whole. On the other hand, if the multi-arm trial can be
regarded as a family of experiments such as a trial evaluating the effectiveness of several
doses or schedules of the same drug, then multiplicity adjustment should be made [21].
1.3.1.1 Bonferroni and Dunnett corrections
The are various methods for controlling the FWER of a multi-arm trial. The simplest
approach is the Bonferroni correction whereby each of the K pairwise comparisons is
conducted at the α/K significance level to ensure the maximum FWER is no higher than
α. This adjustment is simple to implement as it assumes that the observed treatment
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effects are independent of each other. However, the use of a common control arm induces a
correlation between the comparisons, thus making the Bonferroni adjustment conservative
(i.e. the actual type I error rate will be lower than the nominal level). This results in
reduced power or a trial which is larger than necessary. A more powerful multiplicity
adjustment is via the method described by Dunnett [22] which accounts for the between-
arm correlation by considering the joint distribution of the test statistics. Assuming these
test statistics follow a multivariate normal distribution, the FWER can be controlled at
some prespecified level, α, by comparing each of the K experimental arms against the
control at the significance level αp which satisfies
α = ΦK(zαp , . . . , zαp ; ρ)
where ΦK is the K-dimensional multivariate normal distribution function, ρ is the K×K
between-arm correlation matrix with (i, j)th entry equal to A/(A + 1) if i 6= j and 1
otherwise (i, j = 1, . . . ,K), and A is the number of patients allocated to each experimental
arm for each patient allocated to control (i.e. the allocation ratio).
1.3.1.2 Closure principle
Another multiple testing procedure which underpins nearly all other multiple testing pro-
cedures and controls the FWER in the strong sense is the closure principle [16, 23]. This
principle states that a null hypothesis, Hk, in a set of K null hypotheses H1, . . . ,HK may
be rejected at the α level if Hk and all intersection hypotheses containing Hk are also
rejected at the α level. For instance, if there are two treatment arms to be compared
against a common control, then the null-hypothesis H1 may be rejected at the α level if
H1 and H1 ∩H2 are both rejected at the α level.
A simple rejection procedure which uses the closure principle and is more powerful than
the Bonferroni test is the Holm procedure [24]. This test applies the Bonferroni procedure
to the intersection hypothesis H1 ∩ H2. In other words, if pk is the p-value for the test
of hypothesis Hk then H1 is rejected if either (a) p1 < α/2 or (b) p1 < α and p2 < α/2.
Likewise, H2 is rejected if either (a) p2 < α/2 or (b) p2 < α and p1 < α/2. For similar
reasons to those stated above, applying a Dunnett test rather than a Bonferroni correction
to the intersection hypothesis will increase power further if comparisons are correlated.
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1.4 Seamless designs
To eliminate the often lengthy interval between phase 2 and 3 trials, the different phases
can be combined into a single ‘seamless’ trial. In its simplest form, such a trial is conducted
in two stages. The first stage most resembles a phase 2 trial in which an experimental
treatment is compared to a control, often on a short-term outcome. Based on the observed
data, recruitment continues into the second stage of the trial at the end of which the arms
are compared on the phase 3 outcome. A seamless trial which incorporates phases 2 and
3 of testing is often denoted as a phase 2/3 design and an example of such a trial with one
interim analysis is shown in Figure 1.2.
Figure 1.2: Conventional and seamless approaches to phase 2 and 3 trials.
Unlike the conventional approach, the phase 3 analysis in the seamless design uses follow-
up data from all patients recruited over both stages of the trial. This avoids the need to
recruit the required sample size for the phase 3 analysis from scratch and thus reduces
the maximum number of patients required [25]. Another major advantage of a seamless
design is that it can combine two studies into a single trial and thus reduces the number
of protocols, control arms, trial teams, ethical approvals etc, leading to a more rapid and
less resource-intensive evaluation of new treatments [26].
Such designs however, come with challenges. For instance, the design of the phase 3 aspect
of the trial might have to be based only on phase 1 data as the phase 2 study would yet
to have taken place. Sample size estimates are therefore prone to being under or overesti-
mated if, say, insufficient data are available to reliably estimate nuisance parameters. In
addition, phase 2 trials often provide insights into other design aspects of phase 3 trials
such as follow-up frequencies, endpoints and design conduct as well as ways to improve
enrolment, adherence and retention rates [27]. Although seamless designs remove the in-
terlude between phases 2 and 3, Emerson and Fleming [27] argue that this benefit is lost
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by the need for more time to design the trial.
Nonetheless, the increased use of designs which both simultaneously evaluate multiple
treatment arms and adopt a seamless approach to treatment evaluation are likely to greatly
increase the efficiency of the drug development process. In the next section, various
treatment selection designs in which this approach could be implemented are described.
1.5 Treatment selection designs
Like conventional two-arm designs, conventional multi-arm trials recruit a fixed, prede-
termined sample size to each arm before the analysis takes place. Hence there is no
opportunity to cease recruitment to arms which are showing benefit or harm over the
control as the trial is progressing, except in very extreme scenarios in which it would be
unethical to continue the trial. Furthermore, an arm might be performing no better than
control during the trial in which case it would be futile to continue recruitment since a
positive result is not likely to be observed in the final analysis. Prematurely terminat-
ing recruitment to such arms can therefore save resources for evaluating potentially more
promising treatments in the future. Multi-arm trial designs which allow such stopping de-
cisions to be made during the trial are therefore likely to further streamline the treatment
evaluation process over fixed-sample multi-arm designs.
1.5.1 Early designs
In 1988, Thall et al. [28] introduced a multi-arm two-stage selection procedure for binary
outcomes in which the trial is terminated at the end of the first stage without rejection
of the null hypothesis, H0, if no experimental arm is sufficiently better than control.
Otherwise, recruitment continues to the treatment with the highest success rate and the
control in the second stage of the trial culminating in a one-sided between-arm comparison
using all patients recruited to the two arms over both stages.
The design of Thall et al. [28] was motivated by the fact that when several experimental
treatments are ready for testing, there are not always sufficient numbers of patients avail-
able to fully evaluate each one relative to a control. To avoid a lengthy trial in such a
scenario, selecting only the most promising treatment early on in the study reduces sam-
ple size requirements compared to a multi-arm one-stage trial which does not implement
a selection procedure. The relative reductions in sample size increase with the number
of arms included in the trial [28]. In particular, when H0 is true for all arms, the design
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roughly has a 50% chance of terminating at the end of the first stage, thus saving resources
that would otherwise be spent on evaluating an ineffective treatment to the planned end
of the study. To further improve efficiency, the authors present stopping boundaries for
several designs which minimise a weighted sum of the expected sample size (i.e. the av-
erage number of patients recruited to the trial if it is performed multiple times) under
the null and alternative hypotheses. Importantly, Jennison and Turnbull [29] showed that
the FWER is protected under any parameter configuration and hence is controlled in the
strong sense in this design.
A similar two-stage selection procedure for binary outcomes which allows only a single arm
to continue to the final stage of the study was proposed by Thall et al. [30]. Unlike the
previous design, a control arm is not included in the first stage. Instead, a predetermined
threshold based on prior clinical experience is used to decide whether to continue the arm
with the highest success rate to the second stage of the study. In the second stage, patients
are randomised to the selected treatment or a control and only these patients are included
in the comparison of the two arms at the end of the study.
The authors justify the absence of a control arm in the first stage by suggesting that most
new therapies do not have a clinically meaningful benefit over existing therapies and so
the second stage is not likely to be required. As a result, the expected sample size (ESS)
under the global null hypothesis, HG (i.e. when H0 is true for all arms), is smaller than
in the previous design [28]. However, the ESS under the alternative hypothesis is larger
since stage 1 patients are not used in the comparison at the end of stage 2 and so a larger
sample size needs to be recruited to arms which pass the interim analysis.
The designs of Thall et al. [28, 30] are most appropriate when one experimental arm, at
most, is likely to have a substantial benefit over the control on the primary outcome. This
is because only a single treatment arm may be evaluated against the control at the end
of the second stage. Otherwise the effects of other beneficial experimental arms are likely
to be missed. Moreover, simply choosing the treatment which is the best performing on
a single outcome ignores other potentially important aspects such as safety, acceptability
and cost-benefit.
A more flexible two-stage selection design where any number of arms can continue to the
second stage was proposed by Schaid et al. [31] for time to event outcomes. In their design,
several treatments are compared to a control in the first stage. An analysis takes places at
time t1 with the trial being terminated with rejection of H0 if any arm shows a substantial
advantage over the control. Otherwise recruitment continues to the second stage of the
trial to all arms with a treatment effect exceeding some lower boundary which indicates
Chapter 1. Introduction 29
no effect over control. The flexibility of allowing more than one arm to continue beyond
the first stage is important, particularly in trials with time to event outcomes as survival
advantages may not become apparent until later in the trial. Moreover, this flexibility
avoids arbitrarily choosing the best performing treatment when several arms may also
have a similar effect.
1.5.2 Group sequential approaches
1.5.2.1 Two-arm group sequential designs
To introduce the group-sequential approach to trial design we first consider the comparison
of one experimental treatment (E) to a control (C). Let θ denote the treatment effect
of E over C which may be summarised, for example, as an absolute difference between
means for continuous outcome data, a log-odds ratio for binary outcome data or a log
hazard-ratio for time to event data. Furthermore, suppose θ > 0 and θ < 0 correspond
to a beneficial and harmful effect respectively of E over C and θ = 0 corresponds to no
effect.
For a group sequential trial with a maximum of J analyses, let θˆj denote the maximum
likelihood estimate of θ based on all primary outcome data collected up to and including
stage j (j = 1, . . . , J). In the above examples, θˆj is normally distributed with θˆj ∼
N(θ, 1/Ij) where Ij is the Fisher information for θ at analysis j (Ij = 1/Var(θˆj)). A
group sequential test of H0 is often based on the score statistic Sj = θˆjIj or the Wald test
statistic Zj = Sj/
√Ij [32]. In both cases, Sj and Zj are normally distributed with
Sj ∼ N(θIj , Ij)
Zj ∼ N(θ
√Ij , 1)
Details for calculating score statistics for various types of outcome data can be found
in [33].
In a group sequential trial testing the null hypothesis H0 : θ = 0 against the two-sided
alternative H1 : θ 6= 0, the absolute value of the test statistic of choice, Tj = Sj or Zj ,
is compared to a corresponding critical value cj ≥ 0 at a series of interim analyses which
occur when outcome data from a predetermined number of patients have been observed.
At analysis j, if Tj ≥ cj or Tj ≤ −cj then H0 is rejected and the trial terminated with the
conclusion that E is superior or inferior to C respectively. If |Tj | < cj then recruitment
continues to the next planned interim analysis. If, at the final analysis, |TJ | < cJ then the
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trial terminates without rejection of H0.
For a prespecified type I error rate α, the critical values cj (j = 1, . . . , J) are calculated
to satisfy
P (|T1| ≥ c1 ∪ · · · ∪ |TJ | ≥ cJ | H0) = α. (1.1)
This can be achieved using recursive numerical integration as described in Chapter 19 of
[34]. Wang and Tsiatis [35] proposed a family of two-sided group-sequential test boundaries
indexed by parameter ∆ in which the critical values for the standardised test statistic are
given by cj = C(j/J)
∆−1/2. The constant C is found to satisfy (1.1) and analyses are
assumed to be equally spaced. Special cases are the well-known Pocock (∆ = 1/2) [36] and
O’Brien and Fleming (OB&F) (∆ = 0) [37] boundaries; examples of which are presented
in Figure 1.3 on the Wald statistic scale (Zj) for a trial with J = 5 equally spaced
interim analyses, 5% type I error rate and 90% power. Also shown in Figure 1.3 are the
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Figure 1.3: Two-sided group-sequential boundaries for Pocock’s and O’Brien and Flem-
ing’s designs with 5% type I error rate, 90% power and five equally spaced analyses.
The critical values for Pocock’s test are the same at each interim analysis while those for
OB&F’s test start at extreme levels and decrease with each stage. The implication is that
the OB&F test requires stronger evidence for rejecting H0 at earlier stages when sample
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sizes are likely to be small and spurious results have a reasonable chance of occurring [34].
Thresholds become more relaxed at later stages to the point that they are less stringent
than those of Pocock and are almost similar to the critical values for the corresponding
fixed-sample trial. As a result, the maximum duration of the Pocock test is much longer
than that for the OB&F test (see Figure 1.3). However, the Pocock test tends to require
smaller average sample sizes for large treatment effects because the probability of earlier
termination with rejection of H0 is greater [34].
Many clinical trials may only be interested in testing for an effect in a single direction
(e.g. a positive effect of E over C). In such cases the null hypothesis H0 : θ ≤ 0 is
tested against the one-sided alternative H1 : θ > 0. To test such a hypothesis in a group
sequential trial Tj is compared to lower and upper critical values lj and uj respectively at
analysis j. If Tj ≥ uj , the trial is stopped and H0 is rejected. If Tj ≤ lj , the trial is stopped
without rejection of H0. If Tj lies within the region (lj , uj), known as the continuation
region, then the trial continues to the next interim analysis. Upper and lower stopping
boundaries are equal in the final analysis (lJ = uJ) to ensure that the trial is terminated
no later than this point [32]. The magnitude of the upper and lower stopping limits are
not equal at every analyses (uj 6= −lj) so the stopping boundaries are asymmetric. This
in contrast to the two-sided stopping boundaries above which were symmetric (uj = lj
for all j), although asymmetric boundaries may be used in a two-sided group sequential
test [38].
A common choice for an asymmetric one-sided group sequential test is the triangular
test [39], so called for its triangular shape on the score statistic scale. An example is
shown in Figure 1.4 for a design with 5% type I error rate, 90% power and five equally
spaced analyses.
Such designs are more efficient when testing ineffective treatments (i.e. when θ = 0) than
the two-sided group sequential tests described above since the latter do not allow for early
stopping to accept H0. They therefore often proceed to the maximum required sample
size under H0 whereas there is a much smaller chance of this occurring in a triangular
test [34].
When the number of interim analyses or group sizes are not equal to their design values,
the actual type I error rate and power of the group sequential designs described above can
deviate from their nominal levels (e.g. see Table 3.1 in [34]). These requirements may not
be met in practice if, say, more interim analyses than initially planned are performed due
to a slower than anticipated recruitment rate. A more flexible approach for calculating the
critical values at each analysis is via the use an alpha-spending function which does not
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Figure 1.4: Group-sequential boundaries for a triangular test
require the number or frequency of interim analyses to be prespecified in advance [40,41].
This approach works by allocating a certain amount of the overall α to the interim analysis
depending on the timing of all previous interim analyses. More formally, a two-sided α-
spending function is a non-decreasing function α∗ : [0, 1] → [0, α] with α∗(0) = 0 and
α∗(1) = α such that, at the jth interim analysis,
P (|T1| < c1, . . . , |Tj−1| < cj−1, |Tj | ≥ cj | H0) = α∗(tj)− α∗(tj−1)
where tj = Ij/IJ is the fraction of the maximum information observed at the jth analysis.
For a prespecified alpha-spending function, the corresponding critical value, cj , can be
calculated via recursive numerical integration as described in Chapter 7 of [34].
When group sizes are equal, the alpha-spending functions




α∗(t) = α log(1− (e− 1)t)
yield similar critical values to those of the O’Brien and Fleming and Pocock tests re-
spectively [40]. However, by using an alpha-spending function, the timing and number of
interim analyses does not have to be pre-specified.
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For a one-sided test, a similar function, α∗U , can be used to calculate the efficacy stopping
boundaries u1, . . . , uJ such that
P (T1 ∈ (l1, u1), . . . , Tj−1 ∈ (lj−1, uj−1), Tj ≥ uj | H0) = α∗U (tj)− α∗U (tj−1)
where α∗U (0) = 0 and α
∗
U (1) = α
In a similar manner, l1, . . . , lJ can be calculated using an analogous β-spending function
[42] where β is the desired type II error rate, or a ‘(1 − α)’-spending function, α∗L, such
that
P (T1 ∈ (l1, u1), . . . , Tj−1 ∈ (lj−1, uj−1), Tj ≤ lj | H0) = α∗L(tj)− α∗L(tj−1)
where α∗L(0) = 0 and α
∗
L(1) = 1− α [43].
1.5.2.2 Multi-arm group sequential designs
Follmann et al. [44] extend the α-spending function of Lan and DeMets [40] to a multi-
arm setting to allow monitoring of pairwise comparisons between all arms or between
each experimental arm and the control. Strong control of the FWER is achieved by
generalising Dunnett’s procedure [22] (or Tukey’s procedure [45] in the case of monitoring
all pairwise comparisons) to a multi-arm group-sequential setting. Critical values are
calculated via simulation which can be computationally intensive and so the authors also
consider a much simpler Bonferroni correction. Although this is more conservative that the
Dunnett correction, the authors show that the increase in the critical values for multi-arm
analogues of the Pocock [36] and O’Brien and Fleming [37] designs is small, particularly
for smaller α [44]. Furthermore, a Bonferroni correction permits greater flexibility by
allowing different boundaries to be used for different arms, such as a Pocock boundary for
one arm and an O’Brien and Fleming boundary for another.
In the design of Follmann et al. [44] which compares experimental arms to a common
control, arms are dropped from the trial if they are significantly inferior to control at
the interim analysis. To increase power, the authors propose a sequentially rejective
procedure [24] in which boundaries are relaxed for remaining arms if other treatments are
dropped during the course of the trial. For instance, if Kj arms remain at the jth analysis
then the jth significance level corresponding to a group sequential procedure with overall
significance level α/Kj may be used without inflating the FWER. Although dropping arms
for inferiority during the trial can increase efficiency over a fixed sample design, such a
procedure is arguably too stringent, particularly when there is a pressing need to find at
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least one effective new treatment or when resources are limited [46]. Designs which allow
arms to be dropped without rejection of H0 (i.e. for lack-of-benefit) are therefore likely to
be more appealing in practice.
One such design is the multi-stage design proposed by Stallard and Todd [47] which selects
the most promising of several treatments at the end of the first stage. This design extends
the methods of Thall et al. [28] and Schaid et al. [31] in two ways. First, the use of the
efficient score as a test statistic makes the design applicable to trials with either binary,
time to event or normally distributed outcomes and allows for adjustment of covariates.
Second, the design allows the selected treatment to be compared with the control at a
number of interim analyses after the first stage. This increases efficiency above that of
the two earlier designs by allowing the trial to be stopped early with rejection of H0 at
the jth analysis if the score statistic, Sj , exceeds some upper efficacy boundary, uj , or
without rejection of H0 if Sj is less than some futility boundary, lj . If lj < Sj < uj then
the experimental and control arms continue to the next stage of the trial. Upper efficacy
and lower futility boundaries can be calculated using the spending functions described
in Section 1.5.2.1 [40, 42, 43]. These boundaries are also applied in the analysis of the
‘selection’ (first) stage so that if the effect of the most promising treatment lies outside
the continuation region then the trial is terminated at that point with the appropriate
conclusion made.
Like the design of Thall et al. [28], the design by Stallard and Todd [47] is applicable
when it is acceptable to select any one treatment from a group of treatments which are
superior to control. An example might be when evaluating different doses or schedules of
a particular drug. Importantly, the most promising treatment need not always be selected
at the end of the first stage and other outcomes such as safety could play a role in the
decision making process. In such a scenario, the test will be conservative as the type I
error rate will be smaller than the desired value [32]. Use of this design is less appropriate
if the best of several effective treatments is to be selected, in which case a design which
allows more than one arm to continue beyond the first stage is required to allow more
data on each arm to be collected and a more informed selection decision to be made [47].
Such a design, however, is likely to need a much larger sample size.
In practice, the constraint of allowing only one arm to continue beyond the first interim
analysis is likely to be too restrictive. The design by Stallard and Todd [47] can be
generalised further by allowing any number of treatment arms to continue beyond each
stage. Stallard and Friede [48] proposed such a design which controls the FWER in the
strong sense if the number of arms to be included in each stage is specified in advance of
the trial commencing, regardless of which arms are actually continued during the course
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of the trial. This is achieved by considering the sum of the largest increments in the
score statistics of all remaining arms in each stage under the global null hypothesis and
constructing stopping boundaries using an alpha-spending function based on this maximal
value. Since the largest score statistic for an individual arm will be no higher than this
maximal sum, the test is conservative under the global null hypothesis [32].
Although this approach is more flexible than that of Stallard and Todd [47], specifying the
number of arms in each stage may still be impractical. Stallard and Friede [48] therefore
consider the possibility of making a data-dependent choice on the number of arms which
continue to the next stage of the trial using a method proposed by Kelly et al. [49]. In
this procedure, recruitment to the ith treatment arm is continued to the next stage if
θˆi ≥ θˆmax − ε, where θˆi is the observed treatment effect for arm i, θˆmax is the largest
observed effect and ε ≥ 0 is some prespecified constant. If ε = 0 then the design is
equivalent to that proposed by Stallard and Todd [47] since only the best performing
treatment is continued. Friede and Stallard [50] investigate error rates using this rule and
show that while the FWER is still strongly controlled, the degree of conservatism increases
for larger ε.
There are clear limitations in designs which only drop arms for inferiority (e.g. [44]), select
only one treatment at the interim analysis (e.g. [47]), or prespecify the number of arms
allowed in each stage of the trial (e.g. [48]). Acknowledging this, Magirr et al. [46] proposed
a more flexible multi-arm multi-stage design for normally distributed outcomes in which
the number of treatment arms in each stage does not have to be specified in advance of the
trial commencing. Instead, arms can be dropped for futility at interim analyses or the trial
may terminate with rejection of H0 if at least one treatment is shown to be sufficiently
superior to control. By generalising the Dunnett test [22] to a multi-stage trial, stopping
boundaries are derived such that the FWER is controlled in the strong sense.
The approach of Magirr et al. [46] differs to that of Follmann et al. [44] by allowing futility
stopping boundaries to be implemented. For example, the familiar Pocock or O’Brien and
Fleming efficacy boundaries can be used with a constant zero futility boundary added so
that any arms which perform no better than control are dropped from the study. Al-
ternatively, the more efficient triangular test boundaries [39] can be used. Any number
of patients per arm per stage is permitted, although practical constraints such as equal
numbers of patients on each experimental arm are considered. Calculation of stopping
boundaries is via numerical integration which can be computationally intensive partic-
ularly for designs with a large number of arms and stages. However, faster performing
simulation techniques have more recently been proposed [51].
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Jaki and Magirr [52] extend the methods of Magirr et al. [46] to accommodate non-
normally distributed endpoints and assess the impact of deviations to the planned design.
They showed that incorrectly continuing arms which fall below the futility boundary in-
flates the FWER and thus recommend that the futility boundaries are ‘binding’. This
might not be desirable in practice since the decision to drop an arm for futility may de-
pend on several factors [53]. For instance, an arm could appear ineffective on the outcome
on which early stopping is based but appear much more beneficial on other outcomes, thus
making it desirable to study further.
A design for monitoring multiple doses which provides the practical flexibility of non-
binding futility boundaries while controlling the FWER in the strong sense was proposed
by Chen et al. [53]. This flexibility is achieved by deriving the efficacy boundary under
the assumption of no stopping for futility so that it is not relaxed to account for the
increased chance of stopping without rejection of H0 at each analysis. Adding a stopping
boundary for futility therefore decreases the type I error rate below its nominal level,
however, the trade-off is that arms do not necessarily have to be dropped for futility if
they fall below this boundary. Similarly, power is computed assuming no stopping for
futility and so adding such a stopping rule increases the risk of dropping an arm without
rejection of H0, thus decreasing power (by as much as 6% in some instances [53]). Efficacy
boundaries are calculated using either a joint monitoring procedure, whereby all pairwise
comparisons are monitored using a single alpha-spending function [40], or using a marginal
monitoring approach in which the desired FWER is divided between comparisons (e.g.
using a Bonferroni or Dunnett-type correction) and a separate alpha-spending function is
used for each.
1.5.3 Other treatment selection designs
1.5.3.1 Combination test approach
Other approaches to monitoring of multi-arm trials have been proposed which do not nec-
essarily use the group sequential boundaries described above. One such design, proposed
by Bauer and Kieser [54], is a multi-arm extension of a two-arm design by Bauer and
Ko¨hne [55]. This adaptive test procedure combines the p-value calculated at each analysis
across stages using a pre-specified combination function, C, to allow valid inference to be
made at the end of the trial.
For a two-stage design with prespecified type I error rate α, the general procedure of Bauer
and Ko¨hne [55] is conducted as follows [56]:
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1. Conduct the first stage of the trial and calculate the p-value, p1, for the pre-defined
test statistic comparing the two treatments.
2. For pre-determined stopping values α0 and α1 (α0 > α1), stop the trial with rejection
of H0 (efficacy) if p1 ≤ α1 or without rejection of H0 (futility) if p1 ≥ α0. If
α1 < p1 < α0 continue to the next stage.
3. If the decision is to continue, conduct the second stage and calculate the p-value,
p2, for the test statistic estimated using data collected during the second stage only
(thus p1 and p2 are independent).
4. Combine p-values across stages using the combination function C(p1, p2) and decide
whether or not to reject H0 at level α using an appropriate critical value.
A common choice for C is Fisher’s combination function [57] whereby H0 is rejected at
the end of the second stage at level α if
C(p1, p2) = p1p2 ≤ c = exp(−χ24,1−α/2).
To maintain the overall type I error rate at level α, the first stage stopping limits α0 and
α1 are chosen such that α1 + c(logα0 − logα1) = α [55].
Another frequently used combination function is the weighted inverse normal method [58],
C(p1, p2) = 1− Φ[w1Φ−1(1− p1) + w2Φ−1(1− p2)]




2 = 1. For example,
w2i could be proportional to the corresponding fraction of the maximum sample size or
maximum information of the trial accrued in stage i. In this case the design corresponds
to a classical group sequential test if no adaptions to the design are made (see below) [56].
In the case of survival data the assumption that p1 and p2 are independent in step 3 above
might not hold since some events occuring in the second stage may come from patients
recruited in the first stage. However, a result by Tsiatis [59] implies that the difference
between the log-rank test statistics estimated at the end of the first stage and at the end of
the second stage (on all data accrued up to that point) is independent of the log-rank test
statistic for the first stage. These test statistics can therefore be used in the combination
test.
The multi-arm extension by Bauer and Kieser [54] allows multiple arms to be assessed in
the first stage with a subset of arms being continued to the second stage. To provide strong
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control of the FWER in the testing of multiple treatment arms, this design combines the
combination test approach described above with the closed testing principle outlined in
Section 1.3.1.2.
An advantage of this design over the group sequential approaches described above is that
the design of the second stage can be modified at the interim analysis based on observed
and external data, without inflation of the type I error rate and without completely pre-
specifying the adaptations in the trial protocol [60]. Examples of modifications that could
be made include recalculation of sample size based on observed nuisance parameters,
changing the allocation ratio, restricting the inclusion criteria to a certain subgroup of pa-
tients most likely to respond to treatment, or selecting the testing strategy for the second
stage of the trial [56].
However, this flexibility has brought the design under criticism from some authors [27,61]
who have suggested that it leads to reduced interpretability of the results, undermines trial
credibility and integrity and risks making changes based on unreliable interim results. In
particular, making unscheduled changes to the design during a confirmatory trial is dis-
couraged by regulators [62]. Furthermore, statistical significance may be overemphasised
relative to clinical significance if, say, the sample size is reestimated at an interim anal-
ysis in order to detect a smaller treatment effect than originally planned. Stallard and
Friede [48] also note that the combination test approach does not depend on a sufficient
statistic for the treatment effect such as the score, and may therefore lack power over other
designs.
Kelly et al. [49] proposed a multi-arm design which utilises the combination test approach
to generalise the design of Stallard and Todd [47] so that any number of experimental
arms may continue beyond the first interim analysis. The design operates by monitoring
the combined test statistics of the best performing treatment arm in each stage, Sj , with
group sequential boundaries obtained from pre-specified spending functions (e.g. [40,43]).
If Sj crosses the upper efficacy boundary, uj , at the jth interim analysis H0 is rejected and
a treatment (most likely the best performing) is selected. If Sj crosses the lower futility
boundary, lj , the trial is stopped without rejection of H0. Otherwise the trial continues to
the next stage of the study along with any other arms which are not much worse than the
best performing treatment by a prespecified value ε. If ε = 0 then the design is analogous
to that of Stallard and Todd [47] since only the best performing treatment is continued.
The test statistic, Sj , is calculated by transforming the independent p-values for the best
performing treatment in each stage using the inverse normal weighted method [58]: for
prespecified weights, wj , equal to the fraction of information accrued in stage j, the p-value
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estimated using the stage j data, pj , is transformed using Xj = wjΦ
−1(1− pj). The test
statistic Sj = X1 + · · ·+Xj then satisfies the same distributional assumptions as the score
statistic and can be compared to standard group sequential boundaries [49]. However, the
design retains the flexibility of the adaptive design approach described above due to the
way in which the test statistics are constructed [63].
This design maintains the aim of declaring only a single arm to be superior to control at
the end of the trial, as may be required in pharmaceutical trials. For instance, if H0 is
rejected during the trial then the arm with the largest observed treatment effect (B) could
be selected. Alternatively, safety data may play a role and an arm which is slightly less
effective than B but which is safer could be chosen. To control the FWER, p-values are
calculated using Dunnett’s method [22] to adjust for the number of comparisons in each
stage. However, Stallard and Friede [48] showed that the type I error rate of this design
is inflated when there are some truly effective arms in the trial and the most effective
arm is dropped at each analysis. The FWER is therefore only controlled when the null
hypothesis is true for all arms, that is, in the weak sense.
1.5.3.2 Conditional error rate approach
Another approach to treatment selection designs is based on the conditional error function
approach [64,65]. For a two-arm two-stage design the procedure works as follows. At the
interim analysis the conditional error rate for the null hypothesis is calculated on the stage
1 data, X1, using a function A(X1) = P (φ = 1|X1, H0) where φ is a test such that φ = 1
denotes rejection and φ = 0 denotes acceptance of H0. In other words, the conditional
error rate, A(X1), is the conditional probability of rejecting H0 given the first stage data
and assuming H0 is true. At the interim analysis, adaptions to the design such as sample
size reestimation can be made. The second stage is then performed resulting in a p-value,
p2, calculated only on data collected in the second stage. The null hypothesis is then
rejected if p2 ≤ A(X1).
Koenig et al. [66] extended this approach to a two-stage treatment selection procedure
using the closed testing principle [23] to control the FWER in the strong sense and applying
the conventional Dunnett test [22] to each intersection hypothesis. At the interim analysis
a decision to drop any number of treatment arms may be made using any interim data (e.g.
safety or efficacy) and any external information. The design is therefore more flexible than
some of the group sequential approaches described in Section 1.5.2.2. Also at the interim
analysis, the conditional error rate for each individual and each intersection hypothesis is
calculated. The second stage is then performed on all remaining treatment arms with a
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p-value calculated for the test of each individual and each intersection hypothesis which
are then compared to the corresponding conditional error rate.
Friede and Stallard [50] compared the type I error rate and power of this adaptive Dunnett
test to the group sequential design of Stallard and Friede [48] and the combination testing
approach of Bauer and Kieser [54]. For designs with two or three experimental arms in
which either one or all arms are effective, the authors considered two selection rules: a
random one to determine the sensitivity of the approaches when not picking the treatment
with the largest effect, and the rule proposed by Kelly et al. [49] where all arms which
are no less effective than the most promising by a certain margin, ε, are continued. The
adaptive Dunnett test [66] controls the FWER at the desired level for all values of ε that the
authors considered, whereas the combination test [54] and group sequential approaches [48]
become more conservative for larger ε. In terms of power, no method seems to consistently
dominate the others and so the authors suggest choosing a design based on familiarity or
ease of implementation [50].
1.5.4 Incorporating short-term and long-term endpoints
In the designs discussed in Sections 1.5.2 and 1.5.3, treatment selection is based on the same
outcome as used in the final, planned analysis of the study (unless the outcome is switched
in a design using the combination test approach, e.g. see [67]). This outcome should be
observed relatively quickly after randomisation so that interim analyses can occur soon
after the required sample size has been recruited. In some areas however, phase 3 trials
use a long-term outcome (e.g. death) which can be inappropriate for treatment selection
since the full sample size may have accrued by the time enough outcome data have been
observed for the interim analysis [26]. In such instances, it may be more appropriate to
base treatment selection on a short-term endpoint which is on the causal pathway to the
definitive outcome of the study. This is often the approach used in many disease areas
where treatment selection is based on a series of phase 2 trials investigating a short-term
endpoint before conducting a longer-term phase 3 trial.
Several designs which allow treatment selection to be based on a short-term endpoint
have been proposed. Todd and Stallard [68] extend the design of Stallard and Todd [47]
to allow selection of the best performing treatment in the first stage to be based only
on a short-term outcome. This is then followed by a group sequential comparison of
the selected treatment against the control on the primary outcome of the study. In this
design, the short-term and long-term endpoints do not have to be of the same type. For
instance, the authors present an example of a trial with a binary long-term endpoint and
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a continuous short-term endpoint. The design requires specification of an estimate of the
correlation, ρ, between the score statistics for the short-term and long-term endpoints
which can be estimated from previous data. Todd [69] provides formulae for calculating ρ
for combinations of binary or continuous outcomes, discusses issue regarding sensitivity of
error rates to ρ and proposes an adaptive method for re-estimating ρ as the trial progresses.
Todd and Stallard [68] show that their design provides modest savings in sample size over
conducting a separate multi-arm phase 2 trial followed by a two-arm group sequential trial
of the selected treatment, with greater savings when using a larger first stage. However, the
seamless nature of the design means that delays between studies and additional start-up
costs can be avoided (see Section 1.4).
In the two-stage seamless phase 2/3 design for multiple doses described by Liu and
Pledger [70], short-term efficacy and safety data are examined in the first interim anal-
ysis. Low doses which are ineffective and high doses which are harmful are eliminated
while recruitment to other doses continues and are eventually evaluated at the end of the
second stage on a long-term endpoint. The test statistics for stages 1 and 2 are then
combined and used to determine whether to reject H0. A notable feature of this design
is that the test statistic and sample size for the second stage do not need specifying in
advance and can be chosen at the interim analysis, without undermining validity [71].
This approach is important for maintaining overall power since nuisance parameters (e.g.
variance) may differ to those assumed at the start of the trial. However, Friede et al. [72]
criticise the authors’ approach of combining the test statistics for the short-term, first
stage outcome and long-term, final stage outcome for confirmatory testing by suggesting
that it is controversial from a regulatory perspective.
Stallard [73] proposed a treatment selection design which operates in a similar way to the
design of Stallard and Todd [47] but combines long-term and short-term outcome data
from patients at each interim analysis using the ‘double regression’ method described by
Engel and Walstra [74]. This involves first performing a standard regression analysis of
all short-term outcomes observed by the interim analysis to yield a maximum likelihood
estimate of the treatment effect on the short-term outcome for each arm. A second analysis
is then performed in all patients with both short-term and long-term endpoint data using
a regression analysis of the long-term outcome as the dependent variable and treatment
allocation and short-term outcome as covariates. Results from the two regression models
are then combined to produce an estimate of the effect of an experimental treatment
relative to control on the primary, long-term outcome. A single experimental arm, usually
the one with the largest treatment effect, is then continued beyond the first stage into a
group sequential comparison against the control with the treatment effect at each analysis
estimated in the same way as described above. The final analysis is of long-term data only
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and occurs when long-term data have been observed for the required number of patients.
If the trial is stopped early for futility or efficacy then follow-up of patients continues until
all long-term endpoint data have been observed. If the remaining patients are followed up
under protocol conditions and are not switched to the superior treatment then a reanalysis
of all long-term data only is conducted and final inference is based on this analysis [75].
Combining data in this way increases power compared to using long-term data only, with
the effect being more pronounced as the correlation between the endpoints increases [73].
The design might therefore be most effective if the short-term endpoint is the same as the
primary outcome but observed at an earlier time-point. An advantage of this design over
that of Todd and Stallard [68] is that it does not require an estimate of the correlation
between endpoints to be specified in the design of the trial in order to control the type I
error rate, since the correlation is estimated in the double regression analysis. However,
a drawback of this design is that it is currently only applicable to normally distributed
outcomes.
Friede et al. [72] proposed a two-stage design with treatment selection based on an early
outcome and which uses the combination test approach [55] and closure principle [23] to
control the FWER in the strong sense. More specifically, the weighted inverse normal
method [58] is used to combine p-values across stages with p-values for the intersection
hypotheses obtained using Dunnett-type tests. At the final analysis, only the p-values for
the primary endpoint data are combined across stages to avoid the possible regulatory
problem of Liu and Pledger’s [70] design. More than one experimental arm can be con-
tinued beyond the interim analysis which is particularly important as the best performing
treatment on the early outcome may not always be the most promising on the primary
outcome, unless the early outcome is a perfect surrogate [76]. A selection rule such as that
proposed by Kelly et al. [49] can therefore be used by continuing all arms with a response
rate no worse than that in the most effective arm by a certain margin. It should be noted
however, that the test in this design is often conservative when arms are dropped at the
interim without collecting primary outcome data. This is because these data would other-
wise be used in the intersection hypothesis tests at the final analysis and so the effects in
these arms have to be replaced by a conservative estimate [72]. Friede et al. [72] applied
their design to multiple sclerosis and showed that savings in sample size can be substantial
compared to the more conventional approaches to treatment evaluation.
Royston et al. [77] proposed a multi-arm two-stage design for time to event outcomes
in which the interim assessment of each experimental treatment versus control may be
based on an intermediate outcome (I) which is on the causal pathway to the definitive,
primary outcome (D) of the trial. The intermediate outcome does not have to be a perfect
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surrogate outcome for D as defined by Prentice [76], however, it should occur earlier and
more frequently than D. In addition, if the null hypothesis is true for I then it should be
very likely that the null hypothesis is also true for D (high negative predictive value). This
is because one would not wish to have a high chance of dropping such an arm at an interim
analysis when there is a true effect on the primary outcome of the trial. On the other
hand, if the alternative hypothesis is true for I then it is not necessary for the alternative
hypothesis to also be true for D, that is, I does not need a high positive predictive
value [78]. In oncology, for instance, where this design has been successfully implemented
(e.g. the ICON6 [79] and STAMPEDE [80] trials), failure-free survival (FFS), a composite
of progression-free and overall survival, was used for I and overall survival (OS) was used
for D. It should be noted that it is acceptable to use D for interim assessments, however,
this reduces efficiency by delaying the interim analyses compared to when using I.
In the design of Royston et al. [77], the interim analysis occurs once a predetermined
number of I events have been observed in the control arm. Recruitment is then stopped to
experimental arms which fail to show a predetermined level of benefit over the control on I.
Recruitment to more promising treatments continues until the pre-determined number of
D events required for the final analysis have been observed in the control arm. Unlike some
of the designs described above, there is no restriction on the number of arms which can
continue beyond the first interim analysis. However, trials using this design may only stop
for efficacy in very extreme circumstances on D (e.g. if the p-value for the treatment effect
on D is less than 0.001 — see Chapter 9.8 of version 11 of the STAMPEDE protocol [81])
thus reducing efficiency relative to these other designs if evaluating therapies which are
truly effective.
An example of a completed trial using this two-stage design is the GOG-182/ICON5 trial
which consisted of testing four experimental arms against a common control in a two-stage
design in women with advanced ovarian cancer [82]. In the first stage, arms were compared
to control on FFS with the final analysis taking place on OS. The trial began accrual in
2001 but was terminated in 2004 after no experimental arm demonstrated sufficient benefit
on the intermediate outcome at the interim analysis to warrant continued recruitment to
the final stage of the trial. As a result, the evaluation of these four arms was completed
in just 3.5 years, saving approximately 20 years compared to separate trials investigating
overall survival of each new therapy only [78].
The two-stage design was extended by Royston et al. [83] to allow interim analyses to be
carried out on I at multiple timepoints (stages), thus increasing efficiency. This multi-arm
multi-stage (MAMS) design is constructed by specifying a one-sided significance level αj
and power ωj for each pairwise comparison in each stage, j, along with the target hazard
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ratio (HR) for the outcome of interest in that stage. Based on these design parameters, the
timing of each analysis, critical hazard ratio for continuation and sample sizes can then be
calculated using the nstage package in Stata [84]. Royston et al. [83] recommend choosing
high stagewise powers to improve the chance of continuing recruitment to effective arms
beyond each analysis and to ensure high overall power for each arm. Significance levels
should start relatively high (e.g. α1 = 50%) to allow arms which are performing very badly
to be dropped as early as possible, and then reduce with each stage to increase the level
of benefit that needs to be demonstrated for recruitment to be continued. A conventional
one-sided significance level (e.g. 2.5%) can be used in the final stage analysis. The overall
type I error rate, α, and power, ω, for each pairwise comparison is calculated by combining
the stagewise significance levels and powers respectively across stages, accounting for the
between-stage correlation which arises by reusing patients recruited in earlier stages in
each analysis.
An example of this multi-arm multi-stage design as implemented in the 6-arm 4-stage
STAMPEDE trial in prostate cancer [80] is shown in Table 1.1. The critical HR is the
maximum HR that can be observed on the corresponding outcome in order to continue an
arm to the next stage of the trial and is calculated using the one-sided significance level and
power for the corresponding stage. This trial allocates one patient to each experimental
arm for every two patients allocated to the control (2:1:1:1:1:1 allocation ratio). Although
this might not be the optimal allocation ratio (i.e. that which minimises the ESS) [51], it
was actually chosen to allow a more accurate estimate of the control event rate, which is







HR level (αj) events HR
1 0.75 FFS 0.500 0.95 113 1.00
2 0.75 FFS 0.250 0.95 216 0.92
3 0.75 FFS 0.100 0.95 334 0.89
4 0.75 OS 0.025 0.90 403 0.84
Overall 0.013 0.83
Table 1.1: Design of the 6-arm 4-stage STAMPEDE trial in prostate cancer, using the
methodology described by Royston et al. [77, 83]. HR = hazard ratio, FFS = failure-free
survival, OS = overall survival.
As well as dropping poorly performing arms, the STAMPEDE trial has also added new
experimental arms during its course [85]. The first new arm was added more than five
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years after the trial commenced. There are several advantages in adding a new arm to an
existing trial rather than starting a new trial: a new protocol does not have to be created
and an amendment can simply be added to the existing one; recruitment to a new trial
often starts slowly, whereas an existing trial may already have numerous participating
sites actively recruiting; an extra control arm is not needed for the new arm which would
otherwise increase trial competition; and the cost of adding an arm to an existing trial
is markedly lower than the cost of starting a new trial [85]. However, Wason et al. [19]
advise against this practice if FWER control is required unless efficacy boundaries are
appropriately adjusted.
A question yet to be addressed in the MAMS design of Royston et al. [77, 83] is how the
stagewise operating characteristics should be specified in order to achieve designs that are
both feasible; that is, they have the desired overall values of α and ω, and efficient in terms
of minimising the expected number of patients recruited to the trial [83]. Furthermore,
the design is currently only applicable to disease areas where time to event outcomes in
which longer event times are more favourable are investigated and analysed using a hazard
ratio (e.g. as in cancer). The nstage program for Stata which facilitates the design of
such trials [84] was also initially developed with the design of cancer trials in mind and
therefore suffers from the same limitations.
Finally, as pointed out by Wason et al. [19] this design and in particular the STAMPEDE
trial does not explicitly specify or control the FWER. Although the overall pairwise α and
thus the FWER of STAMPEDE is small, more sophisticated methods for controlling the
FWER at a prespecified level are needed to optimise power (i.e. by ensuring the type I
error rate is not too low) and for the design to be used in more confirmatory settings.
1.6 Tuberculosis
With a large number of drugs currently in clinical development, tuberculosis (TB) is an
area which could benefit from the use of novel trial designs such as those described above
to accelerate treatment evaluation. The current TB drug development pipeline is discussed
below and used as motivation for work in future chapters of this thesis.
1.6.1 Background
Despite being all but eradicated from developed countries due to improved living conditions
and effective treatment, TB remains one of the worlds’ major infectious diseases and
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was declared a global emergency by the World Health Organisation (WHO) in 1993.
The disease is still highly prevalent in the developing world with 22 low- and middle-
income countries currently accounting for over 80% of 9 million new active cases per year
worldwide [11, 86]. Despite an available cure, TB was estimated to have caused up to 1.3
million deaths in 2012 [86].
Between the 1940s and 1980s the current first-line regimen for treatment of TB (an inten-
sive phase of isoniazid, rifampicin, pyrazinamide and ethambutol for two months followed
by a continuation phase of isoniazid and rifampicin for four months) was developed. Ri-
fampicin, the most recent drug in this regimen demonstrated to be effective in treating
TB, was discovered over 40 years ago [13, 87]. This regimen is highly effective with up to
95% of patients cured upon completion [87] and only a 5% relapse rate during the 12-18
months following therapy in trial conditions [88].
While relatively inexpensive and effective, the current regimen is inadequate for controlling
the current TB epidemic [89]. A major problem is the reduction in levels of rifampicin
when taken concurrently with antiretroviral therapy (ART) by patients co-infected with
HIV [13, 89–91], which also leads to an increased pill burden and higher toxicity [92].
Currently around 13% of new TB cases occur in patients who are HIV-positive [86] and
the risk of developing TB in people infected with HIV is estimated to be at least 20 times
higher than those who are HIV-negative [11,89].
The current first-line regimen for drug-sensitive TB (DS-TB) is lengthy, comes with a
large pill burden and often clears up symptoms within the first few weeks of use. These
factors discourage patients from fully adhering to treatment which in turn has led to
the rise of drug-resistant strains of TB. This is particularly problematic if the bacilli
develop resistance to the two most powerful first-line drugs (rifampicin and isoniazid),
commonly referred to as multi-drug resistant TB (MDR-TB) [11, 87]. MDR-TB is an
emerging global health threat and it is estimated that there were approximately 450,000
cases among notified TB cases in 2012 [86]. Drug resistant strains of TB require an entirely
different regimen of drugs which are less effective, more toxic, taken for up to two years
with injectables in the first six months, up to 500 times more expensive and much more
difficult to adhere to than the standard regimen for DS-TB [13,89,91,93].
An entirely new regimen for treating TB will therefore be required to achieve the Stop TB
(www.stoptb.org) partnership’s aim of eliminating TB as a global public health problem
by 2050. Four urgent requirements are [91,94]:
1. Shorter, simpler, yet affordable multi-drug regimens for DS-TB which are effective
in programmatic conditions [13] and are easily adhered to, thus reducing the chance
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of more drug-resistant strains of TB developing.
2. Shorter, more effective, less toxic and more affordable regimens for drug resistant
strains of TB, ideally matching the regimen for DS-TB.
3. Regimens which do not interact with ART for HIV infection, enabling HIV positive
and negative patients to be treated with the same regimen.
4. An ultra-short, simple and safe regimen for latent (non-active) TB infection which
is estimated to infect one in three people globally.
A current primary research and development goal is to develop a three-drug, two-month
regimen which is equally effective against both drug sensitive and drug resistant strains of
TB and which can be used by both HIV-negative and HIV-positive patients [94]. Further-
more, a shorter regimen should ideally require drugs to be administered on a less frequent
basis to better accomplish completion of therapy, thereby reducing the chance of a patient
developing drug resistance. The ultimate goal would be to create a simple, fast-acting reg-
imen with low toxicity that is able to cure TB in two weeks or less regardless of whether
patients are co-infected with HIV or whether they are infected with a drug-resistant strain
of TB [89,91,95]. However, Ginsberg [89] states that “several waves of innovation will be
needed to achieve this vision, including adopting a novel paradigm for the development of
multi-drug regimens”.
1.6.2 Current clinical development programme
Phases 2 and 3 of the current clinical pathway for a new TB drug are described below.
Phase 2 is separated into two phases – 2a and 2b.
1.6.2.1 Phase 2a
New TB drugs which are shown to be safe and tolerable in phase 1 trials of healthy
volunteers are likely to then be tested in a phase 2a trial. In this phase, a range of doses of
a new drug are administered as monotherapy and their early bactericidal activity (EBA) is
evaluated by examining the rate of decline in TB in the sputum on a daily basis during the
first 14 days of treatment [96, 97]. This is thought to give an indication of the sterilising
activity of the new drug, that is, its ability to prevent relapse of disease once treatment has
been completed by eradicating all populations of TB organisms [88]. It is unethical to test
a drug given as monotherapy for longer than this 14 day period due to the potential for
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patients to develop drug-resistance to the treatment and also because it is unacceptable
to delay effective first-line therapy without knowledge of the efficacy of the new drug [91].
1.6.2.2 Phase 2b
Doses of a new drug which are shown to have sufficient EBA in phase 2a are continued
to phase 2b trials where they are incorporated into multi-drug regimens with other anti-
TB drugs. Sputum culture status at two months (a binary outcome) is the traditional
endpoint for phase 2b trials and has been shown to correlate with the sterilising activity
of regimens [98]. However, a recent meta-analysis by Horne et al. [99] has shown it to have
low sensitivity (40%, 95% CI 25%–56%), modest specificity (85%, 95% CI 77%–91%) and
low positive predictive value (18%, 95% CI 14%–21%) for predicting relapse, a primary
outcome of a phase 3 trial. Such an outcome measure may therefore not be adequate for
identifying promising regimens to study further. Considering a measure of the longitudinal
profile of culture results, such as time to culture conversion, over the same time period
has been suggested as a more appropriate outcome for phase 2b trials compared to culture
status at a single time point [100], and is increasingly being used in practice [101–103].
However, a current downside of any outcome involving culture status is the delay in de-
termining the outcome after a sample has been taken. Cultures grown on solid media
are grown for up to eight weeks to detect positivity, meaning the two month endpoint
is unknown until nearly four months after the beginning of therapy. Liquid culture sys-
tems which detect growth more quickly and more frequently have been introduced but
not yet extensively studied as markers of treatment response [104]. A rapid and accurate
point-of-care test will not only help to streamline phase 2b trials but will also help reduce
transmission of TB in the long-run [105].
1.6.2.3 Phase 3
Regimens which demonstrate superiority over the standard regimen in phase 2b are likely
to continue to phase 3 where they are compared to the standard regimen on a composite
primary endpoint of treatment failure (consistently positive cultures results during treat-
ment) and relapse (positive culture results after previously being cured) [96, 97]. Due to
the highly effective nature of the current six month regimen in treating DS-TB (relapse
rates of 5% or less in trial conditions, although these are not often observed in routine
practice), a new regimen is unlikely to be deemed superior without an extremely large
sample size. A non-inferiority design is therefore used to determine whether the new reg-
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imen has a comparable efficacy to the standard treatment with the caveat that the new
regimen has some other advantage such as reduced cost, shorter duration, fewer drugs,
or lower toxicity [106]. Current phase 3 TB trials usually require 500-900 patients per
arm [96], followed up for at least 18 months after the completion of therapy. They can
therefore be long, drawn out processes, likely to take at least five years to complete [104]
and require an extensive amount of resources. It is therefore vital that new, effective
regimens are adequately tested during phase 2a and 2b trials using a suitable predictor of
relapse to avoid ineffective regimens being evaluated in phase 3.
1.6.3 Accelerating TB treatment evaluation
There are currently at least ten anti-TB drugs in phase 2 or 3 of clinical development,
more than at anytime in the past 40 years [96] (see Figure 1.5). At least six of these
are new drugs specifically being developed for TB while others are current drugs being
redeveloped or repurposed (e.g. high dose rifampicin). Since TB requires treatment from
a combination of drugs to reduce the risk of drug resistance developing, these new drugs
cannot be administered individually for a long period of time and therefore have to be
evaluated as part of a regimen. The number of potential regimens that could be conjured
from these new drugs (and the drugs in the current standard regimen) is likely to be
huge. Multiple trials will be needed to evaluate them, however, the length, size and cost
of current TB trials are an impediment to their rapid evaluation [86,88].
To increase the rate at which new TB regimens are evaluated, phase 2 and 3 clinical trials
need to become much smaller and shorter in duration. The current phase 2b outcome of
culture status at 2 months results in trials with large sample sizes (e.g. over 400 patients
[101]) and is arguably unable to successfully identify effective new regimens for continued
assessment in phase 3 trials [100]. One solution is to develop a more reliable biomarker
which is observed relatively quickly after initiation of treatment [107]. In addition, the
use of a surrogate endpoint [76] to replace the lengthy primary outcome in phase 3 trials
could go a long way to reducing treatment evaluation by years, however, there is currently
no such outcome available [100].
A possible way to evaluate the many new treatments that are currently in clinical develop-
ment is to add or substitute a single drug into the current regimen at a time. However, such
an approach would lead to a completely novel regimen taking decades to develop [93,95].
This is clearly impractical, and with nearly 4,000 deaths from TB every day globally it is a
public health imperative that TB drug evaluation is drastically accelerated. The Critical
Path to TB Regimens (CPTR) launched by the Bill and Melinda Gates Foundation, the
Chapter 1. Introduction 50
Figure 1.5: Global TB drug pipeline as of June 2013 (www.newtbdrugs.org/pipeline.php).
TB Alliance and the Critical Path Institute brings together drug sponsors, drug develop-
ers, regulators, funders and researchers from industry and academia into collaboration to
speed up the introduction of new and effective regimens, regardless of sponsor [93]. They
aim to achieve this by developing novel drug regimens as a unit rather than new drugs
being added to regimens and tested individually, thus reducing the time required to assess
a completely new regimen by one third to one fourth, or from decades to years [89,108].
The first trial to be conducted under this new paradigm was the New Combination 1
(NC001) trial, the results of which were published in 2012 [109]. This multi-arm trial was
a fourteen day EBA phase 2a study of a three-drug regimen containing the novel drugs
PA-824 and moxifloxacin in combination with the current first-line drug pyrazinamide and
also two two-drug regimens of pyrazinamide with either PA-824 or TMC-207. Since these
new regimens contain neither rifampicin nor isoniazid they have the ability to harmonise
treatment for DS- and MDR-TB, thus potentially reducing the length of therapy for the
latter from two years to less than six months. The results of NC001 showed that a
combination of PA-824, moxifloxacin and pyrazinamide (PaMZ) killed TB bacteria faster
than the standard DS-TB regimen [109]. A subsequent phase 2 study (New Combination
2, NC002) testing PaMZ in patients who have either drug-sensitive or drug-resistant TB
has recently been completed but not yet reported [110].
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This new and efficient method of evaluating regimens as a unit, rather than by replacing
individual drugs in the current regimen, will undoubtedly reduce the length and cost of
early phase clinical development as well as bring about the benefits of multi-arm designs.
A multi-arm approach has also been used in an ongoing phase 3 trial assessing two four-
month regimens of moxifloxacin substituted for ethambutol or isoniazid versus the current
standard regimen [106].
1.7 Summary
In TB, improvements in trial design are needed if potential new regimens are to be assessed
in the quickest possible manner and with the minimum number of resources. The need for
better biomarkers, novel study populations, stronger collaborations and increased funding
have been necessitated; however, the potential benefits of novel trial designs have only
recently been realised [10]. As discussed in this chapter, a range of treatment selection
designs are available for accelerating drug development. However, Phillips et al. [10] have
advocated the use of the multi-arm multi-stage design developed by Royston et al. [77,83]
in TB. This design works by testing multiple new therapies in a single trial, ceasing
recruitment to poorly performing arms during the course of the trial, and allowing interim
comparisons to be made on an intermediate outcome which is observed earlier than the
primary outcome of the trial. These features have led to the success of the design in
speeding up the evaluation of cancer therapies [78] and it may have a similar positive
impact in TB.
Other types of treatment selection design could be used in TB, but seem less appealing
than the MAMS design. For instance, the design of Todd and Stallard [68], which assesses
a short-term endpoint (e.g. culture status at two months) at the end of the first stage and
then a longer-term endpoint (e.g. relapse) at all subsequent stages, might be impractical
since the follow-up period for the phase 3 TB endpoint is very long. Using only a two-
stage design is a possibility (since the long-term endpoint would then only be assessed at
the end of the trial) but may lack efficiency over designs with more stages. Furthermore,
their design only allows one treatment to continue beyond the first analysis which is likely
to be too restrictive in TB. The design of Stallard [73], which combines both short- and
long-term data (albeit continuous) at each analysis, may be more appropriate but also
only allows one experimental arm to be continued beyond the first stage. By contrast, the
MAMS design has no restrictions on the number of arms that can continue beyond each
stage and assesses only the short-term, intermediate endpoint at all interim analyses with
the long-term, phase 3 endpoint analysed at the end of the trial.
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However, before the MAMS design can be implemented in TB, a number of design issues
need addressing. Since the MAMS design was initially developed for use in oncology trials,
and thus only time to event outcomes can currently be used, extending the design to allow
the use of binary intermediate and definitive outcomes (which are often used in TB trials)
is required. A number of methodological challenges have also arisen through the use of
the design thus far in oncology, such as accurately calculating and controlling the FWER
and choosing stagewise operating characteristics to increase efficiency.
1.8 Overview and objective of thesis
In this thesis, the multi-arm multi-stage design of Royston et al. [77, 83] is extended to
make it more widely applicable to other disease areas, particularly TB, and outstanding
design issues such as calculating FWER and finding efficient designs are addressed. Firstly,
in Chapter 2 the MAMS design is extended to enable its use in phase 2b TB studies
where time to culture conversion is the main outcome of interest. In Chapter 3, MAMS
designs which use a binary intermediate and binary definitive outcome are developed, thus
allowing seamless phase 2/3 MAMS TB trials to be constructed with, say, an intermediate
outcome of culture status at a fixed time point and a primary outcome of long-term
relapse. Methods for choosing the stagewise operating characteristics of two-arm multi-
stage designs are developed in Chapter 4 to allow the most efficient designs with the desired
overall type I error rate and power to be found. In Chapter 5, the outstanding issue of
the FWER of the MAMS design is addressed and a calculation is derived. The issue of
FWER control is covered in Chapter 6 along with methods for finding efficient MAMS
designs with more than two arms. In Chapter 7, the methods developed throughout the
thesis are applied to the STAMPEDE trial to determine whether it could have been more
efficient in terms of the required number of events. In addition, hypothetical examples of
MAMS phase 2/3 trials in TB are presented to demonstrate the potential savings in time
and resources that this approach could achieve compared to separate trials of each phase
of evaluation. Finally, the work presented in the thesis is summarised in Chapter 8 and
ideas for future research are outlined.
Chapter 2
Extensions to the multi-arm
multi-stage design for time to
event outcomes
2.1 Introduction
The multi-arm multi-stage (MAMS) design described by Royston et al. [77, 83] was orig-
inally developed with the design of cancer trials in mind and therefore comes with limi-
tations which can prevent its application to other disease areas. For example, the choice
of outcome measure(s) is (are) restricted to time to event outcomes where events must be
observed more slowly on an experimental arm than on control to demonstrate superiority.
In other words, if a hazard ratio (HR) is used to measure the effect of the experimen-
tal arm relative to the control (as is assumed in the design of a MAMS trial) then the
methodology only allows hazard ratios less than 1 to be targeted under the alternative
hypothesis. This is suitable in a trial in cancer, say, where outcomes such as failure-free or
overall survival are used. However, in other disease areas, observing events more quickly
on an outcome may indicate a benefit (i.e. hazard ratios greater than 1 should be targeted
under the alternative hypothesis). Examples of such outcomes include time to healing in
a trial for venous leg ulcers [111] and time to culture negativity (a marker for cure) in
tuberculosis (TB) [100]. Simply taking the reciprocal of the targeted HR and applying
the methodology described by Royston et al. [83] to design the trial is not appropriate, as
will become apparent in this chapter.
Another current limitation of the MAMS design is that it works under the assumption
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that no patient withdraws from the trial or is lost to follow-up and that follow-up con-
tinues until either the primary outcome has been observed or the trial is terminated. In
the STAMPEDE trial [80] for example, the definitive outcome of overall survival can be
determined from a patient’s medical records without the need for regular follow-up visits
and so outcome data could potentially always be obtainable. However, this is not always
possible. In TB for instance, the phase 2b outcome of time to culture conversion (TCC)
requires a much more intensive follow-up regime (e.g. weekly visits [103]) to determine
whether TB bacilli are still present in a patient’s sputum. Follow-up is therefore limited
to a fixed duration to reduce costs. Consequently, this reduces the rate at which events
are observed and can therefore prolong the duration of the trial. Using the methodology
described by Royston et al. [83] to design such a trial will consequently underestimate
stage durations and sample sizes.
When designing a MAMS trial with a time to event outcome, one has to make an as-
sumption about the underlying distribution of the event times in order to predict stage
end times and sample sizes. Although these estimates are not essential for the conduct
of the trial, they are particularly useful in determining roughly when analyses are likely
to take place and how many participants will be recruited. The MAMS design described
in [83] assumes that survival times follow an exponential distribution and therefore as-
sumes a constant hazard function over time. However, such an assumption is often not
appropriate in practice. For instance, the progression-free and overall survival times in
the ICON7 trial (Panels A and D in Figure 2 of [112]) possibly indicate a non-constant
hazard function over time.
In this chapter, the methodology described in [83] is extended to time to event outcomes
where hazard ratios greater than 1 are targeted under the alternative hypothesis. To
allow such outcomes to be used in practice, we implement the extension in the nstage
program in Stata [84] which facilitates the design of MAMS trials and encounters the
same limitations as those described above. A new MAMS design is then introduced for a
time to event outcome where the follow-up of each patient is limited to a fixed duration,
thus allowing a phase 2b MAMS trial assessing TCC to be constructed. In addition, we
incorporate into the design the assumption that event times follow a Weibull distribution,
which is a generalisation of the exponential distribution and should allow stage end-times
and sample sizes to be estimated more accurately. To facilitate the use of this design in
practice, a new Stata program similar to nstage is introduced and is used to demonstrate
the design of an actual MAMS TB trial investigating TCC. Finally, simulations are used
to investigate the accuracy of the new methodology in estimating stage end-times and
error rates in several one- and two-stage designs.
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2.2 Targeting hazard ratios greater than 1 under the alter-
native hypothesis
2.2.1 Notation
Let I denote the intermediate and D the definitive outcome of a MAMS trial. The same
null and alternative hypotheses are used for all experimental arms so that sample size
requirements for each pairwise comparison is the same, thus allowing interim analyses for
each arm to be conducted simultaneously. We therefore develop the sample size calculation
by first considering a single experimental arm, E, compared to a control, C.
For a J-stage trial, let θj denote the true hazard ratio (HR) comparing E relative to C on
the outcome of interest in stage j (j = 1, . . . , J) and let θ0j denote the corresponding HR
under H0. If arms are monitored on the same outcome throughout the trial (I = D) then
θj and θ
0
j are assumed constant for all j. Otherwise θJ and θ
0
J correspond to the true and
null hazard ratios on the definitive outcome and θj and θ
0
j are constant for all j < J and
correspond to the intermediate outcome. Proportional hazards are assumed throughout.
In practice θ0j is usually chosen to be equal to 1 for all j to correspond to no difference
between the two treatments. Finally, let A denote the number of patients randomised to
each experimental arm for every patient that is allocated to the control.
For a minimum effect (often the minimum clinically important difference), θ1j , that one
would like to detect with prespecified power, ωj , for the outcome of interest in stage j,





and (b) θ1j > θ
0
j are shown in Table 2.1. The design of MAMS trials under scenario (a) is
described by Royston et al. [77, 83]. Below we extend the methodology to allow MAMS
trials under scenario (b) to be designed.







H0 θj ≥ θ0j θj ≤ θ0j
H1 θj < θ
0
j θj > θ
0
j
Table 2.1: Null and alternative hypotheses for the true hazard ratio θj on the outcome of
interest in stage j of a J-stage trial for target hazard ratios (a) θ1j < θ
0





2.2.2 Overview of the MAMS design
A two-arm J-stage trial is designed as follows [83]:
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1. Specify the one-sided significance level αj , power ωj and the null and target hazard
ratios θ0j and θ
1
j for each stage, j, of the trial. The power in each stage should
be maintained at a high level (e.g. > 0.9) to ensure effective arms have a high
chance of proceeding beyond each stage and to achieve high overall power for the
trial [78, 83]. A large significance level should be chosen for the first stage to allow
poorly performing arms to be dropped as early as possible and then decreased with
each stage in order to avoid stages becoming redundant. For trials with J ≤ 6 stages,
Royston et al. [83] suggest using αj = 0.5
j for stages j = 1, . . . , J − 1 to help ensure
equally spaced analyses and αJ = 0.025 in the final stage to mimic a conventional
two-sided test at the 5% level.
2. Calculate the cumulative number of events in the control arm, ej0, that are required
for the analysis at the end of the jth stage to take place. This can be done using the
algorithm described in Section 2.4 of [83] if θ1j < θ
0
j or using the algorithm outlined
below if θ1j > θ
0
j . Given the overall recruitment rate per unit of trial time, rj , and
the constant hazard rate for the control arm, λj , the duration of the jth stage, dj ,
can be calculated followed by the cumulative number of patients recruited to the
control arm, nj , and to the experimental arm, Anj , by the end of that stage. Details
of how to calculate dj and nj are given in [83].
3. Calculate the critical value, δj , that the observed hazard ratio must be more favourable
than for recruitment to continue to the experimental arm in the next stage of the




j is given in [83] and a modification is given below
for θ1j > θ
0
j .
2.2.3 Calculation of the critical values, δj
We assume that the observed log hazard ratio on the outcome of interest in the jth stage,
log θˆj , follows a normal distribution as follows:
log θˆj ∼ N(log θ0j , v0j ) under θj = θ0j
log θˆj ∼ N(log θ1j , v1j ) under θj = θ1j
where v0j and v
1


















Chapter 2. Extensions to the multi-arm multi-stage design for time to event outcomes 57
where ej0 is the cumulative number of control arm events required for the analysis (and
observed) at the end of stage j (estimated below).
Let σij = (v
i
j)
1/2, i = 0, 1, denote the standard error of the log hazard ratio under the
relevant hypothesis and let Φ denote the standard normal distribution function. For
θ1j > θ
0
j , the type I error rate in the jth stage (ignoring all previous stages) is
αj = P
(




log θˆj − log θ0j
σ0j
>












log θ0j − log δj
σ0j
⇒ log δj = log θ0j − zαjσ0j (2.2)
Similarly, the power in the jth stage is
ωj = P
(




log θˆj − log θ1j
σ1j
>












log θ1j − log δj
σ1j
(2.3)
⇒ log δj = log θ1j − zωjσ1j (2.4)
By assuming that σ0j = σ
1




log θ0j − log θ1j
zαj − zωj
(2.5)
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Substituting (2.5) into (2.1) and rearranging for ej0 gives an initial estimate of the required
number of control arm events for the analysis at the end of stage j [83]:




log θ0j − log θ1j
)2
(2.6)
An initial estimate of the critical value for the observed log hazard ratio in stage j can
also then be calculated using (2.2):
log δj = log θ
0
j − zαjσ0j = log θ0j − zαj
√
(1 +A−1)/ej0 (2.7)
2.2.4 Estimation of the required number of control arm events, ej0
The analysis at the end of a particular stage occurs when a predetermined number of
events have been observed on the outcome of interest in the control arm. In this section,
the algorithm described in Section 2.4 of [83] for calculating the required number of events
when θ1j < θ
0





The formula in (2.1) provides a good approximation to the variance of the log hazard
ratio when θj = 1 (often H0), however, it overestimates the variance under H1 (i.e. when
θj > 1). To see this, note that underH1 the number of events occurring in the experimental
arm will be greater than Aej0 since events will occur at a faster rate than when θj = 1.
Using the initial estimate of v1j will therefore lead to an overpowered trial. A more accurate








where ej1 is the expected cumulative number of events observed in the experimental arm
under θj = θ
1
j by the end of stage j.
This variance approximation is used in the following algorithm (now implemented in
nstage) to more accurately estimate the number of control events to achieve the desired
level of power in the jth stage when θ1j > θ
0
j :
1. Given design parameters θ0j , θ
1
j , αj , ωj and A, calculate an initial estimate of ej0
using (2.6)
2. Calculate the corresponding critical hazard ratio, δj using (2.7).
3. For a prespecified control hazard rate λj , estimate the stage end time, tj , using the
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algorithm in Section 8.2 of [83].
4. Calculate the cumulative number of events expected in the experimental arm, ej1,
by tj under θj = θ
1
j using the algorithm specified in Section 8.1 of [83].
5. Using (2.3) and the more accurate estimate of v1j given in (2.8), calculate ω
∗
j — the
actual power at the end of stage j.
6. If ω∗j > ωj decrease ej0 by 1 and repeat steps 2 to 6. Otherwise terminate the
algorithm.
Given the stage end times, the estimated cumulative number of patients recruited to the





where t0 = 0 represents the beginning of recruitment.
Note that only step 6 of the above algorithm differs to the one given in [83] for θ1j < θ
0
j .
This is because the initial event estimate in (2.6) leads to an overpowered trial and so ej0
must be reduced to reach the desired level of power. Conversely, when θ1j < θ
0
j the initial
event estimate does not give enough power and so must be increased. This means that
two trials with identical design characteristics but whose target log hazard ratios differ
only in sign will have the same initial estimate of ej0 (using (2.6)) but, after running the
corresponding algorithm, will end up requiring a different number of control events for the
analysis.
To see this, consider a two-arm one-stage randomised trial with a 1:1 allocation ratio (A =
1), α1 = 0.025 and θ
0
1 = 1. Assuming a constant accrual rate of r1 = 100 patients/year and
a median survival time of 1 year, the required number of control events to detect a hazard
ratio of θ11 = 0.667 or 1.5 with power ω1 = 0.90 are shown in Table 2.2 and were estimated
using an updated version of nstage which incorporates the above methodology. Notice
that the trial targeting θ11 = 0.667 requires 133 control events whereas the trial targeting
θ11 = 1.5 requires 9 fewer events, despite the magnitude of the minimum targeted effect
being the same.
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Design characteristic
Target hazard ratio
θ11 = 0.667 θ
1
1 = 1.5
Required number of control events, e10 133 124
Critical hazard ratio, θ1 0.786 1.283
Sample size per arm, n1 182 172
Duration, d1 (years) 3.63 3.45
Table 2.2: Design characteristics of two one-stage two-arm trials whose target log hazard
ratios under H1 differ only in sign.
2.3 Time to event outcomes with a limited follow-up period
The MAMS design proposed by Royston et al. [77, 83] assumes that patients remain in
follow-up until the final event of interest (e.g. death) has been observed or the until trial
ends. This is often achievable when, say, patient outcomes can be obtained from clinical
records and so regular follow-up of patients is not required. In some cases, however, regular
follow-up visits are necessary to determine whether an event has occurred. For instance,
in a TB trial looking at time to culture conversion, patients are followed up at regular
intervals (e.g. weekly [103]) to obtain sputum samples which are then grown in cultures
to determine whether TB bacilli are still present. If not present, then that patient’s
sputum sample is classed as culture negative and the event of interest has been observed.
Such an intensive follow-up period can be costly and time-consuming for laboratories and
so limiting the duration over which cultures are frequently obtained from patients can
reduce costs. In six of the East Africa MRC TB trials studied by Phillips et al. [100],
71% and 90% of patients were culture negative two and three months after randomisation
respectively. Limiting follow-up to either of these time points will therefore capture most
culture conversions and will avoid the need to continue collecting cultures from patients
whose sputum samples might never be negative.
Restricting follow-up of patients to a fixed duration, t∗, after randomisation limits the
maximum value of the distribution function for event times. Using the methodology
described above or by Royston et al. [83] to design a trial with such an outcome is likely to
accurately estimate the required number of events, however, it would underestimate the
stage durations and sample sizes. The design is therefore extended below to accommodate
a time to event outcome which can only be observed during the first t∗ units of time after
randomisation. The methodology is first developed for a one-stage design and then for a
multi-stage design where the same outcome is monitored throughout the trial (I = D).
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In addition, we allow a Weibull distribution to be assumed for the event times to more
accurately estimate stage durations in the case where event times may not be exponentially
distributed, and introduce Stata software for aiding the design of such a trial.
2.3.1 One-stage design
Suppose all patients recruited to a trial are followed up for a fixed, maximum length
of time, t∗. Only events which occur during this time are observed and will contribute
towards analyses while patients who have not experienced the event of interest before t∗
are censored at t∗. Denote by F (t) the distribution function for the probability of an event
at time t. For a maximum follow-up duration, t∗, define the distribution function, F ∗(t),
by
F ∗(t) =
F (t), if 0 ≤ t < t∗F (t∗), if t ≥ t∗ (2.9)
In other words, if a patient has yet to complete follow-up (i.e. t < t∗) then the probability
of having an event by time t is F (t). If, however, a patient has completed follow-up (i.e.
t ≥ t∗) then the probability that they had an event during follow-up is F (t∗).
Figure 2.1 shows the functions F (t1 − t) and F ∗(t1 − t) for the probability of an event by
time t1 for patients recruited at time t of a trial. Here the function F (t) is assumed to follow
an exponential distribution. Clearly, if a patient enters the trial at the current timepoint,
t1, then the probability of them having an event by t1 is zero (F (t1 − t1) = F (0) = 0). In
the case of a fixed maximum follow-up period (t∗), all patients who were recruited before
t1− t∗ will have completed follow-up and so the probability of any one such patient having
had an event observed is F (t∗).
Suppose a one-stage trial is comparing an experimental arm (k = 1) to a control (k = 0)
on a time to event outcome where patients in both arms are followed up for a maximum
duration after randomisation, t∗. Denote by F ∗k (t) and Fk(t) the distribution functions in
arm k as defined in (2.9). The total number of events observed in arm k by time t1 > t
∗
of the trial, e1k, is the area under F
∗
k (t1− t) (i.e. the darker area in Figure 2.1) multiplied
by the recruitment rate to arm k, r1k, i.e.
e1k = r1k(t1 − t∗)Fk(t∗) + r1k
∫ t1
t1−t∗
Fk(t1 − t)dt (2.10)
Given an initial estimate of the number of control events, e10, required for the analysis
(calculated using (2.6)) and the assumed underlying distribution function, F ∗0 (t), for the





















Figure 2.1: Distribution functions F (t1 − t) and F ∗(t1 − t)
control arm, (2.10) can be rearranged to make t1 the subject to calculate the time by
which e10 events will be observed in the control arm (examples are given in Section 2.3.3).







j respectively can then be applied to estimate the number of control
events required to achieve the nominal level of power, ω1. In each algorithm, t1 and e11
are estimated using (2.10) in steps 3 and 4 respectively. Once a final estimate of t1 is
obtained, the approximate sample size of the trial is calculated by N1 = r1t1 where r1 is
the anticipated overall (constant) recruitment rate for the trial.
If patients are followed up indefinitely then more events will be observed on average by time
t1 with the expected additional number of events being the recruitment rate multiplied by
the lighter area in Figure 2.1. Restricting the maximum follow-up duration will therefore
increase the length and, consequently, the sample size of the trial. Longer follow-up may
be costly, but so too is a longer and larger trial. Therefore a trade-off should be made
between these two factors when designing such a trial.
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2.3.2 Multi-stage design
To calculate the number of events observed by the end of a particular stage in a multi-
stage trial we first need to impose the constraint that stage durations should be longer
than the follow-up period, t∗. This simplifies the calculation somewhat as it means that
all patients allocated to a particular arm during stages 1, . . . , j − 1 will have completed
follow-up by the end of stage j and will therefore have the same probability of having had
an event. Thus the only patients still at-risk of an event at the end of stage j are those
recruited during that stage and who have neither had an event or completed follow-up.
To estimate the number of events observed in arm k by the end of stage j we first split
the trial time t by the stage end times (t1, . . . , tj) and estimate the number of patients
recruited during each stage that have had an observable event. The number of patients
allocated to arm k during stage i (1 ≤ i ≤ j) is rik(ti − ti−1) where rik is the recruitment
rate to arm k during that stage. Since all patients recruited during stage i < j will
have completed follow-up, the expected number of those patients who will have had an
observable event is therefore rik(ti− ti−1)Fk(t∗). The number of patients allocated to arm
k during the current stage (j) and who have an observable event by tj is then calculated
using a function similar to (2.10). Therefore, provided stage durations are longer than the





rik(ti − ti−1)Fk(t∗) + rjk((tj − t∗)− tj−1)Fk(t∗) + rjk
∫ tj
tj−t∗
Fk(tj − t)dt (2.11)
where t0 = 0 represents the beginning recruitment.
The requirement that stage durations are longer than t∗ is an important one otherwise
calculation of ejk will become more complex as some patients recruited during stage (j −
1) will still be at-risk of an event by the end of stage j. If t∗ is relatively short then
this requirement is unlikely to be violated, otherwise stage durations can be increased
by tweaking the stagewise operating characteristics of the trial. Furthermore, a slower
recruitment rate is likely to improve the chances of this condition being met but at the
expense of a longer trial [10].
Given the stagewise recruitment rates, rjk, and the underlying event-time distribution,
F ∗k (t), the formula for calculating ejk in (2.11) and its rearrangement with tj as the subject
can then be used to replace steps 4 and 3 respectively in the algorithm in Section 2.2.3
for powering a multi-stage trial.
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2.3.3 Underlying event time distributions
2.3.3.1 Exponential distribution
For an exponential event time distribution with constant hazard hk(t) = λk in arm k and
fixed follow-up duration t∗, the distribution function, F ∗k (t), is
F ∗k (t) =
Fk(t) = 1− exp(−λkt), if 0 ≤ t < t∗Fk(t∗) = 1− exp(−λkt∗), if t ≥ t∗
Using (2.11) the total number of events occurring in arm k by the end of stage j (i.e. by




























+ tj−1 + t∗ (2.13)
This can then be used in step 4 of the algorithm in Section 2.2.4 to predict the stage end
times provided exponentially distributed event times is a realistic assumption.
2.3.3.2 Weibull distribution
A generalisation of the exponential distribution is the two-parameter Weibull model (see
Chapter 4 of [113]). Unlike the exponential model, the Weibull model allows for a non-
constant hazard function which is either monotonically increasing or decreasing over time.
The hazard function for the model is given by
h(t) = λγtγ−1
where λ > 0 is known as the ‘scale’ parameter and γ > 0 is the ‘shape’ parameter. Note
that for γ = 1 the model reduces to the exponential model. If γ > 1 the hazard increases
with time while γ < 1 indicates that the hazard decreases with time. Examples of hazard
functions for various values of the shape parameter γ and their corresponding survival
functions are shown in Figure 2.2.


































Figure 2.2: Hazard and survival functions of Weibull models with shape parameters γ =
0.5, 1 (exponential), 2, 3 and scale parameter λ = 1.
Assuming the underlying survival distribution is exponentially distributed leads to a simple
calculation for the number of events, however, such an assumption is not always realistic.
This is particularly the case for time to culture conversion (TCC) in TB. Figure 2.3 shows
a Kaplan-Meier plot of culture negativity times in the control arm of a recent phase 2 TB
study [103]. Data were extracted from Figure 6 in [103]. Also shown in Figure 2.3 are the
best fitting exponential and Weibull models for the event-time distribution. Clearly, the
Weibull model fits the data much better than the exponential distribution and shows that
the hazard increases with time (since γ > 1). Using a Weibull model to design a MAMS
trial investigating time to culture negativity is therefore more likely to accurately predict
stage end times and sample sizes than using an exponential distribution.
The truncated distribution function for arm k, F ∗k (t), assuming a Weibull model for the
survival times is
F ∗k (t) =
Fk(t) = 1− exp(−λktγ), if 0 ≤ t < t∗Fk(t∗) = 1− exp(−λkt∗γ), if t ≥ t∗
Integration of Fk(t) in (2.11) is more complicated than the exponential case, however, it
can be achieved by integrating its Taylor Series expansion (see Appendix A). Thus, (2.11)
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The final term in (2.14) can be easily calculated using software by continually adding
terms until the change in ejk is negligible. In addition, (2.14) can be rearranged for tj to
estimate stage end times given an estimate of ejk.
2.4 Accounting for delays
Thus far we have assumed that a particular stage of a study begins immediately after the
required number of events for the analysis of the previous stage have been observed. In
practice, this would not be the case since time is needed for data cleaning, data analysis
and for the various committees to meet to decide whether to continue or cease recruitment
to treatment arms in the next stage [85]. Furthermore, events might not be observed or
recorded as soon as they occur. This is currently the case for culture conversion in TB and
the delay could be as long as 6 weeks from collecting the sample to determining whether
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it is culture negative. These delays can have a substantial impact on the length and size
of a MAMS trial and must therefore be incorporated into the design.
We continue with the case where patients are followed-up for a fixed maximum duration
after randomisation. Let τ1 be the delay between an event occurring and it being observed
(assumed to be the same for all patients) and let τ2 be the total delay between observing
the last required event for an analysis and the beginning of the next stage of the trial.
The value of τ2 incorporates the time needed for data cleaning and analysis etc. The
total delay between the last event occurring and the start of the next stage is therefore
τ = τ1 + τ2. If τ > 0, as will often be the case in practice, more patients will be recruited
to the trial than are needed for the interim analysis. The extra patients who are allocated
to arms which are continued to the next stage of the trial will contribute towards the next
analysis and so fewer patients will need to be recruited during that stage than if τ = 0.
However, some patients may be recruited to arms which are subsequently dropped and so
will not contribute towards any future interim analysis. As Choodari-Oskooei et al. [114]
discuss, such patients should still be followed up under protocol conditions and included in
a reanalysis of the final outcome at the planned end of the trial to reduce bias in treatment
effect estimates.
If delays are likely to occur then τ should be added to the final estimate of tj after running
the algorithm in Section 2.2.4 to produce a more accurate estimate of the stage end time.
Equation (2.11) can then be used to calculate the expected number of events occurring
(but not necessarily observed) in the control and each experimental arm by tj . To maintain
the validity of (2.11), the duration of each stage should be longer than t∗ + τ .
2.5 nstagesurv
To facilitate the design of multi-arm multi-stage trials with time to event outcomes ob-
served during a fixed follow-up period, we have developed the nstagesurv program for
Stata which operates in a similar manner to nstage. Given a set of design parameters
(e.g. number of arms and stages, target hazard ratios, stagewise significance levels and
powers etc), nstagesurv estimates the required number of events and the critical hazard
ratio for the analysis at the end of each stage. In addition, stage durations and sample
sizes are predicted for a given underlying Weibull distribution for the event times. The
program also calculates the overall type I error rate, α, and power, ω, for each pairwise
comparison using the formulae given in Section 2.7 of [83]. The syntax for nstagesurv is
described below and an example of its output is shown in the next section.
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2.5.1 Syntax
nstagesurv, nstage(#) accrate(numlist) alpha(numlist) power(numlist)
arms(numlist) hr0(#) hr1(#) lofu(#) lambda(#) [gamma(#) delay(#)
extrat(#) aratio(#) tunit(#)]
Note: the number of values given in each numlist must equal the number of stages in the
trial (specified in nstage()).
2.5.2 Options
Required
nstage(#) # = J , the number of trial stages.
accrate(numlist) overall accrual rate, rj , per unit of trial time (see tunit()) in
each stage.
alpha(numlist) one-sided significance level, αj , for each pairwise comparison in
each stage.
power(numlist) nominal power, ωj , for each pairwise comparison in each stage.
arms(numlist) number of arms actively recruiting in each stage (including con-
trol arm).
hr0(#) hazard ratio under H0.
hr1(#) minimum target hazard ratio under H1.
lofu(#) # = t∗, the maximum length of follow-up for each patient in
units of trial time (see tunit()).
lambda(#) # = λ0, the scale parameter of the event time distribution in the
control arm. If γ = 1 (see gamma()) then lambda() specifies the
constant hazard function for the control arm.
Optional
gamma(#) # = γ, the shape parameter of the survival distribution. Default
# is 1 (exponential distribution).
delay(#) # = τ1, the delay in observing the outcome from the moment it
occurs in units of trial time (see tunit()). Default # is 0 (no
delay).
extrat(#) # = τ2, the delay between observing the final outcome for an
analysis and the beginning of the next stage in units of trial time
(see tunit()). Default # is 0 (no delay).
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aratio(#) # = A, the allocation ratio (number of patients allocated to each
experimental arm for each patient allocated to control). Default
# is 1 (equal allocation).
tunit(#) code for units of trial time: 1 = one year, 2 = 6 months, 3 = one
quarter (3 months), 4 = one month, 5 = one week, 6 = one day,
and 7 = unspecified. Default # is 7 (unspecified).
2.6 Example — the PanACEA trial
The methodology developed above has been used to design the 5-arm 2-stage phase 2b
PanACEA (Pan African Consortium for the Evaluation of Antituberculosis Antibiotics)
trial in TB (ClinicalTrials.gov identifier NCT01785186) comparing four novel regimens
against the standard six-month four-drug regimen. The outcome of interest is time to cul-
ture conversion assessed on a weekly basis over the first 12 weeks (t∗) after randomisation.
A 6 week delay (τ1) is used to account for culture growth in addition to a 4 week delay (τ2)
for data cleaning and analysis and for conducting the data monitoring and trial steering
committee meetings. Based on previous trial data, the underlying hazard function was
assumed to be non-constant and so a Weibull distribution with parameters λ0 = 0.023
and γ = 1.77 was assumed for the control arm to estimate stage end times and sample
sizes. Other design parameters for PanACEA are shown in Table 2.3.
Design parameter Value
Number of stages, J 2
Number of arms (including control) 5
Stagewise accrual rates (per week) r1, r2 9, 9
Stagewise significance levels α1, α2 0.4, 0.025
Stagewise powers ω1, ω2 0.95, 0.90
Hazard ratio under H0, θ
0 1
Target hazard ratio, θ1 1.8
Weibull parameters λ0 = 0.023, γ = 1.77
Length of follow-up (weeks), t∗ 12
Allocation ratio, A 0.5
Delay in observing outcome (weeks) 6
Delay for analysis (weeks) 4
Table 2.3: Design parameters for the 5-arm 2-stage PanACEA trial
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The corresponding output from nstagesurv is shown below for the situation when all
experimental arms are assumed to pass the first stage and thus shows the maximum
number of events, sample size and duration.
nstagesurv, nstage(2) accrate(9 9) alpha(0.4 0.025) power(0.95 0.90) ///
arms(5 5) hr0(1) hr1(1.8) lambda(0.023) gamma(1.77) lofu(12) ///
aratio(0.5) delay(6) extrat(4) tunit(5)
Sample size for a 5-arm 2-stage trial with time to event outcome
and limited follow-up duration
Operating characteristics & stages durations
------------------------------------------------------------------------
Alpha(1S) Power HR|H0 HR|H1 Crit.HR Length* Time*
------------------------------------------------------------------------
Stage 1 0.4000 0.948 1.000 1.800 1.088 26.754 26.754
Stage 2 0.0250 0.899 1.000 1.800 1.439 23.643 50.398
Pairwise 0.0223 0.870 50.398
------------------------------------------------------------------------
Time delay in observing events* = 6.000
Time delay for analysis* = 4.000
* Lengths and durations are expressed in one week periods
Cumulative sample sizes and number of events
----------Stage 1---------- ----------Stage 2----------
Overall Control Exper. Overall Control Exper.
----------------------------------------------------------------------
Arms 5 1 4 5 1 4
Acc.rate 9.0 3.0 6.0 9.0 3.0 6.0
Req.events 95 27 68 295 87 208
Tot.events 181 53 128 343 103 240
Patients 240 80 160 415 139 276
----------------------------------------------------------------------
By comparison, the corresponding 1-stage design with type I error rate 0.0223 and power
0.870 will require 396 patients and take approximately 48 weeks to complete. The two-
stage design will only require more patients than this (415) if recruitment continues to all
arms beyond the first interim analysis. In particular, if no arms show sufficient benefit at
the interim analysis then approximately only 240 patients would be required, thus allowing
patient resources to be redirected to the evaluation of other, potentially more promising,
novel regimens.
In this design, recruitment is assumed to stop as soon as the required number of events
have been observed in the control arm. However, due to the delay in observing outcomes,
more events would have occurred in the trial than are necessary for the analysis (e.g. at the
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end of the final stage 103 control events would have actually occurred once the 87 required
for the analysis have been observed). To combat this, one could predict during the trial
when the required number of events will have actually occurred and curtail recruitment
in the final stage at that point. This can be achieved using the artpep command in
Stata for instance [115], thus reducing the maximum length of the trial by 6 weeks which
is equivalent to recruiting 54 fewer patients in the trial (assuming a recruitment rate of
9 patients/week). However, this will not pose such a large problem once methods are
developed for determining culture status in a shorter time frame and implemented into
practice.
It should be noted that the time to culture conversion outcome is an interval-censored
outcome since culture samples are only taken on a weekly basis. Thus the actual time
to culture conversion may have occured between visits. This often has to be taken into
account in the analysis of such an outcome particularly if the interval between measure-
ments is large in relation to the length of the trial. However, this may not be such an issue
in PanACEA since the weekly intervals are much shorter than projected the minimum
length of the trial of 26 weeks.
2.7 Simulation study
2.7.1 One-stage designs
A simulation study was performed to determine the accuracy of the calculations made by
nstagesurv. One-stage designs were investigated by simulating patient-level data for all
combination of designs from parameters shown in Table 2.4 (288 designs in total). The
following parameter values were used for all simulated trials: t∗ = 10, r1 = 10, τ = 0
and θ0 = 1. Survival times with underlying exponential or Weibull distributions were
explored along with target hazard ratios less than and greater than 1. Stage end times
and stagewise pass/fail rates under H0 and H1 were estimated for each study design in the
simulations and compared to calculated values. Ten-thousand replicates were generated
for each study design to ensure the Monte Carlo standard error of the type I error rate
and power estimates was no higher than 0.005. Hazard ratios were estimated using the
stcox command in Stata. Error rates were assessed when using (a) the significance level
and (b) critical hazard ratio to determine whether the experimental arm was superior to
control.
For each design, the average duration of all simulated trials was within 1% of the cor-
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Design parameter Values investigated
Type I error rate, α 0.025, 0.05
Power, ω 0.8, 0.9
Target HR, θ1 0.5, 0.75, 1.3, 2
Control scale parameter, λ0 0.05, 0.1
Shape parameter, γ 0.75, 1, 1.25
Allocation ratio, A 0.5, 1, 2
Table 2.4: Design parameters for simulations
responding calculated values (data not shown). Figures 2.4 and 2.5 show the difference
between the type I error rates and powers respectively from simulations compared to the
nominal levels. Figures labelled (a) show the difference in error rates when superiority
is assessed by comparing the p-value for the observed HR to the significance level of the
trial, and those labelled (b) show the results when comparing the observed HR to the
corresponding critical hazard ratio (determined by nstagesurv).
Figure 2.4 shows that using the significance level, rather than the critical hazard ratio,
results in type I error rates closer to the nominal value. For target HRs less than 1, the
actual type I error rate often exceeds the nominal value, whereas it usually fails to reach
it for HRs > 1. Figure 2.5 shows that using (a) or (b) results in similar discrepancies
between the actual and nominal power, although the difference in power is more variable
when using the significance level particularly for small control event numbers (e.g. < 50).
In all cases the actual error rates tend to the nominal values as the number of events
increases. These findings are similar to those of Royston et al. [83] who investigated 1-
and 3-stage designs with a target HR of 0.75 and used the critical HR as the cut-off value.
Both the type I error rate and power tended to be underestimated in the calculations (as
is the case here) but the accuracy increased for designs requiring more events.
The discrepancies in Figures 2.4 and 2.5 are an artifact of the stcox command in Stata
which was used to analyse the simulated data. Figure 2.6 shows that this command tended
to underestimate the HR particularly when there were fewer than 100 control arm events.
Thus, when the target HR was greater than one, this underestimation reduced the type I
error rate and power when using a critical HR to determine superiority. For target HRs
greater than 1, the converse is true. In addition, the underestimation was more extensive
for trials observing less than 100 control arm events thus resulting in larger discrepancies
at these points as shown in Figures 2.4 and 2.5. The stcox command also tended to give
standard errors which were slightly higher than the estimate in (2.8) particularly under
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(b) Using critical hazard ratio
Figure 2.4: Difference between type I error rates obtained from simulations and nominal
values for 1-stage designs when using (a) the significance level or (b) the critical hazard
ratio for determining whether the experimental arm is superior to control.
H1 and when fewer than 100 control arm events were observed. Oddly, this resulted in
powers which were slightly lower or higher on average than the nominal values when the
target HR was less than or greater than 1 respectively, as shown in Figure 2.5(a) (note
this is the opposite to what was observed in Figure 2.5(b)).
2.7.2 Two-stage designs
The relationship between the number of control events and the discrepancy in error rates
has implications for multi-stage designs since early stages may only require a small number
of events and so these differences could be amplified over several stages. We therefore
simulated two-stage designs with stagewise operating characteristics α2 = 0.025, ω1 = 0.95
and ω2 = 0.9 and explored first stage significance levels (α1) of 0.1, 0.3 and 0.5. We
hypothesise that the two-stage designs will show larger discrepancies in error rates than
the 1-stage designs in the previous section and that these differences will increase for
designs using a larger first stage significance level and thus smaller first stage. Designs
generated using all combinations of θ1, λ0, γ and A shown in Table 2.4 and for which both
stages were longer in duration than the follow-up period (t∗ = 10) were investigated.
Table 2.5 shows the average difference between the simulated and calculated overall error
rates and powers for the two-stage designs. Also shown are the same results for the
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(b) Using critical hazard ratio
Figure 2.5: Difference between powers obtained from simulations and nominal values for
1-stage designs when using (a) the significance level or (b) the critical hazard ratio for
determining whether the experimental arm is superior to control.
α1
Using significance level Using critical HR
∆α (SD) ∆ω (SD) ∆α (SD) ∆ω (SD)
Target HR< 1
0.1 0.000 (0.002) -0.003 (0.004) 0.004 (0.002) 0.008 (0.004)
0.3 0.002 (0.003) 0.004 (0.007) 0.008 (0.005) 0.021 (0.011)
0.5 0.001 (0.003) 0.008 (0.007) 0.008 (0.005) 0.027 (0.013)
1-stage 0.001 (0.003) -0.011 (0.010) 0.008 (0.005) 0.011 (0.006)
Target HR> 1
0.1 -0.001 (0.002) -0.002 (0.005) -0.003 (0.002) -0.010 (0.004)
0.3 -0.002 (0.003) -0.010 (0.011) -0.005 (0.003) -0.021 (0.016)
0.5 -0.002 (0.002) -0.020 (0.016) -0.006 (0.003) -0.032 (0.020)
1-stage -0.002 (0.003) 0.002 (0.008) -0.006 (0.003) -0.011 (0.007)
Table 2.5: Average difference between overall type I error rates (∆α) and powers (∆ω)
obtained from simulations compared to calculated values for two-stage designs with first
stage significance level α1.
corresponding 1-stage designs with α = α2 = 0.025 and ω = ω2 = 0.9 as investigated in
the previous section. As expected, the difference between the calculated and simulated
error rates increases for larger stage 1 significance levels (i.e. as the required number
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Figure 2.6: Average difference between hazard ratios estimated using the stcox Stata
command and the corresponding underlying HR under (a) H0 (left) and (b) H1 (right)
of events decreases). This difference is more severe when using the critical HR as the
cut-off value while the differences are relatively much smaller when using the significance
level. For the latter in particular, there is little difference between the discrepancies in the
1-stage and 2-stage designs except for the difference in power when α1 = 0.5.
2.8 Discussion
In this chapter the MAMS design for time to event outcomes was extended to allow hazard
ratios greater than one to be targeted under the alternative hypothesis. This is required if
events need to be observed more quickly on an experimental arm than on control for it to
be deemed superior. Examples of such outcomes are time to cure or time to healing. The
extensions to the methodology were also applied to the nstage program in Stata which is
used to aid the design of MAMS trials with time to event outcomes.
An adaptation of the MAMS design was introduced allowing the use of time to event
outcomes which are only observed during a limited period after randomisation. Unlike the
original MAMS design which only assumes exponential event times, a Weibull distribution
can be assumed thus allowing more accurate estimation of stage end times and sample
sizes. In practice, time to event outcomes might not be exponentially distributed, as
shown for the TCC outcome in TB in Section 2.3.3.2. This is also often the case in
cancer where, for example in the ICON7 study, progression-free survival times appear to
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be non-exponential (Figure 2 of [112]). Making a similar extension to the MAMS design
described in [83], which is often used in cancer, or allowing the use of a more general
piece-wise exponential distribution might therefore be useful.
Unlike the original MAMS design, we have only allowed the use of a single outcome
throughout the trial (I = D). Further work could include extending the design to situ-
ations where I and D are different time to event outcomes both observed during a fixed
period, or even to the case where either I or D is observed during a fixed period and the
other outcome can be ascertained at any time. For instance, in TB one could have a trial
where I is time to culture conversion and D is overall survival. Whether such a design is
likely to be required in practice however, is unclear.
To aid the design of a MAMS trial with a time to event outcome observed during a fixed
follow-up period, the nstagesurv program was introduced for Stata. Like nstage, the
program requires the number of arms recruiting in each stage to be specified, however,
this is not likely to be known before the trial commences. When designing a trial it is
recommended to run the design under various combinations of arms to explore the impact
on the sample size and duration of the trial [84]. nstagesurv was used to help design the
5-arm 2-stage PanACEA TB study investigating time to culture conversion which finished
recruitment in March 2014.
The stage durations, type I error rates and powers calculated by nstagesurv were assessed
with simulations of one-stage and two-stage designs. Stage duration estimates were shown
to be highly accurate. For designs requiring a small number of control events there was a
small discrepancy between the calculated and actual type I error rates and powers which
diminished as the number of events increased. These findings are an artifact of the stcox
command in Stata which underestimated HRs for designs with less than approximately
100 events and so other, more accurate means of estimating HRs need to be investigated.
We also assessed these discrepancies when using the nominal significance level or critical
HR to determine superiority of the experimental treatment. Using the significance level as
the cut-off for the observed p-value tended to give error rates closer to the nominal values
especially under H0, and we therefore recommend using the significance levels rather than
critical HRs in practice.
In summary, we have extended the existing MAMS design of Royston et al. [83] to make
it applicable to trials of outcomes in which shorter event times are more favourable. In
addition, we have introduced a new MAMS design for time to event outcomes which are
only observed during a limited time frame after randomisation and developed software for
applying the design in practice. The methodology has already been used in a phase 2b TB
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trial investigating time to culture conversion and holds promise for accelerating treatment
evaluation in this area.
Chapter 3
A multi-arm multi-stage trial
design for binary outcomes
3.1 Introduction
As discussed in previous chapters, the sample size calculation for the multi-arm multi-
stage (MAMS) design described by Royston et al. [83] is only applicable to time to event
outcomes where a hazard ratio (HR) is typically the summary statistic used to compare an
experimental treatment against a control. It is therefore applicable to trials in oncology,
for example, where time to an event such as death is often used as a primary endpoint.
In Chapter 2 we extended the design to a time to event outcome which is only observable
during a limited period of time after randomisation and applied the design to a phase
2b trial in tuberculosis (TB) where time to culture conversion (TCC) is the outcome of
interest. However, if the MAMS design is to be more widely used in other disease areas,
the methodology needs extending further to allow more types of outcome measure to be
used.
In TB, another commonly used outcome measure for phase 2b trials is the absolute differ-
ence in the proportion of patients who have a negative culture status eight weeks or two
months after commencing therapy [101, 116, 117]. Unlike TCC, this is a binary outcome
assessed at a single time point. In phase 3, the absolute difference in the proportion of
patients who either fail to respond to their allocated treatment or relapse after completing
treatment (also binary) is usually assessed one to two years after randomisation [104]. In
this chapter, these examples are used as motivation for extending the MAMS design to
binary intermediate and definitive outcomes observed at the end of fixed follow-up peri-
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ods and analysed using an absolute difference in proportions. Binary (or dichotomous)
outcomes are widely used in many clinical studies and so making such an extension to the
methodology should vastly increase the areas in which the MAMS design could be used.
Unlike the design in the previous chapter, the intermediate and definitive outcomes may
differ thus allowing phases 2 and 3 of testing to be incorporated into a single MAMS study.
The benefits of this design over more conventional approaches to treatment evaluation
(e.g. separate fixed-sample phase 2 and 3 trials) are explored and issues surrounding the
design, such as type I error rate and critical values, are investigated. Simulation studies
using examples in a TB context are used to verify the methodology and to investigate
the bias in treatment effect estimates under various scenarios. Finally, a new software
program for Stata is introduced which facilitates the design of MAMS trials with binary
outcomes.
3.2 Proposed design
Let I denote the intermediate and D the definitive outcome of a MAMS trial. To simplify
matters practically and methodologically, the same null and alternative hypotheses are
used for all experimental arms so that their sample size requirements are identical, thus
allowing corresponding interim assessments of each arm to be conducted simultaneously.
We therefore develop the sample size calculation by first considering a single experimental
arm, E, compared against a control, C.
For a MAMS trial with J stages, let piEj and pi
C
j denote the true event rates for the
outcome of interest in the jth stage of the trial in the experimental arm and the control
arm respectively (j = 1, . . . , J). If the same outcome is used throughout the trial (I = D)
then piEj and pi
C
j are constant for all j. If the intermediate and definitive outcomes differ
(I 6= D) the values piEJ and piCJ correspond to the true treatment effects for the definitive
outcome and piEj and pi
C
j are constant for all j < J and correspond to the intermediate
outcome.
To make the MAMS design directly applicable to phase 2 and 3 trials using binary out-
comes in TB we will develop the methodology for treatment effects parametrised by an
absolute difference in proportions. Future work will focus on extending the methods to
odds ratios and risk ratios which are often used in many other trials of binary outcomes.
Denote by θj = pi
E
j − piCj the true absolute risk difference at the jth interim analysis.
Without loss of generality, assume that a positive value of θj indicates benefit of E over
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C. The null and alternative hypotheses are then
H0 : θj ≤ θ0j , j = 1, . . . , J
H1 : θj > θ
0
j , j = 1, . . . , J.
The value θ0j is constant for all j if the intermediate and definitive outcome measures are
the same (I = D). Otherwise θ0J corresponds to the definitive outcome and θ
0
j is constant
for all j < J for the intermediate outcome. In a superiority trial, θ0j is usually taken to be
0 to represent no difference between arms under the null hypothesis. In a non-inferiority
trial, a negative value of θ0j is used to represent that E is slightly inferior to C under H0.
Having specified the null and alternative hypotheses above, the one-sided significance
level, αj , and power, ωj , for each pairwise comparison is chosen for each stage j of the
trial (j = 1, . . . , J). As stated in Chapter 2, it is recommended to use a high power in each
stage, for example 90% or 95%, in order to achieve high overall power for the trial [83]. A
large significance level should be used in the first stage to allow the first interim analysis
to occur early on in the trial. Over subsequent stages significance levels are decreased to
avoid stages becoming redundant. For trials with 6 or fewer stages, Royston et al. [83]
suggest a ‘rule of thumb’ of αj = 0.5
j for stages j = 1, . . . , J−1 and αJ = 0.025 in the final
stage to mimic a conventional two-sided test at the 5% level. However, further research
by Barthel et al. [118] and Choodari-Oskooei et al. [114] have suggested using a first stage
significance level between 0.2 and 0.3 to reduce error rates and bias. The issue of how
stagewise operating characteristics should be chosen in order to increase the efficiency of
a design has yet to be addressed [83] and will be investigated in a later chapter.
3.2.1 Critical values
For time to event outcomes, Royston et al. [83] calculate and apply critical values to the
observed HRs to determine whether to continue recruitment to an experimental arm in
the next stage of the trial. The critical HR, δj , for the jth interim analysis is a function of
the variance of the treatment effect and is therefore calculated under the assumption that
a predetermined number of control arm events, ej , will have been observed by the interim
analysis. If the interim analysis occurs exactly when ej events have been observed in the
control arm then the critical HR will roughly yield nominal type I and II error rates if it
is strictly adhered to [83].
In the case of binary outcomes, similar critical values for θj would instead be a function
of the control arm event rate, piCj , which is an unknown parameter and a value would
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therefore have to be assumed. Figure 3.1 shows that applying such a critical value, δ,
to the observed treatment effect in a simple 1-stage design does not control the type I
error rate at the nominal level (α1 = 0.025) if the true control event rate differs from the
assumed value (0.3 in this example).
A possible solution is to recalculate the critical value using the observed control event rate
and apply this to the observed treatment effect. However, Figure 3.1 shows that this also
does not provide nominal type I error rates. By contrast, using the significance level as
the critical value for the p-value of the observed treatment effect controls the type I error
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Figure 3.1: Actual type I error rate of a 1-stage design with α1 = 0.025 (dotted line)
under a range of true control event rates when (a) using a critical value which is calculated
assuming a control event rate of 0.3, (b) applying a critical value which is ‘updated’ using
the observed control event rate and (c) using the significance level as the critical value for
the p-value of the observed treatment effect. (Note: the true event rate in the experimental
arm is assumed to be the same as in the control)
The p-value for the observed treatment effect should therefore be used for monitoring as
follows: immediately after the jth interim analysis, continue recruitment to experimental
arms whose treatment effect estimate on the intermediate outcome is statistically signif-
icant at the 100αj% level. Otherwise consider ceasing further randomisations to it. If
the treatment effect estimate on the definitive outcome is statistically significant at the
100αJ% level in the final analysis then the experimental treatment is declared superior to
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the control arm (or non-inferior, depending on the objective).
3.2.2 Sample size calculation
By specifying a significance level, αj , and power, ωj , for each pairwise comparison in the
jth stage we can use standard formulae to calculate the required sample size for each
analysis. For example, the required sample size for the control arm in the jth analysis,
nCj , can be calculated using [119,120]
nCj =
(z1−αj + zωj )2[ApiCj (1− piCj ) + pi1j (1− pi1j )]
A(θ1j − θ0j )2
(3.1)
where θ1j is the minimum effect that one would like to detect with power ωj on the outcome





the target event rate in the experimental arm under H1, zk is the kth percentile of the
standard normal distribution and the E : C allocation ratio is A : 1 so that A patients are
randomised to each experimental arm for every patient allocated to control.
For a MAMS trial with Kj experimental arms recruiting in stage j, the total sample size
required for the jth interim analysis is then
nj = (1 +KjA)n
C
j . (3.2)
3.2.3 Consequences of delayed observations
In clinical trials, patients are often followed up for a set period of time after randomisation
before outcomes are observed. An immediate consequence of delayed observations is that
patients may withdraw or become lost to follow-up before their outcome can be ascertained.
If it is likely that outcome data will not be available for some proportion of patients, λj ,
on the outcome in the jth stage of the study, then the required sample size should be
multiplied by 1/(1−λj) to maintain the desired level of power for a complete-case analysis.
It should be noted that such an analysis assumes that missing data occur completely at
random which might not be plausible, and so appropriate imputation techniques should
also be applied [121].
For simplicity we assume that the attrition rate, λj , will be constant throughout the trial
for each outcome. One might normally expect a higher attrition rate for D than I as
it requires a longer follow-up period. However, it may be easier to obtain the former
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particularly if it can be ascertained from medical records (for example, death), in which
case a lower attrition rate on D may be a more plausible assumption.
Another consequence of delayed observations is that interim analyses cannot take place as
soon as the required sample size has been recruited and randomised. Since recruitment is
continuous, the delay in obtaining data on an outcome means that there will be patients at
each interim analysis who have been recruited to the trial but who have yet to have their
outcome observed. For example, if the follow-up period is six months and the recruitment
rate is a constant 100 patients per year, then an extra 50 patients will be recruited to
the trial but will not have completed follow-up by the time of the database freeze for the
interim analysis. This highlights the need for using an intermediate outcome which is
observed relatively quickly after randomisation. By contrast, the length of the follow-up
period for the definitive outcome is not such an issue as recruitment is stopped in the final
stage once the required sample size has accrued.
The additional patients who are randomised to arms which are subsequently dropped at
the interim analysis will also not be included in any future interim analyses. However, for
reasons concerning bias (see Section 3.4.2 and [114]) these patients should still complete
follow-up under protocol conditions and be included in a final analysis of their allocated
arm against all control arm patients randomised concurrently at the planned end of the
trial. If patients cannot be followed up under protocol conditions, for example, because
their allocated treatment is shown to be harmful and is therefore switched, then their
outcomes should not be included in a reanalysis as they may lead to more biased treatment
effect estimates [75].
The delay in starting the next stage of the trial caused by data cleaning, analysis, various
committee meetings and changing the randomisation codes (if necessary) further increases
the number of patients allocated to an arm which may imminently be dropped from
the trial. A possible solution to avoid randomising patients during this interval and the
follow-up period is to suspend recruitment once the required sample size for the analysis
has accrued and then recommence it at the start of the next stage. However, this is not
recommended since suspending and re-initiating recruitment can be logistically challenging
and is likely to prolong the duration of the trial by slowing the overall recruitment rate
[10,25].
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3.2.4 Calculating the stage durations
The total expected delay, denoted by τj , between recruiting the last of the nj patients
required for the jth interim analysis and the beginning of the next stage of the trial
incorporates the delay in observing the outcome plus the additional delays caused by the
analysis. Denoting the total number of patients recruited to the arms remaining in the
study at the end of stage i by Ni, the number of patients that need to be recruited during
the current stage, j, for the upcoming interim analysis, n˜j , is
n˜j = nj − AKj + 1
AKj−1 + 1
Nj−1(1− λj)
where N0 = 0 and Kj is the number of experimental arms actively recruiting in the jth
stage of the study. It follows that the duration of stage j is
dj =
n˜j
rj(1− λj) + τj
where rj is the anticipated overall recruitment rate in the jth stage (assumed to be constant
within each stage).
The cumulative number of patients allocated to all treatment arms still recruiting at the
end of each intermediate stage is then
Nj = rjdj +
AKj + 1
AKj−1 + 1
Nj−1 j = 1, . . . , J − 1.
In the final stage, recruitment to the trial may be terminated as soon as NJ = nJ/(1−λJ)
patients have been allocated to the remaining treatment arms. It is not necessary to
continue recruitment beyond this point since there are no more planned analyses after the
final analysis.
The stage end-times, tj , are obtained by summing the durations of all preceding stages;
tj =
∑j
i=1 di. These values are particularly useful as they roughly predict when interim
analyses will occur and so help to organise data monitoring and trial steering committee
meetings in advance.
Chapter 3. A multi-arm multi-stage trial design for binary outcomes 85
3.2.5 Pairwise operating characteristics
For a trial with J stages, Royston et al. [83] state that the overall type I error rate, α,
and power, ω, for each experimental arm compared to control is
α = ΦJ(zα1 , . . . , zαJ ;R
0
J) under θj = θ
0
j for all j (3.3)
ω = ΦJ(zω1 , . . . , zωJ ;R
1
J) under θj = θ
1
j for all j (3.4)
where ΦJ is the J-dimensional multivariate normal distribution function with correlation
matrix RhJ (h = 0, 1). The (j, k)th entry of R
h
J is the correlation between the treatment
effects in stages j and k under θj = θ
h
j . The calculation of these correlations is outlined
in Appendix B.
When I and D differ, the calculation of α in (3.3) is made under the assumption that H0
is true for both I and D. However, the maximum type I error rate, αmax, will actually
be larger than α. To see this, consider a two-stage trial in which the experimental arm is
highly effective on I but is ineffective on D. If such an arm is recommended at the end
of the trial then a type I error has been made. However, since the experimental arm is
highly effective on I it will almost always pass the interim analysis, effectively making it
redundant. The design will therefore reduce to a 1-stage trial with a maximum type I error
rate equal to the final stage significance level, αJ (> α). In the STAMPEDE trial (see
Table 1.1 on page 44), the type I error rate has been estimated to be 0.013 [80], however,
this is only when H0 is true for both I and D. By the above argument, the maximum type
I error rate for each pairwise comparison is actually equal to the final stage significance
level of the trial: αJ = 0.025.
The type I error rates of two two-stage I 6= D designs with (a) α1 = 0.5 and (b) α1 = 0.2 are
shown in Figure 3.2 for various underlying treatment effects on the intermediate outcome,
θ1, and under the null hypothesis for D. In both designs α2 = 0.025. Figure 3.2 shows
that even for values of θ1 slightly larger than the null value, θ
0
1, the inflation in the type
I error rate above α is substantial with the maximum value, αmax = α2, practically being
reached when θ1 is equal to the minimum effect targeted under H1, θ
1
1. Furthermore, the
increase is sharper when using a smaller significance level in the intermediate stage. To
control the pairwise type I error rate at a particular level, α∗, in the strong sense (i.e.
under any set of treatment effects) one should therefore set αJ = α
∗ in the design of the
trial.
This raises important questions about how strictly one should adhere to the stopping
guidelines at the interim analyses. For instance, if the treatment effect for an arm is









































Treatment effect on I outcome
a1 = 0.2
Figure 3.2: Type I error rates of two two-stage I 6= D designs over a range of true
treatment effects on the I outcome. Key: θ01 = treatment effect under H0; θ
1
1 = minimum
targeted treatment effect under H1; α = type I error rate assuming H0 is also true for the
I outcome; αj = nominal significance level in the jth stage (j = 1, 2).
statistically non-significant at an interim analysis but it has a highly beneficial effect on
an important secondary outcome (e.g. safety), then it may be desirable to continue the
arm to the next stage of the study for further assessment. Ignoring interim stopping
guidelines in a trial where I 6= D will not inflate the maximum type I error rate, αmax,
since it is controlled only by the final stage significance level (αJ). The interim significance
levels could therefore be considered ‘non-binding’ in that arms do not strictly have to be
dropped at the jth analysis if their treatment effect is statistically non-significant at level
αj [53]. This increases the flexibility of the design, however, efficiency will be lost if
stopping guidelines are ignored.
By contrast, ignoring stopping guidelines will inflate the type I error rate when I = D
since all stagewise significance levels contribute to the overall pairwise type I error rate, α.
However, it is difficult to make the significance levels α1, . . . , αJ ‘binding’ since arms which
are ineffective on I (= D) but have potentially promising effects on secondary outcomes
cannot then be assessed further. If this is likely to be an issue one could decrease αJ to be
equal to the desired pairwise error rate when designing the trial to ensure that the actual
type I error rate will not be no higher than this value. This will allow the significance
levels at the interim analyses to be non-binding but at the expense of a slight increase in
the maximum sample size and potential loss in efficiency.
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3.2.6 Positive predictive value
As shown in Appendix B, the calculation of α and ω using (3.3) and (3.4) when I 6= D
requires an estimate of either the probability of a patient experiencing both outcomes or
the probability of experiencing the definitive outcome given they have had the intermediate
outcome (positive predictive value, PPV) for the control arm and for experimental arms
under H0 and H1.
The PPV is arguably easier to specify as it only requires an assumption for a single
outcome (D, given that I has occurred) to be made, rather than two (both I and D).
For simplicity, we will assume that the PPV in the control arm and an experimental arm
under H0 is the same, which should often be the case in practice.
An estimate of either value can be obtained using data from previous trials, through expert
opinion or both. Since the correlations between treatment effects, and therefore α and ω,
increase as either of these probabilities tend to 1 we recommended slightly underestimating
them to obtain a conservative estimate of ω.
Here we are interested in the PPV of I on D at an individual level to estimate the between-
stage correlation. This is in contrast to the trial-level PPV discussed in Section 1.5.4
where it was stated that there was no requirement for a true alternative hypothesis on I
to translate into a true alternative hypothesis for D. For the remainder of this chapter
PPV will correspond to the patient-level probability P (D = 1|I = 1) (probability that a
patient experiences the definitive outcome given they have experienced the intermediate
outcome).
3.2.7 Probability of passing each stage
Using similar formulae to (3.3) and (3.4), the probabilities of an experimental arm passing
the first j stages of a MAMS trial are
Aj = Φj(zα1 , . . . , zαj ;R
0
j ) under θj = θ
0
j
Ωj = Φj(zω1 , . . . , zωj ;R
1
j ) under θj = θ
1
j
where Φj is the j-dimensional multivariate normal distribution function and R
h
j (h = 0, 1)
is the j × j submatrix of RhJ introduced in Section 3.2.5.
Clearly, A1 = α1, Ω1 = ω1, AJ = α and ΩJ = ω. Other values of interest, particularly
in a seamless phase 2/3 design (e.g. when I 6= D), are AJ−1 and ΩJ−1 which denote the
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probability of continuing recruitment to an arm in the final (phase 3) stage of the trial
under H0 and H1 respectively. Phase 3 trials are often resource intensive and lengthy
and the same may be true for the final stage of a MAMS trial if the intermediate and
definitive outcomes differ. Therefore it is important to have a reasonably small value
of AJ−1 and a large value of ΩJ−1 to increase the chance of only allocating patients to
effective experimental treatments in the final stage.
3.3 Application to tuberculosis
To illustrate how this new MAMS design might be applied and to assess its benefits in
a TB setting, we used the methodology above to calculate sample sizes for phase 2 and
seamless phase 2/3 two-arm two-stage TB trials.
Phase 2 designs were based upon a recent study by Dorman et al. [101] that substituted
moxifloxacin for isoniazid in the standard TB regimen during the intensive phase (first
two months) of treatment. The outcome in this study was culture status eight weeks after
randomisation and this was also used as the basis for the intermediate outcome in the
hypothetical seamless phase 2/3 designs. The definitive outcome was based on the ongoing
phase 3 REMox TB trial (controlled comparison of two moxifloxacin containing treatment
shortening regimens in pulmonary tuberculosis) that investigates the effect of two four
month regimens against the standard six month regimen on relapse rates 18 months after
randomisation [106]. This trial uses a Bonferroni-adjusted one-sided significance level of
1.25% for each treatment arm to ensure the overall type I error rate is no higher than
2.5%. For this example we considered only one experimental arm from REMox and thus
used a one-sided significance level of 2.5%. The designs of these standalone phase 2 and
phase 3 trials are summarised in Table 3.1.
Examples of two-arm two-stage phase 2 and phase 2/3 TB trials were generated using
a conventional one-sided significance level (α2 = 0.025) and power (ω2 = 0.90) in the
final stage. One-sided significance levels (α1) of 0.2 and 0.5 and powers (ω1) of 0.90 and
0.95 for the first stage were explored. Delays of 4 and 14 weeks for observing a patient’s
culture status after randomisation were used to explore their effect on the efficiency of a
multi-stage trial. The latter was chosen as it is the current delay in observing a patient’s
culture status after randomisation due to the 8 week follow-up period plus 6 week wait for
detecting absence of TB (in liquid medium). A 4 week delay was also chosen as it is not
yet certain whether culture status at 8 weeks is an appropriate intermediate outcome for
long-term relapse and observing it after 4 weeks may be more suitable. Furthermore, the
Chapter 3. A multi-arm multi-stage trial design for binary outcomes 89
Design Study
Overall*




Follow-up length 8 weeks** 18 months**
Significance level (1-sided) 2.5% 2.5% 2.5%
Power 80% 85% 68%
Control arm event rate 75% 90%
Treatment effect under H0 0% -6% (NI margin)
Target treatment effect (H1) 13% 0%
Allocation ratio (E : C) 1:1 1:1
Attrition rate 15% 20%
Required sample size*** 320 1122 1442
Table 3.1: Design parameters of a phase 2 TB trial based on Dorman et al. [101] and a
phase 3 TB trial based on REMox [106]. * Calculated assuming independence between
trials (note: overall type I error rate is the maximum over all possible treatment effects).
** An additional 6 week delay is typically required to determine culture status. *** Sample
sizes estimated using equations (3.1) and (3.2). NI = non-inferiority
additional 6 week wait is unlikely to exist in future as techniques for immediate detection
of TB are developed [105] and so 4 weeks may represent the shortest possible delay for
this outcome.
The efficiency of each design was measured by its expected sample size (ESS), that is,
the mean number of patients recruited to the trial before it is terminated [51]. ESS was
calculated under the null hypothesis for the I outcome since the aim of the MAMS design
is to reduce sample size requirements when evaluating ineffective treatments. The ESS
was compared between designs with roughly similar overall operating characteristics to
determine which is likely to require fewer resources when the experimental treatment is
ineffective on I. For a single-stage trial such as those in Table 3.1, the ESS is equal to the
total sample size since there is no opportunity for stopping before the planned end of the
study (except in extreme circumstances such as overwhelming efficacy of an arm).
To calculate the overall operating characteristics in the seamless designs (I 6= D) an
estimate of the positive predictive value, that is, the probability of a patient not relapsing
or being classed as a treatment failure given that they have a negative culture, was obtained
from a meta-analysis by Horne et al. [99] who estimated it to be 95% (95% CI (95%,
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96%)) for cultures taken at 2 months. This value was assumed to be the same for both
the experimental and control arms.
3.3.1 Two-stage phase 2 TB trial designs
Examples of two-arm two-stage phase 2 TB trial designs are shown in Table 3.2. These
are based on the design parameters of the study by Dorman et al. [101] and use culture
status at either 4 or 8 weeks of follow-up for both the intermediate and definitive outcome.
A constant recruitment rate of 200 patients/year was assumed in both stages to estimate
stage durations. All two-stage designs shown in Table 3.2 have the same maximum sample
size since they use identical final stage operating characteristics.
Although the maximum sample sizes of the two-stage designs shown in Table 3.2 are higher
than the corresponding fixed sample sizes, their expected sample sizes are much lower as
they allow recruitment to be stopped early if the experimental treatment does not show
sufficient benefit at the first stage. Increasing the power in the first stage reduces the
difference between the maximum and fixed sample sizes, however, this also increases the
ESS due to a larger first stage. A balance may therefore need to be made between these
two measures. As expected, the correlation between stages increases as the gap between
analyses decreases, however, by comparing designs with the same stagewise significance
levels or stagewise powers it can be seen that this only marginally increases the type I
error rate and power respectively. Unsurprisingly, the ESS is smaller when using a shorter
follow-up period since fewer patients are recruited during the first stage of the trial.
There appears little advantages in using many of the designs in Table 3.2 over the corre-
sponding fixed sample designs as they require much larger maximum sample sizes (possibly
with the exception of design (iv)), thus prolonging the evaluation of any treatment which
passes the first stage. However, should the arm under study perform poorly then the
two-stage designs allow evaluation to be stopped early unlike the fixed sample design,
thus saving resources. It should be noted that many multi-stage designs may exist for
any pair of operating characteristics α and ω, some of which require smaller sample sizes
than others. The next chapter will therefore focus on finding more efficient multi-stage
designs (both in terms of maximum and expected sample size) which are likely to be more
appealing in practice.
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3.3.2 Two-stage phase 2/3 TB trial designs
Examples of seamless two-stage TB trial designs incorporating both phase 2 and 3 of
testing are presented in Table 3.3. For reasons stated in Section 3.2.5, the maximum type
I error rate for these designs is the significance level used in the final stage (α2 = 0.025).
A constant recruitment rate of 200 patients/year was assumed for the intermediate (phase
2) stage and a much higher recruitment rate of 800 patients/year was used for the much
larger second (phase 3) stage. Under these assumptions the maximum duration of each
design is no longer than 5 years. If similar recruitment rates are assumed for the fixed
sample designs shown in Table 3.1 then the maximum duration of conducting both trials
separately is approximately 7.5 years assuming a modest delay between phases of two
years. Furthermore, the overall power of the seamless designs is over 80% which is much
higher than that for conducting trials separately (68%) and maximum sample sizes are
over 100 patients lower.
Design Stage (j) αj ωj nj Nj tj ESS|H0 ρ|H0 ρ|H1 αmax ω
(v)
1 0.5 0.90 56 134 0.67
723 0.10 0.08 0.025 0.813
2 0.025 0.90 1050 1312 3.84
(vi)
1 0.5 0.95 94 178 0.89
745 0.12 0.11 0.025 0.857
2 0.025 0.90 1050 1312 4.00
(vii)
1 0.2 0.90 156 252 1.26
464 0.16 0.14 0.025 0.815
2 0.025 0.90 1050 1312 4.28
(viii)
1 0.2 0.95 214 320 1.60
518 0.19 0.16 0.025 0.858
2 0.025 0.90 1050 1312 4.54
Table 3.3: Characteristics of two-arm two-stage seamless phase 2/3 TB trials where I
= culture status observed 14 weeks after randomisation and D = relapse status at 18
months. Key: for stage j, αj = stagewise significance level, ωj = stagewise power, nj =
total sample size required for analysis j, Nj = cumulative number of patients recruited
by the end of stage j, tj = predicted timing (in years) of the end of stage j, ESS|H0 =
expected sample size under the null hypothesis for I, ρ|Hh = correlation between stages
under hypothesis Hh, αmax = maximum type I error rate, ω = overall power.
The between-stage correlations in these designs are much lower than those in the phase
2 designs in Table 3.2 for two reasons. Firstly, the PPV is effectively 1 in designs where
I = D (see Appendix B) whereas the seamless designs here use a slightly lower value
(PPV=0.95). Secondly, the interim and final analyses are much further apart in terms
of sample size than in the phase 2 designs due to targeting a smaller effect on D, which
further reduces the correlation.
A downside of the seamless designs presented in Table 3.3, as illustrated by the high ESS,
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is that ineffective arms have a reasonable chance of proceeding to the final stage of the
trial. This is due to using a high significance level in the first stage. This is in contrast
to the fixed sample designs in Table 3.1 which use a smaller significance level in the phase
2 trial and have a smaller ESS. The large gap between the first and final analyses in the
2-stage designs means that an extra intermediate stage could be added to the trial to
combat this. For example, adding a second intermediate stage with 95% power and a
10% significance level to design (vi) in Table 3.3 reduces the ESS to 377 with only a 3%
reduction in overall power. This loss in power can be recovered by slightly increasing the
stagewise powers which will also slightly increase the ESS. Identifying multi-stage designs
which maintain the overall operating characteristics but have desirable properties such as
minimising the expected or maximum sample sizes is investigated in the next chapter.
There is clearly much more benefit in using the MAMS design for seamless phase 2/3 TB
trials than for phase 2 alone compared to conventional fixed-sample designs for each phase
of testing. The designs in Table 3.3 show that savings in time and resources and simulta-
neous gains in power can be achieved by using seamless two-arm two-stage trials over the
more conventional approach. For multi-arm multi-stage seamless trials, the savings will
potentially be much greater compared to conducting separate phase 2 and phase 3 trials
for each experimental treatment.
3.4 Simulation study
Performing a standard maximum likelihood analysis in a multi-stage trial ignores stopping
guidelines implemented in previous interim analyses and may therefore result in biased
treatment effect estimates [114]. Choodari-Oskooei et al. [114] investigated the extent of
this bias for two-arm multi-stage trials with time to event outcomes. For arms stopped
at the first interim analysis for lack-of-benefit they showed that on average the estimated
treatment effects appeared slightly less effective than their corresponding true values.
However, the bias was markedly reduced by continuing to follow-up patients under protocol
conditions on the intermediate and definitive outcomes and reanalysing the data at the
planned end of the trial. Importantly, for truly effective arms, they showed that the bias
in the estimated treatment effects on the definitive outcome at the final stage analysis was
of no practical importance.
In the time to event case, interim analyses occur when a pre-specified number of events
have been observed in the control arm. In arms in which recruitment is stopped early there
is scope for continuing to follow-up patients who have not yet experienced the event(s)
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of interest and including them in a reanalysis at the planned end of the trial to obtain
a less biased estimate of the treatment effect. This is also applicable when outcomes are
observed at the end of a fixed follow-up period (e.g. binary outcomes) since not all patients
will have had both their intermediate and definitive outcomes observed by each interim
analysis.
A simulation study was conducted using the two-stage phase 2 and phase 2/3 TB trial
designs shown in Tables 3.2 and 3.3 respectively to quantify the bias in treatment effects
estimated on the definitive outcome at:
(a) The first interim analysis in arms which are not continued to the second stage.
(b) A reanalysis of the same arms (against all control arm patients recruited concur-
rently) after intermediate and definitive outcome data have been obtained from all
patients.
(c) The final stage analysis of all arms which pass the intermediate stage.
Phase 2/3 designs in which the follow-up period for I was 4 weeks (designs not shown)
were also used to investigate the effect of follow-up length in (b).
In addition to bias, the proportion of arms for which recruitment is stopped at the first
interim analysis and the proportion which continue recruiting to the final stage of the trial,
as well as the pairwise type I error rate (α), power (ω) and correlation between stages were
determined in the simulations and compared to their corresponding calculated values.
For each design shown in Tables 3.2 and 3.3, the bias associated with the four pairs of
underlying treatment effects shown in Table 3.4 for the culture status (θ1) and relapse out-
comes (θ2) was investigated in the simulations. Note that for I = D designs in Table 3.2,
only θ1 applies.
By assessing bias in scenarios (a), (b) and (c) for the range of treatment effects in Table 3.4,
recommendations can be made for designing multi-stage trials which reduce bias. This
will help to improve the accuracy of treatment effect estimates which might be used, for
example, in future meta-analyses, policy-making decisions or the design of future trials.
3.4.1 Methods
To perform the bias assessment and assess the accuracy of the calculation of the pair-
wise operating characteristics, individual patient data were simulated for each phase 2
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Arm Description θ1 θ2
A Harmful — treatment effects worse than those
under H0
-5% -10%
B Ineffective — treatment effects under H0 0% -6%
C Mildly effective — treatment effects between
those under H0 and H1
8% -3%
D Effective — treatment effects under H1 13% 0%
Table 3.4: Underlying treatment effects on culture status (θ1) and relapse (θ2) outcomes
for four treatment arms investigated in simulations.
and phase 2/3 design under treatment effects A–D. In each case 40,000 replicates were
generated to estimate pass/fail rates to an accuracy of at least 0.5% at the 5% significance
level. For each patient, missing value indicators for the I and D outcomes were drawn
from Bernoulli distributions with parameters derived from Table 3.1. In the designs where
I 6= D, the probability of observing the definitive outcome was not conditional on ob-
serving the intermediate outcome. This reduces the correlation between stages compared
to the calculation given in Appendix B where all patients with a missing intermediate
outcome are also assumed to have a missing definitive outcome. However, these different
assumptions will indicate the robustness of the calculation of the overall type I error rate
and power.
Patient outcomes were drawn from Bernoulli distributions with control arm event rates
derived from Table 3.1. The underlying event rates for experimental arms A–D were found
by adding on the corresponding treatment effects shown in Table 3.4. Since the phase 3
outcome of relapse is dependent on culture status, the event rate for the former will differ
according to whether a patient’s culture status is positive (I = 0), negative (I = 1) or
missing. The estimate from Horne et al. (95%) [99] for the positive predictive value
(PPV=P (D = 1|I = 1)) was assumed for all arms. The probability P (D = 1|I = 0) for
each treatment arm was then found by rearranging the formula for total probability:
P (D = 1) = P (D = 1|I = 1)P (I = 1) + P (D = 1|I = 0)P (I = 0)
Unconditional event rates were used for patients with missing intermediate outcomes.
When simulating each trial, analyses were triggered once the pre-determined number of
control arm patients had their outcome of interest observed. The pairwise type I error
rate (α) and power (ω) for each design was calculated as the proportion of arms simulated
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under H0 (treatment arm B) and H1 (treatment arm D) respectively which passed all
stages of the trial. For each underlying treatment effect in each design, the absolute bias
in scenarios (a), (b) and (c) was calculated as the average deviation of all corresponding
treatment effect estimates from the true value.
3.4.2 Results
Table 3.5 shows that the overall type I error rate (calculated under H0 for the I outcome),
power and correlation between stages estimated from the simulations agree very well with
the corresponding calculated values shown in Tables 3.2 and 3.3. As expected, when
I 6= D the correlation between stages estimated from the simulations is slightly lower than
the calculated values for reasons given above. However, this only leads to a negligible
difference between the overall type I error rates and powers showing that their calculation
is robust to the assumed degree of dependence between observing each outcome.
Design
From calculation From simulation
ρ|H0 ρ|H1 α ω ρˆ|H0 ρˆ|H1 αˆ ωˆ
I = D =culture status
(i) 0.39 0.39 0.021 0.826 0.38 0.38 0.021 0.828
(ii) 0.50 0.50 0.023 0.870 0.50 0.50 0.024 0.872
(iii) 0.65 0.65 0.020 0.843 0.64 0.65 0.019 0.847
(iv) 0.76 0.76 0.023 0.883 0.76 0.76 0.023 0.885
I= culture status, D = relapse
(v) 0.10 0.08 0.015 0.813 0.07 0.06 0.014 0.809
(vi) 0.12 0.11 0.015 0.857 0.10 0.09 0.015 0.854
(vii) 0.16 0.14 0.008 0.815 0.12 0.11 0.008 0.811
(viii) 0.19 0.16 0.009 0.858 0.15 0.12 0.008 0.858
Table 3.5: Overall type I error rates, powers and correlations between stages obtained
from calculation and from simulations of designs (i)-(viii) in Tables 3.2 and 3.3. Key:
ρ|Hh = correlation between stages under hypothesis Hh, α = overall type I error rate, ω
= overall power. Hats indicate values estimated from simulations.
3.4.2.1 Bias in arms dropped at the first analysis
Table 3.6 summarises the simulation results for the proportion of arms dropped at the end
of the first stage and the absolute bias in their treatment effect estimates on the definitive
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outcome at the interim analysis (scenario (a)) and after all patients have completed follow-
up (scenario (b)). The proportion of arms dropped under H0 (treatment effect B) and H1
(treatment effect D) is as expected given the significance level and power in this stage.
The results show that, on average, treatment effects are underestimated in arms which do
not show sufficient benefit for continuation at the first interim analysis. When I = D the
absolute bias in such arms is quite high when a large significance level (50%) and relatively
low power (90%) is used (i.e. design (i) in Table 3.2) or, more generally, the earlier the
interim analysis occurs. In design (i) the magnitude of the absolute bias is over 9% under
H0. However, the bias is markedly reduced in a reanalysis after all remaining patients
have had their outcome recorded. The reduction in bias is greater when using a longer
follow-up period or, more generally, when more patients can be added to the reanalysis.
In this particular example, the magnitude of the absolute bias under H0 decreases from
9.5% to 6.5% for a 4 week follow-up and to 4.6% if outcome observation is delayed by 14
weeks after randomisation.
When using a relatively low significance level in the first stage (e.g. 20%) the bias is of no
practical importance in arms which are likely to be stopped at that analysis, particularly
after follow-up is complete. When I 6= D, the bias in the treatment effect estimates for D
is much lower than when the same outcome is used throughout the trial, even when the
first stage is small.
3.4.2.2 Bias in arms reaching the final analysis
Table 3.7 shows that treatment effects estimated at the final planned analysis of the trial
are overestimated on average, although the bias is generally not as large as it is for arms
dropped at the first analysis. The results suggest that bias decreases the further the
interim analysis is in terms of sample size from the final analysis (i.e. as the correlation
between stages decreases) and when the chance of proceeding to the final stage of the trial
is higher.
In the examples used in Table 3.7, the bias is practically zero when I 6= D, even for
ineffective arms. This is due to the very low correlation between stages in these designs
(roughly 0.1). However, even when the correlation is higher, for example when I = D,
the bias is still very small for arms which are likely to proceed to the final stage. Bias
is higher for ineffective arms, however, in a well-designed MAMS trial such arms should
have little chance of reaching the final stage.


























































































































































































































































































































































































































































































































































































































































































































































ω1 = 0.90 ω1 = 0.95
arm % Pass E(θˆD) bD % Pass E(θˆD) bD
I = D = culture status at 8 weeks
0.5
A -5% 35 -3.1% 1.9% 29 -2.2% 2.8%
B 0% 51 1.4% 1.4% 50 1.8% 1.8%
C 8% 78 8.6% 0.6% 83 8.7% 0.7%
D 13% 90 13.3% 0.3% 95 13.2% 0.2%
0.2
A -5% 6 0.9% 5.9% 5 2.4% 7.4%
B 0% 20 4.2% 4.2% 20 4.8% 4.8%
C 8% 65 9.5% 1.5% 73 9.5% 1.5%
D 13% 90 13.5% 0.5% 95 13.4% 0.4%
I = culture status at 8 weeks, D = relapse
0.5
A -10% 35 -9.8% 0.2% 30 -9.7% 0.3%
B -6% 51 -5.9% 0.1% 51 -5.8% 0.2%
C -3% 77 -3.0% 0.0% 83 -2.9% 0.1%
D 0% 90 0.0% 0.0% 95 0.0% 0.0%
0.2
A -10% 6 -9.4% 0.6% 5 -9.3% 0.7%
B -6% 20 -5.6% 0.4% 20 -5.5% 0.5%
C -3% 65 -2.9% 0.1% 73 -2.9% 0.1%
D 0% 90 0.0% 0.0% 95 0.0% 0.0%
Table 3.7: Simulation results showing the proportion of trials which continue to the final
(second) stage of the trial (% pass) and the absolute bias in the estimated treatment
effect on D at the final analysis. Key: θD = underlying treatment effect on the definitive
outcome, α1 = significance level in stage 1, ω1 = nominal power in stage 1, E(θˆD) =
average treatment effect on the definitive outcome in the final stage, bD = E(θˆD)− θD =
bias in the average treatment effect estimate on the definitive outcome in the final stage.
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3.5 nstagebin
To aid the design of multi-arm multi-stage trials with binary outcomes observed at a
fixed time point after randomisation, we have developed the nstagebin program for Stata
which operates in a similar manner to nstage [84] and nstagesurv (Chapter 2) for time
to event outcomes. Given a set of design parameters (number of arms, stages, target risk
differences, stagewise significance levels and powers etc), nstagebin estimates the required
sample sizes for the analysis at the end of each stage in addition to stage durations and
overall pairwise operating characteristics. The syntax for nstagebin is described below
along with dialog boxes for simplifying its use, particularly for first-time users. This
program was used to generate the two-stage designs shown in Tables 3.2 and 3.3 and the
output for design (v) is shown below.
3.5.1 Syntax and options
nstagebin, nstage(#) accrate(numlist) alpha(numlist) power(numlist)
arms(numlist) theta0(# [#]) theta1(# [#]) ctrlp(# [#]) [ppvc(#) ppve(#)
aratio(#) fu(# [#]) extrat(#) ltfu(# [#]) tunit(#)]
Note: the number of values given in each numlist must equal the number of stages in the
trial as specified in the nstage() option. The options for nstagebin are as follows:
Required:
nstage(#) # = J , the number of trial stages.
accrate(numlist) overall anticipated constant accrual rate, rj , per unit of trial time
(see tunit()) in each stage.
alpha(numlist) one-sided significance level, αj , for each pairwise comparison in
each stage.
power(numlist) nominal power, ωj , for each pairwise comparison in each stage.
arms(numlist) number of arms recruiting in each stage (including control arm).
theta0(# [#]) absolute risk difference under H0 for the I and D outcomes.
theta1(# [#]) minimum risk difference targeted under H1 for the I and D out-
comes.
ctrlp(# [#]) anticipated control arm event rate for the I and D outcomes.
Required only if the intermediate and definitive outcomes differ:
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ppvc(#) positive predictive value P (D = 1|I = 1) for the control arm.
ppve(#) positive predictive value P (D = 1|I = 1) for the experimental
arm under H1.
Optional:
aratio(#) # = A, the allocation ratio (number of patients allocated to each
experimental arm for each patient allocated to control). Default
# is 1.
fu(# [#]) length of follow-up period in units of trial time (see tunit()) for
the I and D outcomes. Default # is 0 (I and D outcomes both
observed immediately after randomisation).
extrat(#) delay in units of trial time (see tunit()) between observing the
final required outcome for an analysis and the beginning of the
next stage. Default # is 0 (no delay).
ltfu(# [#]) loss to follow-up rate for the I and D outcomes. Default # is 0
(no loss to follow-up for either outcome).
tunit(#) code for units of trial time: 1 = one year, 2 = 6 months, 3 = one
quarter (3 months), 4 = one month, 5 = one week, 6 = one day,
and 7 = unspecified. Default # is 7 (unspecified).
3.5.2 Output
nstagebin, nstage(2) arms(2 2) alpha(0.5 0.025) power(0.9 0.9) theta0(0 -0.06)
theta1(0.13 0) ctrlp(0.75 0.9) ppvc(0.95) ppve(0.95) accrate(200 800)
fu(0.27 1.5) extrat(0.075) ltfu(0.15 0.2) tunit(1)
n-stage trial design version 1.0.0, 07 May 2014
---------------------------------------------------------------
Sample size for a 2-arm 2-stage trial with binary outcome
---------------------------------------------------------------
Control arm I (D) event rate = 0.75 (0.90)
Attrition rate for I (D) outcome = 0.15 (0.20)
Operating characteristics
--------------------------------------------------------------------------
Alpha(1S) Power theta|H0 theta|H1 Length* Time*
--------------------------------------------------------------------------
Stage 1 0.5000 0.900 0.000 0.130 0.670 0.670
Stage 2 0.0250 0.900 -0.060 0.000 3.172 3.842
Pairwise 0.0147 0.813 3.842
Maximum 0.0250
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--------------------------------------------------------------------------
* Length (duration of each stage) is expressed in year periods
Cumulative sample sizes per arm per stage
---------Stage 1--------- ---------Stage 2---------
Overall Control Exper. Overall Control Exper.
---------------------------------------------------------------------------
Number of active arms 2 1 1 2 1 1
Accrual rate* 200.0 100.0 100.0 800.0 400.0 400.0
Patients for analysis 56 28 28 1050 525 525
Patients recruited** 134 67 67 1312 656 656
---------------------------------------------------------------------------
* Accrual rates are specified in number of patients per year
** Accounts for loss-to-follow-up rate and includes patients recruited
during follow-up periods
3.5.3 Dialog menu
In our experience, first-time users of nstagebin (and also nstage) often find the program
challenging. To improve its usability we have created an accompanying dialog box to
simplify the way in which design parameters can be entered into the program. Once
installed, the box can be accessed by typing “db nstagebin” into the Stata command
line. The tabs of the dialog box are presented in Figures 3.3–3.6 and show the input for
the example above.
In the first tab (‘Design parameters’ — Figure 3.3) the number of stages, allocation ratio,
trial time units and delay required for interim analyses are entered. In the second tab
(‘Operating characteristics’ — Figure 3.4) the significance levels, powers, accrual rates
and number of recruiting arms are chosen for each stage of the trial. In the third tab
(‘Intermediate outcome’ — Figure 3.5) the design parameters for the intermediate outcome
(if it differs to the primary outcome) are entered. These include the control event rate,
risk differences under H0 and H1, length of follow-up and loss to follow-up rate. On the
final tab (‘Primary outcome’ — Figure 3.6) the analogous parameters are entered for the
definitive outcome. Also on the third tab, the positive predictive values of I on D are
entered for the control and experimental arms.
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Figure 3.3: Screenshot of the first tab of the nstagebin dialog box: general trial design
parameters.
Figure 3.4: Screenshot of the second tab of the nstagebin dialog box: stagewise operating
characteristics.
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Figure 3.5: Screenshot of the third tab of the nstagebin dialog box: parameters for the
intermediate outcome (if applicable).
Figure 3.6: Screenshot of the final tab of the nstagebin dialog box: parameters for the
primary outcome.
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3.6 Discussion
In this chapter the MAMS design initially developed by Royston et al. [77, 83] has been
adapted to allow the use of binary intermediate and definitive outcomes which are ob-
served at the end of a fixed follow-up period and analysed using an absolute difference
in proportions. Throughout, TB has been used as an example of a disease area where
this MAMS approach could dramatically speed up treatment evaluation compared to the
traditional approach of separate, two-arm phase 2 and 3 trials. Savings in time and re-
sources and simultaneous gains in power are particularly large when using the MAMS
design to incorporate both phase 2 and phase 3 into a single seamless trial. However,
savings are also likely to be made when using the design for a multi-arm phase 2 trial if
poorly performing arms are dropped during the trial. Many new and repurposed drugs
are currently in clinical development for TB and so a large number of new regimens are
likely to be available for testing in phase 2 and 3 trials in the near future. Evaluating
them in separate, single stage trials will not only be costly but will prolong the discovery
of a simpler and shorter effective regimen by decades. Use of novel trial designs such as
the MAMS design is therefore recommended [10].
Further work is needed to determine the best intermediate outcome for long-term relapse
before the MAMS design described here can be used to evaluate TB treatments in a
seamless phase 2/3 trial. The methods used by Barthel et al [118], who evaluated the
performance of the MAMS design for time to event outcomes in four cancer trials, could
be applied to past TB trials. If the rate at which trials are incorrectly stopped for lack-
of-benefit on culture status at eight weeks is high then other intermediate outcomes will
need considering, such as culture status at other time points. Another candidate for the
intermediate outcome is time to culture conversion which is increasingly being used in
phase 2 trials and is arguably a more reliable endpoint for deciding whether to continue
a treatment to phase 3 [122]. The PanACEA consortium is conducting a MAMS trial
(ClinicalTrials.gov identifier NCT01785186) using this endpoint but since this is a phase 2
trial the definitive outcome is also time to culture conversion. Incorporating this outcome
into a MAMS design with a binary definitive outcome will require further extensions to
the methodology.
The amount of bias likely to be generated in various examples of phase 2 and phase
2/3 TB trials was investigated and was shown to often be of no practical importance in
arms reaching the final analysis. This is particularly the case for effective arms or when
treatment selection is based on an intermediate outcome different to the definitive outcome.
In general, the bias at the final analysis increases as the treatment effects estimated at each
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stage become more correlated. This is caused by having short stage durations in which
only a small amount of new data can be collected. Ensuring that stages are adequately
spaced is not only practical from the perspective of everyone involved in the trial but it
will also limit the amount of bias likely to be generated.
As shown by Choodari-Oskooei et al. [114], we also found that having an early first in-
terim analysis increased the bias of treatment effect estimates in arms dropped at this
analysis, particularly when the intermediate and definitive outcomes were identical. Bias
was markedly reduced in a reanalysis after all patients had completed follow-up. It should
be noted however, that the average treatment effect in arms which are stopped early for
lack-of-benefit (i.e. are statistically non-significant) will necessarily appear less effective
than their true value [123]. Freidlin and Korn [124] suggest that the most appropriate
comparator for the x% of trials stopped at the first interim analysis is the average treat-
ment effect estimate of the same outcome in the corresponding x% most extreme trials in
the corresponding fixed sample-size design (i.e. the design that has no interim analyses).
When taking this into consideration the bias estimates in Table 3.6 are nearly halved (data
not shown).
A calculation for the maximum type I error rate for a single experimental arm was given,
thus allowing strong control of this measure in a trial. However, as discussed in Sec-
tion 1.3.1 on page 23, in a multi-arm trial it may be more important to control the family-
wise type I error rate (FWER). In Chapter 5, a calculation will be derived for the FWER
of the MAMS design described here and by Royston et al. [77, 83]. This will allow the
MAMS design to be used in trials where FWER control is required, such as confirmatory
studies [20].
In summary, we have extended the MAMS design introduced by Royston et al. [83] to
binary intermediate and definitive outcomes, potentially opening up its use in many other
disease areas. We also introduced Stata software for facilitating the design of such trials in
practice. However, for the design to be potentially used in any disease setting, the method-
ology needs extending further to all types of outcome measures and also any combination
of outcomes (e.g. a continuous I and a binary D outcome). We applied the MAMS design
for binary outcomes to a TB setting and showed considerable savings in time, sample size
and gains in power are possible compared to more conventional approaches to phase 2 and
3 trials which are still routinely used in practice.
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4.1 Introduction
The nstage program in Stata [84] is currently used to facilitate the design of trials which
use the multi-arm multi-stage (MAMS) approach described by Royston et al. [83] for time
to event outcomes. Among other things, this program requires the user to choose the
number of stages and the significance level and power in each stage of the trial in order
to determine the required sample sizes, number of events, approximate timing of each
analysis and the overall type I error rate, α, and power, ω, for each pairwise comparison.
Similar programs (nstagesurv and nstagebin) were introduced in Chapters 2 and 3 for
other time to event outcomes and binary outcomes respectively.
When designing a trial, one usually wishes to control the overall operating characteristics
α and ω rather than the stagewise operating characteristics at particular levels (e.g. α =
0.025, ω = 0.9). Designs which achieve these pairwise operating characteristics are called
feasible [125]. However, using the appropriate nstage- command alone to find such designs
is currently quite challenging as users cannot simply enter their desired values of α and
ω and be presented with a list of stagewise operating characteristics to use. Instead, one
has to use a trial-and-error approach by searching over various sets of stagewise operating
characteristics until a feasible design is found. This approach is not ideal as there are likely
to be many feasible multi-stage designs for any pair of values of α and ω, some requiring
smaller sample sizes than others. Finding a wide range of such designs will therefore be
important to ensure that the chosen design is the most efficient and/or the most suitable
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to use in practice. However, achieving this using the appropriate nstage- command alone
will be difficult and time-consuming and so a new approach to designing MAMS trials is
needed.
Previous MAMS trials (e.g. the STAMPEDE trial) have used the recommendations given
by Royston et al. [83] to choose the stagewise significance levels and powers. They advise
using high power in the intermediate stages (e.g. at least 0.95) and also the final stage
(e.g. at least 0.90) to ensure high overall power for the trial. The reason for using higher
power in the intermediate stages is to give effective arms a strong chance of reaching the
final stage [78]. Royston et al. [83] then go on to suggest using a descending geometric
sequence such as αj = 0.5
j for the significance levels in the intermediate stages and using
a final stage one-sided significance level of 0.025 to mimic a conventional two-sided 0.05
significance test. It should be noted that these recommendations were made for practical
reasons to ensure that analyses are roughly equally spaced and to allow a decision on
dropping arms to be made reasonably early in the trial, rather than to achieve a particular
overall type I error rate or power. For instance if, say, the overall desired power is 0.8 then
the recommended stagewise powers may be too high. Royston et al. [83] also acknowledge
that a more systematic approach is needed to find stagewise operating characteristics
which give efficient designs.
In adaptive designs with treatment selection such as the MAMS design, efficiency can be
measured by the number of patients that are expected to be recruited to the trial before it
is terminated, known as the expected sample size (ESS). Finding feasible MAMS designs
which minimise the ESS for a particular underlying treatment effect, referred to as optimal
designs [51], are therefore of particular interest. Popular choices of optimal designs in trials
which can stop for lack-of-benefit only (e.g. Simon’s 2-stage design [126]) are those which
minimise the ESS under the null hypothesis or the maximum sample size (MSS), known
as the null-optimal and minimax designs respectively. However, both designs have been
shown to perform relatively poorly under effects for which they are not optimised [127].
For instance, the null-optimal design has a high maximum sample size while the minimax
design has a high ESS under the null hypothesis. Instead, designs which minimise a more
balanced weighted sum of these two optimality criteria, known as admissible designs [127],
can possess the desirable properties of both the null-optimal and minimax designs.
In this chapter, we first propose a method for finding a set of feasible two-arm multi-
stage trials by applying a grid search technique to the stagewise operating characteristics.
Constraints are added for designs with more than two stages to accelerate the search
procedure. Admissible designs are then found for examples in which the intermediate and
definitive outcomes are either the same or are different. We compare the efficiency of these
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admissible designs to those found using a method based on the recommendations made
by Royston et al. [83] for choosing stagewise parameters (described above). The effect
that the number of stages has on the efficiency of two-arm trials is explored and a Stata
program for finding admissible designs with binary outcomes is introduced. Throughout,
multi-stage designs with binary outcomes are considered but the methods can be easily
applied to designs with other types of outcome.
4.2 Finding feasible designs
Given a pairwise type I error rate, α, and power, ω, for a J-stage trial, some basic principles
for choosing the stagewise significance levels and powers are as follows:
1. The significance level and power in each stage must be no lower than the correspond-
ing overall desired values: αj ≥ α and ωj ≥ ω for all j = 1, . . . , J .
2. Significance levels should decrease with each stage so that stopping guidelines become
more stringent as the trial progresses: αj+1 < αj for all j = 1, . . . , J − 1.
3. The power in the intermediate stages of the trial should ideally be at least as high
as the final stage power to give effective experimental arms a stronger chance of
reaching the planned end of the trial, thus allowing more data to be collected for
these arms: ωj ≥ ωJ for all j = 1, . . . J − 1.
4. Since treatment effect estimates at different stages will be correlated, sets of stagewise
operating characteristics which satisfy α1α2 . . . αJ ≤ α and ω1ω2 . . . ωJ ≤ ω need
only be considered.
4.2.1 Two-stage designs
In the simplest case of a 2-stage design there are two significance levels (α1 and α2) and
two powers (ω1 and ω2) to choose. To find a set of feasible designs, a grid search over
all values of α1, α2, ω1 and ω2 satisfying the above principles can be used. To limit the
search time it should only be necessary to search over α1, ω1 and ω2 in increments of
0.01. Using a smaller incrementation is not likely to result in designs with much greater
efficiency and will avoid the use of ‘unusual’ operating characteristics. However, to ensure
a reasonable number of feasible designs are found, the final stage significance level, α2,
should be searched over in smaller increments, for example 0.001, as it has the largest
influence over the overall type I error rate.
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Significance levels between 0.1 and 0.5 need only be considered for the first stage to avoid it
being too lengthy (which may reduce efficiency) or too small (which could increase bias and
the risk of spurious findings). All powers equal to or above ω should be considered for stage
1. Given suitable values of α1 and ω1, the principles listed above then imply that the choice
of significance level and power in the final stage is constrained by α ≤ α2 ≤ min(α1, α/α1)
and ω ≤ ω2 ≤ min(ω1, ω/ω1) respectively.
4.2.2 Multi-stage designs
To find feasible designs with more than two stages, a similar grid search over all plausible
stagewise operating characteristics could be used. However, the addition of an extra two
parameters to search over for each additional stage will drastically increase the search time,
thus making it impractical. Limiting the number of parameters that are to be searched
over by imposing constraints on the choice of stagewise operating characteristics can ease
this problem.
A reasonable starting point is to restrict the power in all intermediate stages to be the
same and allow only the power in the final stage to differ. This means that only two power
parameters need to be considered. Principle 3 implies that the power in each intermediate
stage, ωI , should be at least as high as the power in the final stage, ωD, to allow effective
arms a strong chance of proceeding to the final stage of the trial. The multi-arm multi-
stage STAMPEDE trial in prostate cancer, for instance, uses ωI = 0.95 and ωD = 0.90 [80].
For the same reasons as in the 2-stage case, it should only be necessary to explore powers
in increments of 0.01.
To limit the number of significance level parameters that need to be searched over (e.g. to
a maximum of two) and to satisfy principle 2 above, a monotonically decreasing function
can be used to automatically determine the significance levels which are not included in the
search. An ‘α-function’ similar to that proposed by Royston et al. [83] which determines




1 j = 1, . . . , J − 1. (4.1)
To find a range of feasible designs using this function, various values of α1 can be searched
over with the final stage significance level, αJ , chosen such that the desired type I error
rate is achieved. However, very few sets of significance levels will be searched over using
this function and so few, if any, feasible designs are likely to be found. This will be
demonstrated later in this chapter.
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An alternative, more flexible, family of functions defined by a parameter 0 ≤ r ≤ 1 and





J − 1 + αJ
j − 1
J − 1 j = 1, . . . , J. (4.2)
By performing a grid search over α1 and αJ , this function can be used to automatically
determine the significance levels for stages j = 2, . . . , J − 1 for a range of prespecified
values of r. The search time will therefore be longer than it is when using (4.1), however,
a larger number of feasible designs are likely to be found.
The shape of both of the above α-functions are shown in Figure 4.1 for J = 3, 4 and 5
stages, α1 = 0.5, αJ = 0.05 and, for (4.2) only, r = 0 (linear), 0.5 and 1 . The stagewise
significance levels corresponding to each function are shown in Table 4.1 with intermediate
significance levels rounded in units of 0.01 for practical reasons. In a later section, the
























































Figure 4.1: Examples of α-functions generated using (4.1) (“Royston’s function”) and
(4.2) for r = 0, 0.5 and 1, J = 3, 4 and 5 stages, α1 = 0.5 and αJ = 0.05.
Figure 4.1 shows that as r increases, the α-functions in (4.2) become more curved. This
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Number of
Stage
r in (4.2) Royston’s
stages, J 0 0.5 1 function (4.1)
3
1 0.50 0.50 0.50 0.50
2 0.28 0.20 0.15 0.25
3 0.05 0.05 0.05 0.05
4
1 0.50 0.50 0.50 0.50
2 0.35 0.25 0.18 0.25
3 0.20 0.13 0.09 0.13
4 0.05 0.05 0.05 0.05
5
1 0.50 0.50 0.50 0.50
2 0.39 0.28 0.20 0.25
3 0.28 0.17 0.11 0.13
4 0.16 0.10 0.07 0.06
5 0.05 0.05 0.05 0.05
Table 4.1: Stagewise significance levels obtained from the α-functions shown in Figure 4.1
for 3-, 4- and 5-stage designs.
causes the significance level to decrease more rapidly during the initial stages, thus increas-
ing their sample size and duration (except for the first stage, whose duration is determined
by the fixed value α1). The functions then level off and so the number of patients recruited
in the later stages will decrease. From Table 4.1 it appears that using a value of r greater
than 1 for a large number of stages (e.g. J = 5) will result in negligibly small decre-
ments in the significance levels between later stages, thus making them too small. On
the other hand, α-functions which curve in the opposite direction will have very short
early intermediate stages, while later stages will be lengthy. Such designs are likely to be
impractical and inefficient and therefore only values of r between 0 and 1 are considered
in this chapter.
Table 4.1 also shows that for three or four stages, the significance levels found using (4.1)
almost coincide with a set found using (4.2). In the 5-stage example, the decrease in the
significance level between the penultimate (α4 = 0.06) and final stages (α5 = 0.05) using
Royston’s function is too small and unlikely to result in a practical design. Nonetheless,
both families of functions are considered later in this chapter to see which produce the
most efficient designs.
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4.2.3 Technical and practical considerations
No multi-stage design is likely to have pairwise operating characteristics exactly equal to
the desired values of α and ω and so it will be necessary to class designs with operating
characteristics close to these values as feasible. In the examples later in this chapter, we
consider designs with pairwise operating characteristics α± δα and ω ± δω to be feasible,
where δα and δω are small enough without being too lenient and yet large enough so that
a reasonable number of feasible designs are found. Our empirical investigations suggest
that δα = δω = 0.0005 are a reasonable choice.
A practical requirement of a multi-stage design is that each stage should be long enough to
accumulate a ‘meaningful’ amount of new data for the next interim analysis [80]. Not only
does this help to reduce the amount of bias generated by the design but it is also practical
from the perspective of the trial team and trial committees as it ensures that interim
analyses (for which a considerable amount of work is often required [85]) are adequately
spaced. This practicality can be achieved by imposing a constraint in the feasible design
search so that only those designs which will recruit a prespecified proportion, pi, of their
maximum sample size during each stage of the trial are chosen. The maximum value of pi
is determined by the number of stages that one wishes to use, and vice-versa. In general,
it will either be necessary to choose a value of pi less than 1/J for a J-stage trial or, for a
given value of pi, no more than b1/pic stages may be used.
4.3 Optimal designs
There are likely to be many feasible designs for any pair of values of α and ω. It is therefore
not appropriate to choose any such design as it may not be the most efficient one to use in
practice. Instead, designs which are the most efficient (i.e. minimise the expected sample
size) for a particular underlying treatment effect, referred to as optimal designs, are of
particular interest.
4.3.1 Expected sample size
Let N denote the realised sample size of a multi-stage trial and let θI be the true treatment
effect for the binary intermediate outcome. Assuming the stopping guidelines at each stage
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will be adhered to, the expected sample size, E(N |θI), of a two-arm J-stage trial is
E(N |θI) = N1 +
J−1∑
j=1
(Nj+1 −Nj)P (experimental arm passes stage j|θI) (4.3)
where Nj is the total sample size recruited to the trial by the end of stage j. In the time to
event case, the stage-end times are instead governed by the observed number of events in
the control arm. The expected number of events is therefore a more appropriate measure
to consider in this case and can be calculated by simply replacing the sample sizes in (4.3)
with the estimated number of events observed under θI .
The probability in (4.3) is calculated as follows. Assume that θI > θ
0
I represents a positive
effect of the experimental treatment over control on the intermediate outcome where θ0I is
the treatment effect under H0. For any θI , the probability of the experimental arm passing























where σj is the standard deviation of the observed treatment effects under θI in the jth
stage. If θI < θ
0
I represents a beneficial effect of the experimental treatment, a similar
calculation shows






The cumulative probability of an experimental arm passing the jth stage of the trial is
then
P (experimental arm passes stage j|θI) = Φ(zp1 , . . . , zpj ;Rj) (4.4)
where Rj is the between-stage correlation matrix for the first j stages of the trial (see
Appendix B for binary outcomes or [83] for time to event outcomes).
In trials which allow stopping for lack-of-benefit only, E(N |θI) is monotonically increasing
over θI and ranges between the minimum and maximum possible sample sizes N1 and
NJ respectively. In the class of MAMS designs discussed here, there is also often the
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opportunity for stopping early at an interim analysis for overwhelming benefit on the
definitive outcome. For instance, the STAMPEDE trial uses the Haybittle-Peto rule [128,
129] so that if p < 0.001 on D for a particular arm then that arm (or the whole trial) is
stopped for efficacy [81]. Such a rule will have a negligible impact on the ESS for very
small treatment effects but it may be more influential as the effect on D increases; that is
unless there is little data available on this outcome at the interim analysis. Incorporating
this stopping guideline into the calculation should be straightforward when I = D but
may be more complex when I 6= D since the ESS will be a function of two correlated
parameters — θI and the underlying treatment effect on D, θD. However, since the same
efficacy stopping rule is used in any MAMS design, it is unlikely to have an impact on
distinguishing which designs are the most efficient in terms of ESS. For this reason and
also to avoid complicating the calculation of ESS, we will ignore the efficacy stopping
guideline throughout this chapter.
4.3.2 Null-optimal designs
A major reason for using stopping guidelines for lack-of-benefit is to reduce the amount
of resources required when evaluating ineffective treatment arms. The design which best
achieves this will be the one which minimises the ESS under the null hypothesis, H0.
Under H0, θI = θ
0
I and so pj = αj , as expected. Hence
P (experimental arm passes stage j|H0) = Φ(zα1 , . . . , zαj ;Rj)
which is denoted by Aj using the notation in Section 3.2.7. Thus the expected sample size
under H0 is
E(N |H0) = N1 +A1(N2 −N1) + · · ·+AJ−1(NJ −NJ−1) (4.5)
Designs which minimise E(N |H0) are referred to as ‘null-optimal’ and are a suitable choice
of design if, for example [130]:
• The experimental treatment is very expensive or toxic and should therefore be
stopped as early as possible if it is ineffective.
• The trial requires a very large sample size and should therefore be terminated as soon
as possible to save large amounts of future time and resources if the experimental
treatment is ineffective.
• There is reason to believe that the null hypothesis is true, in which case the trial
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should arguably not go ahead.
4.3.3 Minimax designs
Another useful measure of sample size which, unlike the ESS, will be known in advance
of the trial commencing is the maximum number of patients that could be recruited
to the trial, or maximum sample size (MSS). If there is some reason to believe that the
experimental treatment is truly effective, for instance, because of data from previous trials,
then it will be important to limit MSS as much as possible to avoid a lengthy trial. This
would also be desirable if, say, recruitment to a trial is likely to be slow (for example,
because the disease in question is rare) in order to limit the maximum possible duration
or size of the trial. Designs which have the lowest maximum sample size are referred to
as minimax designs [126].
4.4 Admissible designs
Although the null-optimal and minimax designs are appealing in certain circumstances,
Jung et al. [131] showed that in Simon’s 2-stage design they are unlikely to be the most
suitable choice of design in practice. For instance, the null-optimal design tends to have a
relatively large MSS, while the minimax design has a relatively large ESS under H0. By
plotting the expected and maximum sample sizes of various feasible 2-stage designs, Jung
et al. [131] found that designs often exist which have an expected sample size close to that
of the null-optimal design but a smaller maximum sample size, or a maximum sample size
similar to the minimax design but a smaller expected sample size.
Such designs can be found by minimising the following loss function, L(q) for some q ∈
[0, 1], defined by Jung et al. [127] which is a weighted sum of the expected sample size
under H0 and the maximum sample size:
L(q) = qmax(N) + (1− q)E(N |H0) (4.6)
Feasible designs which minimise (4.6) for some q ∈ [0, 1] are called admissible. Special
cases are the null-optimal (q = 0) and minimax (q = 1) designs, but other admissible
designs which minimise a more balanced weighting of the two measures may exist. Jung
et al. [127] found that these ‘balanced’ admissible designs are often much more appealing in
practice as they usually possess similar desirable properties to the null-optimal or minimax
designs but do not have such large maximum or expected sample sizes respectively.
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Likewise, Wason et al. [125] found that when stopping for efficacy is also allowed, the
design which minimises the maximum expected sample size, referred to as the δ-minimax
design, is unlikely to be the most appealing one to use in practice. Admissible designs can
often be found which have a marginally higher maximum ESS but a much smaller MSS
and vice versa.
4.5 Example when I = D
4.5.1 Design parameters and fixed sample sizes
The methods described in Section 4.2 were used to find feasible 2-, 3-, 4- and 5-stage trials
where the intermediate (I) and definitive (D) binary outcomes were the same. Admissible
designs were found for overall operating characteristics (α, ω) = (0.025, 0.9), (0.025, 0.8)
and (0.05, 0.8) and a minimum target treatment effect (risk difference), θ1, of 0.2. To
compare the choice of admissible designs when the required sample size is much larger, a
target effect of θ1 = 0.1 was also investigated.
Other design parameters were: 1:1 allocation ratio, control arm event rate of 0.5, target
effect under H0 of θ
0 = 0, no loss to follow-up and no follow-up period (i.e. outcomes ob-
served immediately after randomisation). The required sample sizes for the corresponding
fixed-sample designs, i.e. those designs with no interim analyses, are shown in Table 4.2














Table 4.2: Required sample sizes of fixed sample designs with type I error rate α and
power ω to detect a minimum treatment effect of θ1.
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4.5.2 Admissible I = D designs
Designs with overall operating characteristics within ±0.0005 of the desired values and
which planned to recruit at least 10% of the maximum sample size in each stage (pi = 0.1)
were considered feasible. For designs with more than two stages, α-functions shown in
(4.2) using r = 0, 0.25, 0.5, 0.75 and 1 were used in the feasible design search. The
set of admissible designs was then found for each set of design characteristics (α, ω, θ1, J).
Designs which minimised L(q) defined in (4.6) for any q between 0 and 1 in 0.01 increments
were deemed admissible. For each set of design parameters, several designs were often
deemed admissible for q = 1 (minimax design) and so the design with the lowest ESS
under H0 was chosen. Admissible designs were also found using the α-function shown in
(4.1) for comparison.
In total, 36 2-stage, 80 3-stage, 41 4-stage and 17 5-stage feasible designs were found for
(α, ω, θ1) = (0.025, 0.9, 0.2) using (4.2). Table 4.3 shows the stagewise operating charac-
teristics of the admissible 2-, 3-, 4- and 5-stage designs for this set of design parameters.
The range of values of q (‘q-range’) for which each design minimises the loss function are
also presented along with the sample size of the smallest stage in each design. As expected,
stages tend to become smaller as the number of stages increases. For instance, the size
of the smallest stage in the 5-stage minimax design is just 26 patients whereas it is 70
patients for the 2-stage design.
Minimax designs (admissible for q = 1) use a high power in the intermediate stages so
that the lowest possible power is chosen in the final stage, thus reducing the maximum
sample size. The stagewise powers in the intermediate and final stages then balance out
as q decreases (i.e. as E(N |H0) becomes more of a factor in choosing a design). In all
cases, admissible designs used a small value of r (r ≤ 0.5 — i.e. a less curved α-function).
The maximum sample size of all designs in Table 4.3 is at least as large as that for the
fixed-sample design (N = 242). This increase in the maximum sample size is required
to compensate for the use of interim analyses where a type II error may be made, thus
maintaining the power at the desired level. The increase in maximum sample size therefore
tends to be larger for designs using more stages. Interestingly, in this example, the 2-stage
minimax design has the same maximum sample size as the fixed-sample design showing
that it is possible to implement an interim analysis without resulting in a potentially larger
trial.
The general pattern observed in Table 4.3 is that as the maximum sample size of the
admissible designs increases, the ESS under H0 decreases. Figure 4.2(a) plots these values
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and shows that this trend is non-linear. In particular, designs can be found which have a
similar ESS under H0 to the null-optimal or a similar MSS to the minimax designs, but
which also have much more desirable values of the MSS or E(N |H0) respectively. For
example, in the 5-stage null-optimal design (admissible for q ∈ [0.00, 0.23]) E(N |H0) is
124 and the MSS is 288 whereas the 5-stage design which is admissible for q ∈ [0.24, 0.56]
has an MSS which is 26 patients lower and E(N |H0) is just 8 patients higher.
Figure 4.2(a) also illustrates that E(N |H0) tends to be lower for designs using a larger
number of stages. For admissible designs with roughly equal MSS, E(N |H0) is substan-
tially reduced by using three stages rather than two particularly for larger maximum
sample sizes. In some cases using more than three stages can reduce E(N |H0) slightly
further, however, the small saving may not warrant the added workload of an extra interim
analysis. Interestingly, this was also the case for admissible designs targeting a treatment
effect of θ1 = 0.1 (Figure 4.2(b)). This shows that 3-stage designs provide a good tradeoff
between efficiency and the maximum number of interim analyses required regardless of
the required sample size. Similar results were observed in plots of E(N |H0) vs MSS for
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Figure 4.2: Expected sample sizes under H0 versus maximum sample sizes of admissible
2-, 3-, 4- and 5-stage designs for α = 0.025, ω = 0.9 and target treatment effects of (a)
θ1 = 0.2 (left) and (b) θ1 = 0.1 (right). The vertical dashed lines represent the sample
size, N , of the corresponding fixed-sample designs: (a) N = 242 and (b) N = 1030.
A limitation of these plots is that they only consider the ESS for highly effective arms
(equal to the MSS) and the ESS under H0. In reality, the true effect of a treatment
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is likely to lie somewhere in between. Considering the ESS of admissible designs over
a range of other underlying treatment effects may therefore be of value when choosing
which design to use. Figure 4.3 shows the ESS over a range of true treatment effects, θ,
for designs in Table 4.3 which minimise L(q) for q = 0 (null-optimal), 0.5 (‘balanced’) or
1 (minimax). The ESS for values of θ between 0 (the null effect) and 0.25 (roughly where
the ESS is maximised in this example) were calculated using (4.3). Figure 4.3 shows that
the null-optimal and minimax designs would not perform well for very large or very small
treatment effects respectively. By contrast, the balanced designs tend to have relatively
low expected sample sizes over the full range of treatment effects. They are therefore
likely to be a better choice of design in practice particularly if there are no strong beliefs
about the effectiveness of the treatment under study. Considering plots such as those in
Figures 4.2 and 4.3 for all admissible designs are clearly useful in deciding which design
to use for a particular trial.
4.5.3 Comparison with Royston’s α-functions
As stated in Section 4.2.2, multi-stage designs could also be generated using an α-function
similar to that proposed by Royston et al. [83], as shown in (4.1). We used a similar
approach to that above to find admissible 3- and 4-stage designs using (4.1) for all sets of
operating characteristics that were investigated in the previous section and compared their
resulting maximum and expected sample sizes under H0 to the corresponding admissible
designs found using (4.2). In all examples, a minimum risk difference of θ1 = 0.2 was
targeted under H1.
Two-stage designs were not considered because exactly the same search procedure is im-
plemented in both cases (i.e. a full grid search). Five-stage designs were also not explored
as they were shown in the previous section to carry little, if any, added efficiency over
4-stage designs.
The results comparing admissible 3- and 4-stage designs found using (4.1) and (4.2) are
presented in Figure 4.4. Although the admissible designs identified using (4.1), represented
by the solid points, tend to only be slightly less efficient that those found using (4.2), the
number of admissible designs is substantially smaller. For instance, there were only two
4-stage admissible designs found using (4.1) for (α, ω) = (0.025, 0.9) due to the relatively
small number of feasible designs which were discovered using this approach (e.g. ten 3-
stage and four 4-stage designs for this set of operating characteristics). By comparison,
using (4.2) results in a larger number of feasible, and hence admissible, designs to choose
from. Due to the inflexibility of the α-function in (4.1) and the results in Figure 4.4, we
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Figure 4.3: Expected sample sizes over a range of underlying treatment effects for 2-, 3-,
4- and 5-stage null-optimal (q = 0), minimax (q = 1) and balanced (q = 0.5) designs with
α = 0.025, ω = 0.9 and θ1 = 0.2. The horizontal dotted line is the size of the fixed-sample
design (N = 242).
will not consider this function further.
Interestingly, the original design of the 4-stage STAMPEDE trial [80] was generated using
the recommendations made by Royston et al. [83] and in a later chapter we will investigate
whether a more efficient design could have been used for this trial, thus potentially saving
time and patient resources.
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a=0.05, w=0.8, q1=0.2
Figure 4.4: Expected sample sizes under H0 versus maximum sample sizes of admissible
3- and 4-stage designs obtained using α-functions shown in (a) (4.1) and (b) (4.2) for
θ1 = 0.2 and (α, ω) = (0.025, 0.9), (0.025, 0.8) and (0.05, 0.8). Vertical dashed lines are
the sample sizes of the corresponding fixed-sample designs.
4.6 Example when I 6= D
The previous section explored admissible designs where the D outcome is also used for
interim monitoring (I = D). In this section, designs using the same definitive outcome are
considered but using an I outcome which differs to D. As discussed in Chapter 3, when
the intermediate and definitive outcomes differ, the maximum type I error rate is equal
to the significance level in the final stage, αJ . This parameter therefore does not have to
be searched over when finding feasible designs since it is set equal to α, thus decreasing
the search time. However, a trial team may wish to instead control a different measure
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of the type I error rate such as that when the null hypothesis is also true for I. This is
not recommended as it may result in a design with an inadequately large type I error rate
should the arm under investigation be effective on I but not D.
When designing a multi-stage trial where I 6= D, several other factors have to be taken
into consideration compared to when I = D. One is the choice of the minimum targeted
treatment effect on the I outcome, θI . Firstly, θI should be no smaller in magnitude
than the target effect on D, θD, otherwise fewer patients might be required for the final
analysis than an interim analysis. On the other hand, targeting a larger effect on I than
on D is permitted and might be necessary if only a large effect on I is likely to translate
into a clinically important benefit on D. This will lead to shorter intermediate stages
which might not be practical but will nonetheless increase the efficiency of the trial by
allowing poorly performing arms to be dropped sooner. However, in doing so one might
increase the risk of missing smaller effects on I which could translate into a benefit on
D. For practical reasons, the STAMPEDE trial targeted a hazard ratio of 0.75 on both
the failure-free survival (FFS) and overall survival (OS) outcomes to help create more
uniformly spaced analyses, despite it being quite reasonable to expect larger effects on
FFS than OS [132–134].
To explore the impact of the choice of θI on the efficiency of a MAMS trial, targeted
effects on I of θI = 0.2 and θI = 0.25 were explored in designs which also targeted a
minimum risk difference of 0.2 on D. A positive predictive value (PPV) of 0.9 is assumed
throughout.
Tables 4.4 and 4.5 show 2-, 3- and 4-stage admissible designs for θI = 0.2 and 0.25 respec-
tively and (α, ω, θD) = (0.025, 0.9, 0.2). The tables show that admissible designs in which
θI = θD tend to use α-functions which are more linear (r ≈ 0) than when θI > θD. More
curved α-functions tend to be used for the latter to help reduce the large gap between the
penultimate and final analyses of the trial which is caused by targeting a larger treatment
effect on I than D. However, for a large number of stages this can result in the later
intermediate stages becoming impractically short due to increasingly smaller reductions
in the significance level between these stages (see Table 4.1).
Figure 4.5 plots the ESS under H0 and the MSS of the admissible designs in Tables 4.4
and 4.5 and shows that targeting a larger treatment effect on I can considerably increase
the efficiency of the trial under H0. For instance, the expected sample sizes under H0 of
the admissible designs for θI = 0.25 were on average over 15% lower than for θI = 0.2.
Despite this, when designing such a trial one should always target an effect on I no higher
than the minimum effect that is anticipated to translate into benefit on D in order to
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Figure 4.5: Expected sample sizes under H0 versus maximum sample sizes of admissible
2-, 3- and 4-stage designs with I 6= D, α = 0.025, ω = 0.9 and minimum target treatment
effects on I (θI) of (a) 0.2 (left) and (b) 0.25 (right). The vertical dashed lines represent
the sample size of the corresponding fixed-sample design (N = 242).
As in the I = D case (see Figure 4.2), Figure 4.5 also shows that the 3-stage designs tend
to be much more efficient under H0 than using two stages, while little extra efficiency,
if any, is gained by using four stages. Again, the null-optimal and minimax designs are
usually not the most suitable choice in practice as other admissible designs exist with
similar characteristics to these designs but much lower MSS or ESS under H0 respectively.
For instance, Table 4.4 shows that the MSS of the 4-stage design which is admissible
for q = (0.14, 0.40) is 32 patients lower than that for the 4-stage null-optimal design
in exchange for an ESS which is just 5 patients higher. Similar results can be seen in
Appendix D for other sets of operating characteristics.
The maximum sample sizes of all admissible designs above are higher than the corre-
sponding fixed-sample designs, as was the case for I = D designs. However, if the I 6= D
designs incorporated two phases of testing (e.g. in a seamless phase 2/3 design) then the
maximum sample sizes are likely to be somewhat smaller (depending on the size of the
phase 2 trial) than the total sample size of the phase 2 plus phase 3 fixed-sample trials.
In addition, the interlude between phases will be removed further reducing the maximum
duration of the trial.
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If the PPV is assumed to be lower than the value specified in the above example (0.9) then
the estimated correlation between the intermediate and final stages will be lower. This
means that the stagewise powers may have to be increased slightly to maintain the overall
desired power. As stated in Chapter 3, we recommend slightly underestimating the PPV
to avoid the risk of underpowering the trial. Alternatively, an adaptive approach similar
to that proposed by Todd [69] for bivariate group sequential trials could be used in which
the PPV is reestimated during the trial using observed data. The stagewise operating
characteristics of future stages can then amended to maintain the overall power, however,
the effect of implementing such a procedure in the MAMS design will require further work.
4.7 nstagebinopt
To aid the search for admissible two-arm multi-stage designs with binary outcomes, we
have developed the nstagebinopt program for Stata which implements the methods de-
scribed in this chapter for designs where I = D or I 6= D. The program works by first
finding a set of feasible designs for a given number of stages and overall operating char-
acteristics using a prespecified set of α-functions and then outputs the admissible designs
from this set for all q ∈ [0, 1]. The syntax and output of the program is described below.
4.7.1 Syntax
nstagebinopt, nstage(#) alpha(#) power(#) theta0(# [#]) theta1(# [#])
ctrlp(# [#]) [aratio(#) ppv(#) ltfu(# [#]) fu(# [#]) accrate(numlist)
pi(#) r(numlist) acc(#) save(string) plot]
4.7.2 Options
Required:
nstage(#) # = J , the number of trial stages.
alpha(#) overall desired maximum type I error rate.
power(#) overall desired power.
theta0(# [#]) absolute risk difference(s) under H0 for the I and D outcomes.
theta1(# [#]) minimum risk difference(s) targeted under H1 for the I and D
outcomes.
ctrlp(# [#]) anticipated control arm event rate(s) for the I and D outcomes.
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Optional:
aratio(#) # = A, the allocation ratio (number of patients allocated to each
experimental arm for each patient allocated to control). Default
# is 1.
ppv(#) positive predictive value P (D = 1|I = 1), assumed to be the
same in all arms (only needs specifying if I 6= D).
ltfu(# [#]) loss to follow-up rate for the I and D outcomes. Default # is 0
(no loss to follow-up for either outcome).
fu(# [#]) length of the follow-up period(s) in units of trial time for the
I and D outcomes. Default # is 0 (I and D outcomes both
observed immediately after randomisation).
accrate(numlist) overall anticipated constant accrual rate per unit of trial time in
each stage. This option is required only if fu() is specified and
is greater than zero.
pi(#) # = pi, the minimum proportion of the maximum sample size
that should be recruited in each stage. Default # is 0.1.
r(numlist) α-functions defined by parameter r which will be used to find
feasible designs. Default is r = {0, 0.25, 0.5} if I = D and r =
{0, 0.25, 0.5, 0.75, 1} if I 6= D.
acc(#) maximum absolute difference in type I error rate and power of
feasible designs from the values specified in alpha() and power()
respectively. Default # is ±0.0005.
save(string) file name in which to save the characteristics of the admissible
designs.
plot produces a plot of the expected sample sizes under H0 versus
maximum sample sizes of the J-stage admissible designs.
4.7.3 Algorithm
The algorithm that nstagebinopt uses to find the set of admissible designs proceeds as
follows:
1. For a value of r specified in r() and initial values of α1 = 0.5, ωI = ω, ωD = ω and
αJ = α, calculate αj using the specified α-function for j = 2, . . . , J − 1.
2. Calculate the required sample size, nj , for the jth analysis (j = 1, . . . , J).
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3. Estimate the overall pairwise type I error rate, α∗.
4. If the absolute difference between α∗ and α is less than the value specified in acc(),
estimate the overall pairwise power, ω∗.
5. If the absolute difference between ω∗ and ω is also less than the value specified in
acc(), calculate the ESS of the design under H0.
6. Store the design in a temporary dataset containing the set of feasible designs.
7. If I = D, repeat steps 2–6 for all plausible values of α1, αJ , ωI and ωD based on the
principles outlined in Section 4.2. If I 6= D then αJ does not need to be searched
over and is fixed at α.
8. Repeat steps 1–7 for all other values of r specified in r().
9. Load the dataset containing the final set of feasible designs. For each design, cal-
culate the loss function L(q) = qmax(N) + (1 − q)E(N |H0) for each q ∈ [0, 1] in
increments of 0.01. Output admissible designs and the range of values of q for which
they minimised the loss function.
4.7.4 Output
nstagebinopt outputs the stagewise operating characteristics, expected sample sizes un-
der H0 and maximum sample sizes of each admissible J-stage design which minimises the
loss function qmax(N) + (1− q)E(N |H0) for some q ∈ [0, 1]. The program can also save
this information in a Stata dataset by specifying the save() option and can produce a
plot of E(N |H0) versus max(N) by choosing the plot option. Each admissible design can
then be entered into the nstagebin program (see Section 3.5) to see the design in more
detail (e.g. stage durations and sample sizes).
The output from nstagebinopt is shown below for the 2-stage I = D and I 6= D designs
explored in Sections 4.5 and 4.6 respectively with α = 0.025 and ω = 0.9. A minimum risk
difference of 0.2 is targeted under H1 on D in both cases, with an effect of 0.25 targeted
on I in the latter.
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nstagebinopt, nstage(2) alpha(0.025) power(0.9) theta0(0) theta1(0.2) ctrlp(0.5)
-----------------------------------------------------------------
q-range Stage Sig. Power Alloc. E(N|H0) max(N)
level ratio
-----------------------------------------------------------------
[0.00,0.27] 1 0.29 0.94 1.00 151 272
2 0.030 0.94
-----------------------------------------------------------------
[0.28,0.33] 1 0.32 0.95 1.00 154 264
2 0.028 0.93
-----------------------------------------------------------------
[0.34,0.52] 1 0.33 0.96 1.00 158 256
2 0.027 0.92
-----------------------------------------------------------------
[0.53,0.82] 1 0.31 0.97 1.00 167 248
2 0.026 0.91
-----------------------------------------------------------------
[0.83,1.00] 1 0.34 0.99 1.00 196 242
2 0.025 0.90
-----------------------------------------------------------------
Note: each design minimises the loss function q*max(N)+(1-q)*E(N|H0) for
weights q specified in q-range.
nstagebinopt, nstage(2) alpha(0.025) power(0.9) theta0(0 0) theta1(0.25 0.2) ///
ctrlp(0.5 0.5) ppv(0.9)
-----------------------------------------------------------------
q-range Stage Sig. Power Alloc. E(N|H0) max(N)
level ratio
-----------------------------------------------------------------
[0.00,0.07] 1 0.28 0.95 1.00 130 284
2 0.025 0.94
-----------------------------------------------------------------
[0.08,0.14] 1 0.28 0.96 1.00 131 272
2 0.025 0.93
-----------------------------------------------------------------
[0.15,0.52] 1 0.28 0.97 1.00 133 260
2 0.025 0.92
-----------------------------------------------------------------
[0.53,1.00] 1 0.20 0.98 1.00 144 250
2 0.025 0.91
-----------------------------------------------------------------
Note: each design minimises the loss function q*max(N)+(1-q)*E(N|H0) for
weights q specified in q-range.
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4.7.5 Speed of nstagebinopt
For nstagebinopt to be of any practical use, it must run relatively quickly. The length
of time taken in seconds by the program to find the 2-, 3- and 4-stage admissible designs
in Tables 4.3 and 4.5 are shown in Table 4.6. Calculations were performed on an Intel(R)
Core(TM) i7 2.9GHz processor with 4GB RAM.




Table 4.6: Time taken in seconds for nstagebinopt to output the set of admissible 2-, 3-
and 4-stage designs shown in Tables 4.3 (I = D) and 4.5 (I 6= D). Key: J = number of
trial stages.
For any number of stages the program performed much more quickly for designs with
I 6= D than I = D. This is because when I 6= D, the final stage significance level is set
equal to the maximum desired type I error rate in order to control it in the strong sense
at that level. Thus, there is one less parameter to search over. For 2-stage designs, the
program output the set of admissible designs in less than one second for both I = D and
I 6= D. It was considerably slower for more than two stages due to the extra parameter, r,
being searched over and the added computation that designs using more stages requires.
Nonetheless it still only took less than 13 seconds when I 6= D. For I = D, it can take
the program 2–3 minutes to find 3- and 4-stage admissible designs, however, this is not so
long that the program becomes impractical to use.
4.8 Discussion
Designing a multi-stage trial to have a particular pairwise type I error rate and power using
nstage [84], nstagesurv (Chapter 2) or nstagebin (Chapter 3) alone is both difficult and
time-consuming. A cumbersome trial-and-error approach is required in which users must
continually tweak the stagewise operating characteristics until a design with the desired
α and ω is found. This approach is problematic as not all feasible designs are likely be
found and thus the most efficient, or optimal, designs for a particular true treatment effect
may be missed. The methods presented in this chapter address this problem by using a
systematic search procedure to find a large set of feasible designs and then selecting those
which minimise the loss function L(q) = qmax(N) + (1− q)E(N |H0) for some q ∈ [0, 1],
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known as admissible designs.
The null-optimal (q = 0) and minimax (q = 1) designs are special cases of admissible
design and are often popular choices for trials which allow stopping for lack-of-benefit
only [126]. However, we and other authors have shown that they are usually not the best
choice of design in practice [131]. For instance, the null-optimal design often requires a
large maximum sample size while the minimax design usually has a large ESS under H0.
Instead, other admissible designs can often be found which have similar characteristics to
the null-optimal and minimax designs but which have lower maximum or expected sample
sizes respectively. Such designs also tend to be more efficient for true treatment effects
between those under the null and alternative hypotheses which are more likely to be seen
in practice. We therefore recommend finding admissible designs for all values of q ∈ [0, 1]
and investigating their expected sample sizes under various treatment effects (e.g. as in
Figure 4.3) before choosing one to use in practice. Generally, designs which are admissible
for a broader range of values of q will perform better over a wider range of treatment
effects and may therefore be a safer choice of design in practice.
For two-arm trials we found that using three stages often provides much more efficiency
under H0 over 2-stage designs and that little more is gained by using four of five stages,
regardless of sample size. Further work is needed to explore whether this is also true
for time to event outcomes. Since a considerable amount of effort is usually required to
conduct interim analyses (see [85]), a 3-stage design will therefore provide a good trade-off
between efficiency and the maximum number of analyses required. Using fewer stages also
allows a larger amount of data to accrue between analyses which can help to reduce bias
in treatment effect estimates (see Chapter 3).
Throughout, we have assumed that trials can be stopped at an interim analysis for lack-
of-benefit only. However, as noted in Section 4.3.1, an efficacy stopping guideline is also
likely to be applied to the definitive outcome at each stage (e.g. the Haybittle-Peto rule).
Such a stopping boundary will have a negligible impact if the arm is ineffective, however, it
may be quite influential in reducing the expected sample size when evaluating a treatment
which is truly effective on D. Thus, the maximum sample size might be a less relevant
quantity than the ESS under H1, say. However, since the same efficacy stopping rule
would be used in all designs, we feel that ignoring it is unlikely to influence the set of
admissible designs which is identified. Further work is needed to fully investigate this and
to incorporate the efficacy stopping guideline into the methodology if found otherwise.
The loss function we used included two optimality criteria: the ESS under H0 and the
MSS. However, other factors could be used in place of or in addition to these criteria
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such as the expected sample size under H1. Mander et al. [135] defined admissible designs
of single-arm two-stage trials which can stop for futility or efficacy to be those which
minimised a two-parameter loss function incorporating the expected sample sizes under
H0 and H1 and the maximum sample size. However, when stopping for futility only, the
authors found that using the ESS under H1 as an optimality criteria in addition to the
MSS was shown to have little influence on the choice of admissible design. Using a similar
loss function for the MAMS designs discussed here will therefore not be necessary unless
the efficacy stopping guideline is shown to be influential in the admissible design search.
The methods presented in this chapter were used to find admissible multi-stage trials with
binary outcomes and a Stata program was developed to help implement the methods in
practice. Developing other Stata programs which apply similar methodology to MAMS
trials of other types of outcome measure such as time to event, should be relatively straight-
forward and is an area of future work. However, a major difference is that in the time to
event case, analyses are triggered by the number of control arm events rather than the
number of patients followed up and so consideration should be given to the expected and
maximum number of events required rather than the analogous values for sample size.
We introduced the family of α-functions shown in (4.2) which allows a larger number of
stagewise significance levels to be searched over than a function similar to the one proposed
by Royston et al. [83] shown in (4.1). Figure 4.4 showed that this allowed a larger set
of more efficient admissible designs to be found. However, the most efficient admissible
designs will be found through a full grid search over all plausible stagewise operating
characteristics, as used for 2-stage designs. The extra efficiency of these designs compared
to those found using sets of α-functions defined in (4.2) requires further research; however,
we feel the differences will be negligible if several values of r are used. Furthermore, a full
grid search is likely to be very time-consuming for designs with three or more stages and
may therefore be impractical.
In this chapter we have addressed the problem of how to find efficient two-arm multi-stage
trials with particular pairwise operating characteristics. Similar methods could be used
to find admissible multi-stage trials with more than two arms, however, as yet there is
no rapid calculation available for the expected sample size of such trials. Moreover, in a
multi-arm trial the probability of rejecting at least one true null-hypothesis, known as the
familywise error rate (FWER), is often of greater interest particularly if, say, various doses
of a drug are to be evaluated against a control [15] or the trial is confirmatory [19]. Methods
for finding optimal or admissible designs which control the FWER at a prespecified level
are therefore needed and will be investigated in a later chapter.
Chapter 5
Familywise error rate of multi-arm
multi-stage designs
5.1 Introduction
So far, the overall type I error rate for a single experimental arm compared to the control,
known as the pairwise type I error rate (PWER), has been calculated for the multi-arm
multi-stage designs described in Chapters 2 and 3 and by Royston et al. [83]. This measure
gives the probability of recommending a particular treatment at the end of the trial when
it is truly ineffective, regardless of other arms in the study. For trials with more than
one experimental arm, the probability of recommending at least one ineffective or harmful
treatment at the end of the study, known as the familywise error rate (FWER) [16], is
arguably a more important quantity than the PWER as it gives the type I error rate
for the trial as a whole. However, for the MAMS designs discussed here, a general and
accurate calculation of the FWER is not yet available. It is therefore important that such
a calculation is developed if such designs are to be used in confirmatory trials for instance,
where limiting the maximum FWER (strong control) is often mandatory [19,20].
This chapter first outlines a calculation for the FWER of a MAMS design which allows
early stopping of recruitment to an experimental arm for lack-of-benefit only. As will
be explained, different calculations for the maximum FWER are required depending on
whether I = D or I 6= D, as is the case for determining the maximum PWER (see
Section 3.2.5). The calculation is applied to multi-arm two-stage trials with time to
event outcomes and checked using simulation of individual patient data. In addition, the
influence that the underlying treatment effect on the intermediate outcome has on the
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FWER in I 6= D designs is investigated to illustrate the scenario in which it is maximised.
The effect that design parameters such as allocation ratio and number of stages have on
the FWER is discussed and corrections are made to the probs option in nstage to more
accurately calculate the probability of any number of arms passing each stage of the trial
under certain sets of hypotheses. Lastly, a new subroutine for calculating the FWER of a
MAMS design is described and integrated into the nstage family of Stata commands to
allow it to be used in practice.
5.2 Calculation of FWER
A result by Magirr et al. [46] states that the FWER of a multi-arm multi-stage study with
a single outcome (i.e. when I = D) which is normally distributed is maximised under
the global null hypothesis (HG), that is, when H0 is true for all treatment arms. Further
work has shown this result also applies to other types of outcome [52, 136]. Calculation
of the FWER under this set of underlying treatment effects is therefore of prime interest
when I = D if the FWER is to be controlled in the strong sense, that is, under any set of
treatment effects. When I 6= D, recall from Chapter 3 that the PWER is maximised when
an experimental arm is sufficiently effective on I that it always passes all intermediate
stages but H0 is true on D. In Section 5.2.3 we argue that the FWER will also be
maximised when this is true for all experimental arms in the study.
In both cases, a conservative estimate of the FWER can be easily calculated by assuming
the correlation between treatment effect estimates for different arms at each stage is zero:
for a study with K experimental arms each with maximum pairwise type I error rate αmax,
the FWER will be no higher than 1 − (1 − αmax)K [18]. So, for example, in a four-arm
study with αmax = 0.025, an estimate of the FWER is 0.073. However, the actual value
will be lower than this since treatment effect estimates for different arms will be correlated
due to the use of a common control arm. Using this conservative calculation to control
the FWER at a particular value is therefore not recommended as it will result in a trial
which is larger than necessary. Nonetheless, the resulting design will still be more efficient
than conducting separate two-arm trials for each experimental arm since only one control
arm will be required. However, more efficient designs are likely to be found by using an
accurate calculation of the FWER which accounts for the correlation structure.
Magirr et al. [46] give analytical expressions for computing the FWER of multi-arm multi-
stage studies with a single normally distributed outcome using multi-dimensional integra-
tion. However, Wason and Jaki [51] show that this calculation becomes impractically slow
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as the number of stages increases. For instance, they reported that it took over eight
hours to calculate the FWER, power and expected sample size for a 5-arm 4-stage trial,
whereas it took just under 6 minutes for a 5-arm 3-stage design. The authors therefore
proposed a faster, alternative calculation by simulating trial-level data, namely the z-test
statistics for each arm at each stage. However, this calculation is restricted to designs with
normally distributed outcomes and which plan to recruit the same number of participants
to the control arm in each stage [51]. In the MAMS designs of interest here, the latter
constraint is not likely to be met (e.g. see examples in Tables 3.2 and 3.3 of Chapter 3),
other types of outcome may be of interest and I and D may differ.
5.2.1 Simulation of trial-level data
Below, the technique used by Wason and Jaki is generalised to designs where unequal
numbers of patients can be allocated to the control arm in each stage and where interim
analyses can be conducted on an intermediate outcome which differs to the definitive
outcome of the trial. The calculation is applicable to any type of outcome provided the
test statistic for the treatment effect is normally distributed (e.g. log hazard ratio). By
simulating the joint distribution of the z-test statistics, the familywise error rates under a
range of underlying treatment effects can be quickly estimated for designs where I = D or
I 6= D. Furthermore, this technique will be useful for estimating the expected sample sizes
of MAMS designs with more than two arms which will be explored in the next chapter.
We first describe a procedure for simulating the joint distribution of the z-statistics for all
experimental arms at each stage under a general set of underlying treatment effects. For
a (K + 1)-arm J-stage trial let Zjk denote the z-statistic for the kth experimental arm
(k = 1, . . . ,K) on the outcome of interest at the end of stage j (j = 1, . . . , J). For example,
Zjk may be the z-test statistic for the log hazard ratio or the log-rank test statistic for a







where θjk is the true treatment effect for the kth experimental arm on the outcome of
interest in stage j, θ0j is the corresponding treatment effect under H0 and σjk is the
standard deviation of the observed treatment effects under θjk. Under the null hypothesis
for arm k, Zjk ∼ N(0, 1) since θjk = θ0j .
Let ρjj′ = Corr(Zjk, Zj′k) denote the correlation between the test statistics in stages j
and j′ for arm k. The calculation of ρjj′ is given in [83] for time to event outcomes and
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in Appendix B for binary outcomes. A result by Dunnett [22] implies that the corre-
lation between the observed treatment effects in any two treatment arms in stage j is
Corr(Zjk, Zjk′) = A/(A + 1) where A is the number of patients allocated to each experi-
mental arm for each control patient.
To simulate the joint distribution of the z-test statistics, Zjk, standard normally dis-
tributed random variables xjk (j = 1, . . . , J) are first generated for k = 0, . . . ,K such that
the correlation between xjk and xj′k is ρjj′ . This can be achieved using the drawnorm













is then used to give simulated random variables with the required distribution and corre-
lation structure described above (proof shown in Appendix E).
This method for simulating Zjk differs to that used by Wason and Jaki [51]. In their pa-
per, the authors first generate standard normal random variables, xjk, with the required
between-arm, rather than between-stage, correlation and then go on to use an expression
similar to (5.1) to generate z-statistics which also have the appropriate between-stage
correlation. This approach only seems tractable if the intermediate and definitive out-
comes are identical otherwise the between-stage correlation structure becomes much more
complex and may be difficult to be induced using a simple expression such as (5.1).
5.2.2 FWER when I = D
Recall that for MAMS designs with a single outcome (I = D), Magirr et al. [46] state that
the FWER is maximised under the global null hypothesis, HG, that is, when θjk = θ
0
j for all
j and k. Note that under this set of parameters the final term in (5.1) vanishes. Simulating
the random variables Zjk under HG and calculating the proportion of replicates which,
for any k and without loss of generality, Zjk < zαj for all j therefore gives the maximum
FWER. In other words, the FWER is the proportion of all replicates for which at least
one ineffective experimental treatment arm passes all J stages. Wason and Jaki suggest
that 250,000 replicates provide a good estimate of the FWER in practice [51] and ensures
that the Monte Carlo standard error for the estimate is no higher than 0.001.
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5.2.3 FWER when I 6= D
In a MAMS design, a type I error is made by incorrectly rejecting the null hypothesis for
the definitive outcome only. Wrongly dismissing the null hypothesis on the intermediate
outcome would not result in a type I error for the trial as it is not the primary outcome.
In other words, if an arm is superior to control on I at the final analysis but not on D then
that arm should not be recommended. Therefore in designs where the I and D outcomes
differ, the null hypothesis is true for experimental arm k if it is true for the definitive
outcome only (i.e. θJk = θ
0
J), regardless of the true treatment effect on I.
In I 6= D designs the FWER will again be maximised under the global null hypothesis,
that is, when H0 is true for all experimental arms on the definitive outcome. However, the
set of treatment effects on I which will produce this maximum value need to be found.
Recall from Chapter 3 that the PWER is maximised under H0 when an arm is sufficiently
effective on I that it always passes all interim analyses. The FWER will also be maximised
when this is true for all experimental arms. To see this, consider the following two sets of
parameters configurations:
(1) θjk = θ
0
j for all j and k (denote by HG)
(2) θjk = −∞ for all j < J and θJk = θ0J for all k (denote by HD).
Scenario (1) is equivalent to H0 being true on both the I and D outcomes for all experi-
mental arms. In scenario (2), all experimental arms are infinitely effective on I (assuming
θjk < 0 is beneficial) but H0 is true on D.
In scenario (2) all experimental arms will always pass the interim analyses, thus making
them redundant. The design will therefore effectively reduce to a multi-arm trial with a
single stage since all arms will reach the final analysis. As the treatment effect on I tends
towards the null value in scenario (1), experimental arms will inevitably be dropped from
the trial at interim analyses. Consequently, fewer arms will reach the final stage and hence
fewer type I errors can be made. As a result, the FWER must be maximised under HD.
This will be demonstrated in an example in Section 5.3.
The maximum FWER can therefore be calculated in a similar way to that for a 1-stage
trial by using a Dunnett probability [22] which is simpler and computationally quicker
than the simulation in Section 5.2.1. For a design with K experimental arms, final stage
significance level αJ and a normally distributed test statistic for D, the maximum FWER
is given by
FWER = ΦK(zαJ , . . . , zαJ ;C) (5.2)
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where ΦK is the K-dimensional multivariate normal distribution function and C is the
K×K between-arm correlation matrix with (j, k)th entry equal to A/(A+1) if j 6= k and
1 otherwise.
Calculating the FWER in scenario (1) (i.e. under HG) may still be of interest particularly
if I has high specificity for D, in which case a true null hypothesis for D is likely to
correspond to H0 also being true for I. In this scenario the FWER is not likely to be as
high as the maximum value calculated under HD and so controlling it under this worst-
case scenario may therefore be too conservative. Nonetheless, only limiting the FWER
under HG will technically control the FWER in the weak sense (i.e. under a single set
of parameters) and is likely be inadequate for a trial requiring strong FWER control
regardless of the specificity of I.
5.3 Example
We first calculate the FWER for 2-stage I = D and I 6= D designs with time to event
outcomes. For I 6= D, median survival times on the control arm of 2 and 4 years were
assumed for the intermediate and definitive outcomes respectively. The same definitive
outcome was also used in the I = D designs. The minimum hazard ratio targeted under
H1 was 0.75 for both outcomes. All designs used a significance level and power of 0.5 and
0.95 in the first stage respectively, and 0.025 and 0.9 in the final stage respectively. For
the I 6= D designs, the correlation between hazard ratios on I and D at a single time point
(see [83]) was assumed to be 0.6.
Table 5.1 shows the pairwise and familywise error rates calculated under HG for designs
with 2 and 5 experimental arms. These values are lower for the I 6= D designs since the
correlation between stages is smaller due to the use of different outcomes. However, the
maximum FWER of the I 6= D designs, calculated under HD, is somewhat higher than
the FWER of the analogous I = D design. This is arguably a disadvantage of using an I
outcome which differs to D since one then has to control the pairwise or familywise error
rate using the final stage significance level only, resulting in a larger maximum sample size.
However, this is likely to be outweighed by a lower expected sample size which is achieved
by using an I outcome observed earlier than D. Also shown in Table 5.1 are estimates of
the maximum FWER obtained by simulating individual patient data for 100,000 trials.
These estimates are slightly higher than the calculated values due to the stcox program
in Stata (which was used to analyse the simulated data) slightly underestimating hazard
ratios — see Figure 2.6.
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Design α αmax K
FWER Conservative estimate
HG HD HD (IPD) 1− (1− αmax)K
I = D 0.0231 0.0231
2 0.0424 0.0424 0.0441 0.0457
5 0.0858 0.0858 0.0898 0.1102
I 6= D 0.0201 0.0250 2 0.0378 0.0454 0.0477 0.0494
5 0.0758 0.0914 0.0950 0.1189
Table 5.1: Pairwise and familywise error rates of 3- and 6-arm 2-stage designs with time to
event outcomes. Key: K = number of experimental arms; HG = global null hypothesis on
I and D; α = pairwise type I error rate (PWER) under HG; HD = global null hypothesis
under which PWER and FWER are maximised; αmax = PWER under HD; FWER =
familywise error rate; IPD = individual patient data simulation (100,000 replicates).
In general, the size of the difference between the FWER under HG and HD for I 6= D
designs will depend upon the significance levels in the intermediate stages. For a fixed
final stage significance level (and thus a fixed maximum FWER), reducing α1, . . . , αJ−1
will increase this difference. To demonstrate this, Figure 5.1 shows the FWER when the
true treatment effect on I varies from the null effect (in this case a HR of 1) in one or
both experimental arms of a 3-arm 2-stage trial with α1 = 0.5 (left panel) and α1 = 0.2
(right panel). When θ1k < 1 in one or both experimental arms, the inflation in the FWER
is much sharper for the design using the smaller first stage significance level, i.e. when
the difference between the FWER under HG and HD is larger. This difference will also
be larger for designs using more stages (i.e. as the probability of dropping arms before
the final stage increases). Figure 5.1 shows that in both cases the maximum FWER
(which is the same for each design as they use the same final stage significance level and
allocation ratio) is achieved roughly when the effect of both experimental arms on I is
equal to the minimum effect targeted under H1. The figure also supports the argument
made in Section 5.2.3 that the FWER is maximised when all arms are highly effective on
I but ineffective on D, and that the FWER then decreases as the effects on I become less
beneficial.
Also shown in Table 5.1 is a conservative estimate of the maximum FWER which assumes
no correlation between treatment arms and is calculated using 1 − (1 − αmax)K . These
estimates are only slightly higher for K = 2 than the more accurate estimates obtained
using simulation or a Dunnett probability, however, they give a much larger overestimate
for designs with more arms. Using this measure to control the FWER at a particular level
is therefore not recommended as it will result in a trial that is larger than necessary.































Figure 5.1: FWER of 3-arm 2-stage designs with α1 = 0.5 (left) or α1 = 0.2 (right)
when the underlying HR on I (θI) varies in one or both experimental arms. Key: θ1k =
underlying effect on I in experimental arm k.
5.4 Design parameters affecting the FWER
5.4.1 Allocation ratio
The correlation, r, between pairs of z-statistics testing different treatment arms against
a common control arm is one factor which influences the FWER. The more correlated
treatment arms are, the lower the FWER will be if all other design parameters remain the
same. For instance, if r = 1 the FWER will be equal to the pairwise type I error rate, α,
since if one ineffective arm is recommended then so will all others. On the other hand, if
arms are uncorrelated (r = 0) the FWER will be 1− (1− α)K where K is the number of
experimental arms. The correlation, r, is given by A/(A + 1) where A is the number of
patients randomised to each experimental arm for each patient allocated to control [22].
Therefore as the allocation ratio to the control arm increases, so too does the FWER
since the correlation between arms is reduced. This might be counter-intuitive, however,
increasing the relative size of the control arm decreases the variance of its effect estimate
which then accounts for less of the total variance of each treatment effect estimate, thus
reducing correlation.
Although using a larger value of A will reduce the FWER, it will also increase the required
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sample size of the trial. For a fixed-sample (1-stage) multi-arm trial, the optimal allocation
ratio (i.e. the one that minimises the sample size for a fixed power) is approximately
A = 1/
√
K [22, 51]. The 6-arm STAMPEDE trial uses an allocation ratio close to this
optimal value (A = 0.5). However, Wason and Jaki [51] showed that for a MAMS trial
using stopping guidelines for efficacy and futility, the optimal allocation ratio (i.e. the one
that minimises the ESS for a given power and FWER) is closer to A = 1. This is because
arms can be dropped during the trial and so fewer than K experimental arms are likely
to be recruiting after the initial stage. Nonetheless, deviating from the optimal value in
favour of the control does not seem to greatly increase sample size requirements and could
even decrease the overall cost of the trial if the control arm is much cheaper than the
experimental arms [19]. It should also be noted that increasing the allocation to control
has been shown to discourage patients from joining a trial in some settings [19,137]. This
may be particularly problematic as a multi-stage trial progresses and arms are dropped
since the chance of receiving an experimental arm will become even smaller. The trial
may then be less attractive to patients, potentially decreasing the recruitment rate.
Since Wason and Jaki [51] considered MAMS designs which can stop for efficacy as well as
futility, we will perform a similar investigation to theirs in the next chapter to determine
optimal allocation ratios for MAMS designs which allow stopping for lack-of-benefit only.
5.4.2 Number of stages
In I 6= D designs the calculation of the maximum FWER in (5.2) is based purely on the
final stage significance level, allocation ratio and number of arms and so the number of
stages will not influence its value. However, whether two I = D designs which share the
same pairwise type I error rate, allocation ratio and number of arms will also have the
same FWER is less clear. To investigate this, the familywise error rates of all 2-, 3-, 4-
and 5-stage admissible I = D designs found in Section 4.5 were calculated for 2, 3, 4, 5
and 6 experimental arms using the simulation technique described in Section 5.2.1.
The results in Figure 5.2 show that the FWER is roughly equal for all designs with
the same pairwise type I error rate and number of experimental arms regardless of the
number of stages or sample size of the trial. The small observed variation is caused by
a mixture of simulation error (250,000 replicates were used for each FWER calculation)
and by permitting feasible designs to have pairwise type I error rates within ±0.0005 of
the desired value, α.
Also shown in Figure 5.2 are the FWERs for the corresponding 1-stage designs (horizontal
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dashed lines) calculated using a Dunnett probability [22] with pairwise type I error rate
equal to α + 0.0005 (i.e. the upper limit allowed for feasible designs). Although not
mathematically equivalent, these values are also approximately equal to the FWER of the
corresponding multi-stage designs. This suggests that to control the FWER in a multi-
stage design, one simply has to find the pairwise α that would be required for controlling
the FWER in the corresponding 1-stage design. Once the required α is determined, the
methods described in Chapter 4 can be used to find feasible multi-stage designs which
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Figure 5.2: FWER of all admissible 2-, 3-, 4- and 5-stage I = D designs found in Section 4.5
for trials with 2, 3, 4, 5 and 6 experimental arms. Dashed horizontal lines are the FWER
for the corresponding K-arm 1-stage designs, calculated using Dunnett’s method [22].
5.5 Correction to the probs option in nstage
The probs option in nstage reports the approximate probabilities of the number of exper-
imental arms reaching each stage of the trial under the global null and global alternative
hypotheses [84, 138]. These values inform users of the number of arms that are likely to
be recruiting in each stage of the trial and thus allow alterations to be made to the design
if these numbers are higher or lower than desired. For instance, if a large number of arms
is likely to reach the final stage of the trial under the global null hypothesis then either
additional interim analyses could be added or the stagewise significance levels lowered to
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improve the chance of eliminating these arms at an earlier stage.
These probabilities are currently calculated using binomial distributions as described by
Barthel [138]. However, as the author acknowledges, this calculation does not take into
account the correlation between arms at each analysis caused by the use of a common
control arm. As a result, Barthel demonstrated through simulation of individual patient
data (IPD) that the probabilities calculated using this method are inaccurate [138]. For
instance, in a particular example of a 4-arm 3-stage trial which is used below, the proba-
bility of no experimental arms reaching the final stage under the global null was 0.81 in a
simulation, whereas the approximation given by the probs option was 0.93.
Simulating the joint distribution of the z-statistics, as described in Section 5.2, takes
into account the correlation structure between arms and stages and therefore allows more
accurate estimates of the probabilities given by the probs option to be attained. Using
this method, the probability of k out of K experimental arms reaching stage j of the
trial is simply the proportion of replicates in which any k experimental arms pass stages
1, . . . , j − 1 of the trial.
To demonstrate the improved accuracy of the new calculation, consider the example given
by Barthel [138] of a 4-arm 3-stage design with the same intermediate and definitive time
to event outcomes. The significance levels at stages 1, 2 and 3 are 0.25, 0.1 and 0.025
respectively, the power is 0.95 for the intermediate stages and 0.9 for the final stage and the
minimum targeted hazard ratio under H1 is 0.752. In Table 5.2 the probabilities of k out of
3 experimental arms (k = 0, . . . , 3) reaching stages 2 and 3 of the trial were calculated using
binomial distributions (Barthel’s method), by simulating the z-test statistics for each arm
at each stage (trial-level data), and by simulating individual patient data. Calculations
were performed under the global null (HG0) and global alternative (HG1) hypotheses.
Table 5.2 shows that the probabilities calculated via simulation of Zjk using (5.1) are
much closer to the results of the IPD simulation than those obtained using binomial
distributions. In some cases, the binomial calculation gives very poor estimates. For
instance, the probability of one arm reaching the second stage under HG0 is estimated
to be 0.42 using the binomial approximation whereas it is estimated to be 0.25 through
simulation of trial- and patient-level data. To more accurately calculate the probabilities
given by the probs option, we have therefore implemented the methods described in
Section 5.2 into nstage using the subroutine described in the next section.
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Prob. of k experimental arms Prob. of k experimental arms
reaching stage 2 reaching stage 3
Under HG0 k = 0 k = 1 k = 2 k = 3 k = 0 k = 1 k = 2 k = 3
Binomial approx. 0.422 0.422 0.141 0.016 0.927 0.071 0.002 0
Simulating (5.1) 0.539 0.249 0.140 0.073 0.808 0.139 0.041 0.012
Simulating IPD 0.533 0.250 0.140 0.077 0.808 0.138 0.041 0.013
Under HG1 k = 0 k = 1 k = 2 k = 3 k = 0 k = 1 k = 2 k = 3
Binomial approx. 0 0.007 0.134 0.859 0.001 0.025 0.236 0.738
Simulating (5.1) 0.005 0.024 0.095 0.876 0.010 0.039 0.133 0.817
Simulating IPD 0.004 0.019 0.095 0.882 0.007 0.034 0.132 0.827
Table 5.2: Probability of k = 0, 1, 2 or 3 experimental arms reaching stages 2 and 3 of
a 3-stage I = D design, calculated under the global null (HG0) and global alternative
(HG1) hypotheses using simulation of trial-level and patient-level data and using binomial
distributions.
5.6 The nstagefwer subroutine
To enable the maximum FWER to be calculated in the design of a MAMS trial and to
more accurately estimate the probabilities given by the probs option, we have developed
the nstagefwer subroutine which simulates the joint distribution of the z-statistics for
each arm at each stage using the methods described in Section 5.2. Since these meth-
ods are applicable to any type of normally distributed test statistic, nstagefwer can be
incorporated into nstage, nstagesurv or nstagebin.
The options for nstagefwer are outlined below. The required input is passed to the
subroutine by the relevant nstage- program depending on the design parameters specified
by the user.
Required:
nstage(#) # = J , the number of stages in the trial.
arms(#) # = K + 1, the total number of arms (experimental + control) at
the start of the trial.
alpha(numlist) one-sided significance levels for each stage.
aratio(#) # = A, the allocation ratio (number of patients allocated to each
experimental arm per control arm patient).
corr(matrix) between-stage correlation matrix.
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muz1(numlist) expected z-statistic in each stage under the minimum targeted
treatment effect (used for calculating probs under HG1).
Optional:
reps(#) number of simulations (can be specified by the user in the main
program). Default # is 250,000.
seed(#) set the seed for the simulations (can be specified by the user in the
main program). Default # is Stata’s default seed number.
ineqd specify that I 6= D so that the correct estimate of the maximum
FWER is presented.
This subroutine has been incorporated into an updated version of nstage which now
outputs the FWER of a MAMS design with more than two arms by default. If I 6= D,
nstage will output both the pairwise and familywise error rates under HG and HD (see
Section 5.2.3). The subroutine runs relatively quickly (e.g. a few seconds even for a large
number of arms and stages), however, the nofwer option has been added to nstage to
circumvent the FWER calculation if desired.
The output produced by specifying the probs option in the previous version of nstage
in which the probabilities were calculated using binomial distributions is shown below for
the 4-arm 3-stage example used in Section 5.5.
Approx. prob. of k experimental arms reaching stage 2:
---------------------------------------------
k (#arms) 0 1 2 3
---------------------------------------------
Under H0 0.422 0.422 0.141 0.016
Under H1 0.000 0.007 0.134 0.859
---------------------------------------------
Approx. prob. of k experimental arms reaching stage 3:
---------------------------------------------
k (#arms) 0 1 2 3
---------------------------------------------
Under H0 0.927 0.071 0.002 0.000
Under H1 0.001 0.025 0.236 0.738
---------------------------------------------
The output from the updated version of nstage, in which the probabilities are more
accurately calculated using nstagefwer, is shown below for the same example. Instead
of showing the probabilities of k out of K experimental arms reaching each stage of the
trial, the new output shows the probabilities of k arms passing each stage of the trial.
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The two are synonymous in that the probability of k arms reaching stage j is the same
as the probability of k arms passing stage j − 1. However, the new output also gives the
probability of k arms passing the final stage of the trial, thus giving the distribution of
type I errors under HG0.
Probability of k experimental arms passing each stage under global H0
----------------------------------------
k(#arms) 0 1 2 3
----------------------------------------
Stage 1 0.539 0.249 0.140 0.073
Stage 2 0.808 0.139 0.041 0.012
Stage 3 0.943 0.047 0.008 0.001
----------------------------------------
Probability of k experimental arms passing each stage under global H1
----------------------------------------
k(#arms) 0 1 2 3
----------------------------------------
Stage 1 0.005 0.024 0.095 0.876
Stage 2 0.010 0.039 0.133 0.817
Stage 3 0.026 0.073 0.188 0.713
----------------------------------------
5.7 Discussion
The methods presented in this chapter address the need to accurately calculate the fam-
ilywise error rate of the multi-arm multi-stage design originally described by Royston et
al. [77, 83] and its extensions presented in Chapters 2 and 3. The calculation, which is a
generalisation of the simulation described by Wason and Jaki for another form of MAMS
design [51], simulates the joint distribution of the z-test statistics at each stage for each
arm. It is applicable to any normally distributed test statistic and thus can be applied to
various outcomes such as time to event, continuous or binary.
When I 6= D, the FWER was shown to depend on the underlying treatment effects on the
intermediate outcome of the trial. In discussing the requirements for I, various authors
have stated that if the alternative hypothesis is true for I it need not also be true for
D [78, 80, 83]. However, in this chapter we have shown that arms which are effective
on I but not on D have a strong chance of reaching the final stage of the trial and are
therefore more likely to show a false positive result compared to arms which are ineffective
on both outcomes (HG). If the maximum FWER is not controlled or if it is only controlled
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under HG, it is therefore important (but not critical) to use an I outcome which has high
specificity for D to avoid inflating the FWER; that is, if an arm has no effect on D then
it should also have no effect on I. In various oncology trials which have used or are using
the MAMS design [79, 80], the definitive outcome of overall survival is incorporated into
the intermediate outcome of failure-free survival which may help to increase its specificity.
Nonetheless, if strong FWER control is required, it remains necessary to control the type
I error rate using the final stage significance level rather than by the type I error rate
under HG, in which case the specificity of I is irrelevant.
A subroutine was introduced for the nstage family of commands to calculate and output
the FWER of a MAMS design by default. Furthermore, the subroutine corrects the
previous calculation for the probability of the number of arms passing each stage of the
study as given by the probs option. Running the subroutine within nstage takes just a
few seconds which is in contrast to using an algebraic calculation which could potentially
take hours [51].
Interestingly, the FWER was shown in Figure 5.2 to be invariant to the number of stages
in I = D designs with the same pairwise type I error rate, allocation ratio and number
of experimental treatment arms. In other words, designs with two or more stages had the
same FWER as a 1-stage design with pairwise significance level equal to the pairwise type
I error rate in the multi-stage designs. This fact can be used to find designs which control
the FWER in the strong sense at a particular level, such as 0.025 or 0.05, which may be
required in a confirmatory trial [19,20]. To do this, the required pairwise type I error rate,
α, for a trial with K experimental arms can be found to satisfy the Dunnett probability
FWER = ΦK(zα, . . . , zα;C)
where C is the K × K between-arm correlation matrix in (5.2). If I 6= D, a similar
technique can be applied using (5.2) to determine the final stage significance level which
will control the maximum FWER at the pre-specified level. The methods described in
Chapter 4 can then be used to find feasible designs with the required pairwise, and thus
familywise, error rates. In the next chapter, optimal and admissible multi-arm multi-stage
designs which control the FWER are explored in a similar manner to the investigation of
admissible designs for two-arm trials in Chapter 4.
Other useful quantities for a MAMS design can be calculated by simulating the joint
distribution of the z-statistics as described in Section 5.2. For instance, the speed of the
simulation study used in Chapter 3 to assess bias can be greatly increased simply by
simulating trial-level rather than patient-level data. This could allow a more broad range
Chapter 5. Familywise error rate of multi-arm multi-stage designs 150
of designs and scenarios to be investigated in future. Another important measure for a
MAMS trial is its expected sample size (ESS) under various sets of treatment effects. As
shown in Chapter 4, there is a relatively simple formula which can be used to calculate ESS
for a two-arm multi-stage trial under any true treatment effect. For a MAMS trial, such
a formula would be much more complex and computationally intensive and so simulation
of Zjk can instead be used. This is explored in the next chapter.
Chapter 6
Optimal and admissible multi-arm
multi-stage trial designs
6.1 Introduction
In Chapter 4, methods were presented for finding two-arm multi-stage designs which con-
trol the overall type I error rate and power at prespecified levels, known as feasible designs.
The set of feasible designs which minimised a weighted sum of the expected sample size
(ESS) under the null hypothesis and the maximum sample size (MSS), known as admis-
sible designs [127], were then found. Null-optimal and minimax designs are special cases
of admissible design and have the lowest expected or maximum sample sizes of all feasible
designs respectively. However, they were shown to perform relatively poorly at treatment
effects for which they were not optimised. For instance, the null-optimal design had a
relatively high MSS and so performs poorly when evaluating highly effective arms, while
the converse is true for the minimax design. By contrast, admissible designs which min-
imised a more balanced sum of the expected and maximum sample sizes were shown to
perform well over a wider range of treatment effects. They are therefore more likely to
be a suitable choice of design in practice, particularly if there are no strong prior beliefs
about the effectiveness of the treatment under study.
The results of Chapter 4 showed that 3-stage admissible designs are often much more
efficient in terms of the expected sample size under H0 than 2-stage designs. The extra
gains in efficiency in designs with more than three stages were shown to be relatively
small and not likely to justify the increased administrative burden of additional interim
analyses. Whether these findings also apply to admissible designs evaluating more than
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one experimental arm is yet to be determined.
The null-optimal and minimax designs are examples of optimal design as they minimise the
ESS under a particular hypothesis. Wason and Jaki [51] explored optimal designs for the
class of multi-arm multi-stage trials described by Magirr et al. [46]. In their investigations,
the authors found designs which minimised the expected sample size under different sets
of treatment effects such as the global null hypothesis (all arms equally as effective as
control) and the set of treatment effects which maximised the expected sample size (“worst-
case scenario”). Although each design performed well under its corresponding optimality
criteria, they generally performed less well under other parameter configurations. The
authors therefore suggested balancing the optimality criterion of interest with some other
criterion, to find more appealing designs (i.e. admissible designs).
Wason and Jaki also investigated the optimal control:experimental allocation ratio of
these optimal designs and found that it tended to be closer to 1:1 than the optimal ratio
of
√
K : 1 for a fixed-sample design with K experimental arms [19, 22, 51]. This is due
to allowing arms to be dropped during a multi-stage trial, resulting in the possibility of
there being fewer than K experimental arms recruiting by the end of the study. However,
the choice of optimal allocation ratio is actually not so clear cut as it depends on the
underlying effects of the experimental arms which are often difficult to predict in advance
of the trial.
In this chapter, we consider optimal and admissible designs of MAMS trials with more
than one experimental arm and which allow stopping for lack-of-benefit only (for reasons
stated later, we ignore the efficacy stopping guideline which is common to all designs).
A calculation of the ESS using the simulation procedure in Section 5.2 is first described
allowing this measure to be determined for trials with more than one experimental arm and
under any set of underlying treatment effects. Optimal and admissible designs are then
defined and found for multi-arm analogues of the two-arm multi-stage trials with binary
outcomes explored in Chapter 4. Consideration is also given to optimal and admissible
MAMS designs using time to event outcomes. In all examples the FWER is controlled in
the strong sense using the methods outlined in Chapter 5. In addition, optimal allocation
ratios are investigated for these optimal and admissible designs when evaluating different
numbers of treatment arms and the reductions in ESS that they achieve over using a 1:1
ratio are reported. Finally, the nstagebinopt Stata program described in Chapter 4 for
finding two-arm multi-stage admissible designs is extended to multi-arm trials with an
option added for controlling the maximum FWER if desired.
Chapter 6. Optimal and admissible multi-arm multi-stage trial designs 153
6.2 Methods
6.2.1 Expected sample size
In Chapter 4 a simple calculation was given for the ESS of a two-arm multi-stage trial
under any treatment effect on the I outcome. For a multi-arm trial, such a calculation
will be much more complex and may be too computer intensive for practical use [51]. We
therefore use the procedure described in Section 5.2.1 for simulating the joint distribution
of the test statistics for each arm at each stage to calculate the ESS of a (K + 1)-arm
J-stage trial (J,K > 1) under any set of underlying treatment effects on the intermediate
outcome, θ = {θ1, . . . , θK}. Note that if I 6= D, the effect of each arm on the definitive
outcome can be ignored as only the effect on the I outcome influences the progress of each
arm through the trial and thus expected sample size.
By simulating the joint distribution of the z-statistics for each arm at each stage of the trial
(ignoring stopping guidelines), the probability of k out of K experimental arms passing
the jth stage, pjk, can be computed for all j < J and k under θ. This is analogous to
the procedure used by the probs option in the nstage program to estimate pjk under the
global null and alternative hypotheses (see Section 5.5). The expected sample size under
θ is then





pjk(1 + kA)(nj+1 − nj) (6.1)
where nj is the cumulative number of patients allocated to the control by the end of
stage j, N is the total sample size of the trial and the C : E : E : . . . allocation ratio is
1 : A : A : . . . .
Recall that the MAMS design may also use a stopping guideline for overwhelming efficacy
on the definitive outcome at each interim analysis (e.g. the Haybittle-Peto rule) [81]. As
discussed in Chapter 4 for two-arm trials, these guidelines will have a negligible impact
on ESS for very small treatment effects but may be more influential on the ESS for more
effective arms. When I = D, incorporating the stopping guideline into the ESS calculation
should be straightforward. However, when I 6= D the calculation becomes much more
complicated as the ESS is then a function of the treatment effects on both I and D and
also the correlation between these two effects.
When accounting for efficacy stopping in multi-arm trials, an added complication in cal-
culating the ESS is that there are several possible consequences of an arm crossing the
efficacy boundary. For instance, the trial may be stopped as a whole; recruitment may
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only be stopped to the effective arm while the rest of the trial continues as planned; or
recruitment to the control arm may be stopped with the effective arm becoming the new
control. One might have to calculate the ESS for each possible scenario since the action
that would be taken might not be planned in advance.
In Chapter 4 the stopping guidelines for efficacy were ignored primarily because the same
guideline would be used in any MAMS design and would therefore be unlikely to impact
which designs are deemed admissible. For the same reason and because of the added
complications described above, we will also ignore these guidelines in this chapter.
6.2.2 Definition of optimal designs
For MAMS trials with stopping guidelines for efficacy and lack-of-benefit, Wason and Jaki
investigated designs which minimised the ESS (i.e. were optimal) under the following
criteria [51]:
1. Global null hypothesis, HG: θk = θ
0 for all experimental arms k where θ0 is the
treatment effect under H0.
2. The least favourable configuration (LFC), so called because it gives the lowest prob-
ability of concluding that the only effective arm in the trial is superior to control.
Without loss of generality, under the LFC θ1 = θ
1 where θ1 is the minimum effect
targeted under the alternative hypothesis on I and all other treatment effects, θk
(k > 1), are equal to some beneficial yet uninteresting effect, θ∗.
3. The worst-case scenario (WCS) in which θk = θ
∗ for all k > 1 and θ1 is equal to
some effect δ which maximises the expected sample size.
Optimal designs which minimise the ESS in scenarios 1, 2 or 3 are referred to as HG-
optimal, LFC-optimal and δ-minimax designs respectively.
When early stopping for efficacy is not permitted (or ignored), the set of treatment effects
in scenarios 2 and 3 are no longer of interest. The LFC is relevant when early stopping
for efficacy is permitted because if one arm passes the efficacy boundary then recruitment
to the whole trial, rather than just that particular arm, may be terminated. However,
when efficacy stopping boundaries are not used, the progress of one arm through the
trial no longer has any bearing on any other arms in the study. The least favourable
configuration, i.e. that which gives the lowest power, will therefore be when the effect in
only one arm is equal to the minimum effect targeted under the alternative hypothesis,
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while the underlying effect in all other arms is equal to the null effect. Furthermore, when
stopping only for lack-of-benefit, the maximum expected sample size, i.e. that achieved
under the ‘worst-case scenario’, will simply be the maximum sample size of the trial. This
will occur when all arms are sufficiently effective on the intermediate outcome I that they
always pass all interim analyses.
Interestingly, Wason and Jaki [51] only consider situations in which at most one experi-
mental arm is effective. As the number of experimental arms increases, it is more likely
in practice that more than one arm will be effective. In our investigation we will there-
fore consider optimal designs which minimise the expected sample size when k out of K
experimental arms are effective on the I outcome (k = 0, . . . ,K). More formally, designs
which minimise E(N |θ) for
θ = {θi = θ1 for i = 1, . . . , k and θi = θ0 for i = k + 1, . . . ,K}
will be deemed optimal and referred to as Hk-optimal designs. Here, Hk is the hypothesis
that k out of K arms have the minimum effect under the alternative hypothesis (θ1)
and the remaining K − k arms have the null effect, θ0. So, for example, the H0-optimal
design will be analogous to the HG-optimal design in scenario 1 above, while the HK-
optimal design will be that which minimises the expected sample size when the effect in
all experimental arms is equal to that under the alternative hypothesis (i.e. all arms are
effective).
6.2.3 Criteria for admissible designs
Admissible two-arm multi-stage designs were defined in Chapter 4 to be those which
minimised the loss function qmax(N)+(1−q)E(N |H0) for some q ∈ [0, 1]. Unlike optimal
designs, admissible designs can take into account more than one optimality criteria and
can therefore have more desirable expected sample sizes over a wider range of treatment
effects. This was shown to be the case in Figure 4.3 on page 122 where the ESS of the
balanced design (admissible for q = 0.5) was relatively close to that of the null-optimal
and minimax designs for very small or large effects respectively, and tended to have the
lowest ESS for intermediate effects.
In a multi-stage trial with more than one experimental arm, the maximum sample size
is less likely to be required than in a two-arm study because at least one experimental
treatment is more likely to be dropped at an interim assessment [51]. This measure is
therefore less relevant in defining admissible designs than it is in a two-arm study. Instead,
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we will define the set of admissible designs to be those which minimise a loss function,
L(q), which is a weighted sum of the expected sample size under the global null hypothesis,
H0, and the hypothesis in which all arms are effective, HK , i.e.
L(q) = qE(N |HK) + (1− q)E(N |H0) (6.2)
for q ∈ [0, 1]. Note that the H0- and HK-optimal designs are special cases of admissible
design and minimise (6.2) for q = 0 or q = 1 respectively.
These optimality criteria were chosen as they are at the extremes of what is likely to be
seen in practice. Thus, designs which minimise a balanced sum of these two measures are
likely to perform well over a wide range of scenarios (similar to what was observed in the
two-arm case). Applying weights to expected sample sizes under other hypotheses could
be used in addition to those under H0 and HK . However, as discussed in Chapter 4, using
other optimality criteria when stopping for lack-of-benefit only is not likely to influence
the choice of admissible designs.
6.2.4 Controlling the familywise error rate
The familywise error rate (FWER) of the MAMS designs in the examples that follow will
be strongly controlled at conventional levels (e.g. 2.5% or 5%). As discussed in Chapter 5,
the maximum FWER of I 6= D designs can be calculated using a Dunnett probability
by treating the design as a multi-arm fixed-sample design with pairwise type I error rate
equal to the final stage significance level, αJ . Searching over a range of values of αJ and
choosing that which corresponds to the desired FWER will thus control it in the strong
sense. For instance, if the desired FWER is 0.05 then the final stage significance level for
a 3-arm study with 1:1 allocation ratio should be 0.0276.
In a MAMS design in which I = D, the FWER can be controlled by applying a simi-
lar procedure to the pairwise type I error rate, α. Once the required pairwise operating
characteristics are determined, the methods described in Chapter 4 can then be used to
find stagewise operating characteristics which result in feasible designs. Since no set of
stagewise operating characteristics will achieve the required overall operating character-
istics exactly, all designs with a FWER and pairwise power within a prespecified narrow
margin of the targeted values will be deemed feasible. For instance, if the target FWER
is 0.05± 0.0005 in a 3-arm trial then designs with pairwise α in the range 0.0274–0.0279
(and the desired ω) will be deemed feasible.
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6.2.5 Optimal allocation ratio
When allowing stopping for lack-of-benefit and efficacy, Wason et al. [51] showed that the
optimal C : E allocation ratio in scenarios 1–3 in Section 6.2.2 is between 1:1 and
√
K : 1
(i.e. that for a fixed-sample (K + 1)-arm design). Whether this is also the case when only
allowing stopping for lack-of-benefit is unclear. In particular, the optimal allocation ratio
is likely to depend on the number of arms which are effective on the I outcome. If all arms
are effective then they are all likely to reach the final stage and so the optimal allocation
ratio should be closer to
√
K : 1. However, if only one arm is effective then an allocation
ratio closer to 1:1 might be more efficient since only that arm is likely to be recruiting by
the end of the study.
In this chapter we investigate the optimal allocation ratios of optimal and admissible
MAMS designs under various scenarios and present the reductions in sample size that
they achieve over a conventional 1:1 allocation. Throughout, the allocation ratio will be
denoted by A — the number of patients allocated to each experimental arm for each
patient allocated to control.
6.3 Example when I = D
We first applied the methods outlined in Section 6.2 to find optimal and admissible MAMS
designs investigating a single binary outcome (I = D) and with FWER = 0.025, pairwise
power ω = 0.9 and minimum target risk difference under the alternative hypothesis of
θ1 = 0.2. Designs with other (FWER, ω) combinations of (0.025, 0.8) and (0.05, 0.8) were
also explored.
Feasible designs were found by first determining the pairwise type I error rate giving the
desired FWER as described in Section 6.2.4, and then using the method described in
Section 4.2 to find stagewise operating characteristics. In this search procedure the same
stagewise power, ωI , is used in all intermediate stages and the final stage power, ωD, is
chosen such that ωD ≤ ωI (see Principle 3 in Section 4.2). The α-function defined in (4.2)
in Section 4.2.2 was used to search over sets of stagewise significance levels using values
of r of 0, 0.25, 0.5 and 0.75. Designs with K = 2 and 5 experimental arms and J = 2, 3,
4 and 5 stages were investigated.
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6.3.1 Optimal designs
Expected sample sizes of all feasible designs were calculated using the simulation method
described in Section 6.2.1 under all sets of hypotheses H0, . . . ,HK . Feasible 3-arm multi-
stage designs which minimised the expected sample size under H0, H1 or H2 (referred to as
H0-, H1, and H2-optimal designs respectively) are presented in Table 6.1 for J = 2, . . . , 5
stages and 1:1 allocation ratio (A = 1).
Table 6.1 shows that the optimal designs tend to become more efficient under H0 (i.e.
E(N |H0) decreases) as the number of stages increases. However, the ESS under H2 (i.e.
when all arms are effective) tends to increase with the number of stages. If an H0-
optimal design is to be used, one therefore has to make a trade-off between the increased
efficiency under H0 and the number of stages and efficiency under H2. By contrast, the
H1-optimal designs have expected sample sizes under H0 and H2 which fall between those
of the H0- and H2-optimal designs while (by definition) having the lowest ESS under
H1. Furthermore, there appears to be little difference between the ESS under H1 of the
H1-optimal designs across stages.
The expected sample sizes of all optimal designs in Table 6.1 are plotted in Figure 6.1.
The figure shows that the H0-optimal designs are usually the least efficient than the other
optimal designs when any arms are effective while H2-optimal designs have a relatively
large ESS under H0. On the other hand, Figure 6.1 also shows that the H1-optimal designs
usually perform well under any of the three hypotheses with expected sample sizes close
to the optimal values under H0 and H2 in addition to the lowest ESS under H1. Similar
results were found for 3-arm designs with other operating characteristics (see Appendix F).
Optimal designs were also found for 6-arm multi-stage trials with the same design char-
acteristics as the 3-arm designs above. Figure 6.2 shows the expected sample sizes under
H0, . . . ,H5 of H0-, H2- and H5-optimal designs with (FWER, ω) = (0.025, 0.9) and similar
plots are shown in Appendix F for other operating characteristics. These plots show simi-
lar patterns to those in the 3-arm case in that the relative performance of the H0-optimal
designs worsens as the number of effective arms increases, while the converse is true for
designs which are optimal under H5 (i.e. when all arms are effective). The H0-optimal
designs tend to perform better than the H5-optimal over a wider range of treatment effects
when using fewer stages, but the advantage diminishes as the number of stages increases.
By contrast, the H2-optimal designs have expected sample sizes close to the optimum
values under H0 and H5 while also having the lowest expected sample sizes under most
other hypotheses. Based on these results and those for 3-arm designs, it therefore appears























































































































































































































































































































































































































































































































































































































Number of effective arms
Figure 6.1: Expected sample sizes of H0-, H1- and H2-optimal 3-arm multi-stage designs
shown in Table 6.1 when 0, 1 or 2 experimental arms are effective.
that the design which is optimal when about half of the number of experimental arms
are effective is a more suitable choice of design in practice than the H0- or HK-optimal
designs.
6.3.1.1 Optimal allocation ratio
The optimal designs presented thus far have used a 1:1 allocation ratio. However, as
discussed in Section 6.2.5 and as shown by Wason and Jaki [51] for other MAMS designs,
increasing the relative size of the control arm can result in more efficient designs. To
explore this further, the optimal allocation ratios, A∗, were found for the 3- and 6-arm
H0-, H1- and HK-optimal designs with FWER = 0.025 and ω = 0.9 investigated in the
previous section. Allocation ratios A between 0.3 and 1 were searched over in increments
on 0.01.
The optimal allocation ratios are shown in Table 6.2 along with the percentage differences
in E(N |H0), E(N |H1) and E(N |HK) relative to the corresponding optimal designs with
A = 1. The optimal allocation ratio is smaller (i.e. the relative size of the control arm is
bigger) for a larger number of experimental arms, as is also the case for multi-arm fixed-





















































































































































































































































































































































































































































































































































































































































Number of effective arms
FWER=0.025, w=0.9
Figure 6.2: Expected sample sizes of H0-, H2- and H5-optimal 6-arm multi-stage designs
with FWER = 0.025 and ω = 0.9 when 0, . . . , 5 experimental arms are effective.
sample designs. For designs optimised under HK , that is, when all experimental arms are
assumed to be effective, A∗ is roughly equal to the optimal value for the corresponding
multi-arm fixed sample design. This is because under such a hypothesis all arms are likely
to reach the planned end of the study and so it will roughly translate to a fixed-sample
trial. By contrast, Table 6.2 shows that designs which are optimised when assuming a
smaller number of arms are effective tend to have an optimal allocation ratio which is
closer to 1:1 since not all arms are likely to reach the final stage. There was no discernible
relationship between A∗ and the number of stages which Wason et al. [19] also noted for
the MAMS designs they investigated.
Table 6.2 shows that using the optimal allocation ratio rather than 1:1 reduces the ESS
under the hypothesis for which the design is optimised. This reduction is greater when
assessing a larger number of experimental arms. For instance, Table 6.2 shows that the
expected sample size under H0 of the H0-optimal 6-arm 3-stage design is nearly 11%
lower than the corresponding optimal design using A = 1, whereas it is just over 3% lower
for the 3-arm 3-stage design. Even greater gains in efficiency are made under HK for
the HK-optimal designs. For example, using A
∗ in the 6-arm 3-stage H5-optimal design
results in a 15% decrease in E(N |H5) over the corresponding design with 1:1 allocation,
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whereas the decrease is just under 5% in the 3-arm case. However, Table 6.2 also shows
that while using A∗ decreases the ESS under some hypotheses, it can increase expected
sample sizes under others. For instance, although E(N |H2) is reduced by almost 6% when
using A∗ in the 3-arm 2-stage H2-optimal design, E(N |H0) is increased by almost 24%
and E(N |H1) by 3%. This is unlikely to be an acceptable trade-off. Similar results can
be seen for other designs in Table 6.2. When searching for an optimal allocation ratio, we
therefore recommend investigating the effect it has on expected sample sizes under a range
of plausible hypotheses rather than just under that for which the design is optimised. An
alternative procedure is to search for the allocation ratio which consistently gives lower
expected sample sizes than 1:1 under a range of hypotheses rather than that which gives
the lowest ESS under a particular hypothesis.
A potential problem with most of the allocation ratios in Table 6.2 is that they are not
very practical. For instance, the optimal allocation ratio of the H1-optimal 3-arm 2-stage
design is A∗ = 0.69 which corresponds to a C : E allocation of 100:69. However, deviating
slightly from A∗ should not greatly reduce efficiency and so more practical allocation
ratios may be used. For instance, a more conventional 3:2 allocation ratio corresponds
to A = 0.67 and achieves similar gains in efficiency as A∗ over a 1:1 allocation in this
example.
6.3.2 Admissible designs
The results of the previous section show that designs which are optimised under a single,
extreme set of treatment effects can be a poor choice of design in practice as they often
perform poorly under other parameter configurations. This is especially true for H0- and
HK-optimal designs when all or none of the experimental arms are effective respectively.
This highlights the need to consider a range of alternative scenarios or more than one
optimality criteria when choosing a MAMS design to guard against the possibility of
overly large sample sizes if the assumed underlying treatment effects are not true.
Designs which are optimal when about half of the experimental arms are effective perform
consistently well over a wider range of treatment effects but this might not always be
the case, particularly under H0 or HK . Nor might such a design be practical in terms
of, say, roughly equally spaced analyses. As an alternative to optimal designs, one can
search for the set of admissible designs which minimise a weighted sum of E(N |H0) and
E(N |HK) using the loss function shown in (6.2). This is likely to be a more efficient
computational process than searching for optimal designs since only the expected sample
sizes for two hypotheses (H0 and HK) need to be calculated rather than for K. Below, we
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find admissible designs for 3- and 6-arm trials using the same operating characteristics as
in the previous section.
Table 6.3 shows the set of 3-arm admissible designs for 2, 3, 4 and 5 stages, FWER = 0.025
and ω = 0.9. A plot of the ESS of these designs under H0 and HK is shown in Figure 6.3
along with those for 6-arm admissible designs with the same operating characteristics.
Similar plots for other sets of operating characteristics are shown in Appendix G.
Firstly, Table 6.3 shows that the set of admissible designs can give a greater choice of
stagewise operating characteristics than searching for optimal designs alone and this is
shown to be more so the case for other examples in Appendix G. For instance, when
searching for 3-arm optimal designs using the methods in Section 6.2.2, only a maximum
of three designs will be found for a particular number of stages. By comparison, seven
3-stage admissible designs were found for (FWER, ω) = (0.05, 0.8) and eight 4-stage
admissible designs were found for (FWER, ω) = (0.025, 0.8).
The optimal designs are also often special cases of admissible design. For instance, the
designs which are admissible for q = 0 and q = 1 correspond to the H0- and HK-optimal
designs respectively. Table 6.3 shows that the H1-optimal design also tends to coincide
with an admissible design, usually for some mid-range value of q when it does not coincide
with a H0- or HK-optimal design. However, this might not always be the case.
Figure 6.3 shows that as the expected sample size of the admissible designs under H0
decreases, the expected sample size under HK increases. A similar relationship was also
observed between the maximum and expected (under H0) sample sizes of two-arm admis-
sible designs (e.g. see Figure 4.2 on page 120). One therefore has to make a trade-off
between these two measures by making a prior judgment about the relative probability
of each hypothesis being true or the relative importance of each ESS measure and use a
suitable value of q to reflect this.
This also applies to the number of stages one requires since choosing a larger number
of stages can reduce E(N |H0) but often at the expense of increasing E(N |HK). As in
the two-arm case, Figures 6.3, G.1 and G.2 show that E(N |H0) is considerably reduced
by using three stages over two and that it is decreased only slightly further by adding
a fourth stage, regardless of the number of arms being studied. The extra efficiency of
5-stage designs over four stages is negligible and unlikely to justify the use of an extra
interim analysis. If there are no strong preferences to minimise the ESS under either H0
or HK then we recommend using a more balanced admissible design (e.g. q = 0.5) with
three or possibly four stages to guard against overly large sample sizes in either case and
to reduce the administrative burden of the trial.
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Figure 6.3: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm
(right figure) multi-stage admissible designs with FWER = 0.025, ω = 0.9, θ1 = 0.2 and
1:1 allocation ratio. The vertical dashed lines represent the size of the corresponding fixed-
sample designs. Solid scatter points are also Hk-optimal designs for some k (0 < k < K).
In Figure 6.3 there are a few instances where two admissible designs with the same number
of stages are practically identical in terms of their expected sample sizes. Such designs
have very similar values of the loss function for all q ∈ [0, 1] and so in terms of efficiency
it would not matter which of the two designs are used in practice.
6.3.2.1 Optimal allocation ratio
The admissible designs in the previous section use a 1:1 allocation ratio, however, the
results in Table 6.2 showed that allocating a larger proportion of patients to control can
reduce expected sample sizes in a MAMS trial. We therefore found the set of 3-arm and
6-arm admissible designs with 2.5% FWER and 90% power using any allocation ratio
between 0.3 and 1 in increments on 0.01.
Figure 6.4 plots the expected sample sizes of the 3-arm and 6-arm admissible designs under
H0 and HK for a 1:1 allocation ratio (dashed lines) and the optimal allocation ratio (solid
lines). It shows that using the optimal allocation ratio reduces expected sample sizes much
more under HK than H0 with the reduction being much greater for a larger number of
treatment arms. However, as discussed previously, using an optimal allocation ratio can
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Figure 6.4: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm
(right figure) multi-stage admissible designs using a 1:1 allocation ratio (dashed lines) and
the optimal allocation ratio (solid lines).
also have adverse effects. For instance, the ESS under H0 is considerably higher for the
3-arm 2-stage design which is admissible for q = 1 (i.e. the H2-optimal design) and uses
the optimal allocation ratio compared to the corresponding design using a 1:1 allocation
ratio (note: these are the same H2-optimal designs investigated in Table 6.2 which showed
a 24% difference in ESS under H0). Nonetheless, by searching for admissible designs and
plotting their expected sample sizes, we can find (in this example) another 2-stage design
with similar ESS under H2 to the H2-optimal design but an ESS under H0 which is almost
100 patients lower. This highlights the need for finding the full set of admissible designs
for numerous stages and allocation ratios before choosing one to use in practice.
6.4 Example when I 6= D
In the investigations above we assumed that the D outcome was observed immediately
after randomisation (i.e. there was no follow-up period). In practice D may be observed
after a relatively long fixed follow-up period. Using D for I in this case may therefore
be inappropriate since the maximum sample size could have accrued by the time enough
outcome data have been collected for an interim analysis. However, an I outcome may
exist which is on the causal pathway to D and fulfills the requirements of an intermediate
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outcome in a MAMS trial described by various authors [78,80,83]. In this case, a MAMS
design can be used to assess D but with interim assessments made on the more quickly
ascertained I outcome.
We therefore repeated the investigation in the previous section using the same operat-
ing characteristics to look at the properties of admissible I 6= D designs. To strongly
control the FWER, the final stage significance level rather than the overall pairwise α
is adjusted (see Section 6.2.4). The I outcome is assumed to be observed immediately
after randomisation (no follow-up period) and the same target treatment effects are used
for both outcomes (θ0j = 0 and θ
1
j = 0.2 for all j). In addition, the positive predictive
value of I on D is assumed to be 0.9. The expected sample sizes under H0 and HK are
plotted in Figure 6.5 for 2-, 3-, 4- and 5-stage admissible designs with 3 and 6 arms, 1:1
allocation ratio (A = 1), FWER = 0.025 and ω = 0.9. Similar plots for other operating
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Figure 6.5: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm (right
figure) multi-stage admissible designs with I 6= D, FWER = 0.025, ω = 0.9, 1:1 allocation
ratio and minimum target treatment effects on I and D of θ1 = 0.2. The vertical dashed
lines represent the size of the corresponding fixed-sample designs.
Since the maximum FWER is controlled by the final stage significance level rather than
the pairwise type I error rate, αJ is smaller in I 6= D designs than when I = D. Thus,
the maximum sample sizes and expected sample sizes under HK of admissible I 6= D
designs tend to be larger than the corresponding designs in which D is used for interim
assessments. By comparing Figures 6.5 and 6.3, or those in Appendices G and H for designs
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with similar operating characteristics, one can see that the ESS curves are shifted more
to the right (i.e. are further from the fixed sample sizes) for I 6= D designs. Nonetheless,
if the follow-up period on D in lengthy then using it for interim assessments is not likely
to be practical for reasons stated above.
All figures show a similar general picture to those for I = D admissible designs in that
using three stages can considerably increase efficiency under H0 over 2-stage designs. Little
more in gained by using four or five stages, regardless of the number of arms being studied.
However, an exception to this pattern can be seen in the 6-arm case in Figure 6.5 where two
5-stage designs appear much more efficient than designs with fewer stages. We therefore
stress that all admissible designs should be found for various numbers of stages when
designing a MAMS trial to avoid missing those which are the most efficient. Moreover,
searching for a single design with a prespecified number of stages and which is admissible
for a particular value of q is not recommended as more efficient designs may be missed. For
instance, if we were to search only for the 5-stage minimax design in the 3-arm example
above then Figure 6.5 shows that we would have missed more desirable designs with lower
expected sample sizes under H0 and HK and which also use fewer stages.
6.5 Time to event outcomes
When assessing time to event outcomes, the timing of each interim analysis is determined
by the number of observed control arm events rather than sample size. A more appropriate
measure of efficiency in such trials is therefore the expected number of events under a
particular hypothesis. Using expected sample size is not recommended as it depends
on many underlying factors such as accrual and event rates which are not likely to be
accurately predicted in advance of the trial. Furthermore, the ESS will require a much
more complicated calculation because the number of patients recruited to each arm in a
particular stage is dependent on the number of arms which are recruiting in that stage.
Calculating the expected number of events for designs assessing time to event outcomes
is trickier than calculating the ESS for binary outcomes since the number of events ob-
served in each experimental arm will depend on its underlying event rate. For example,
if the underlying hazard ratio is less than one then fewer events will be observed in the
experimental arm than control. If the interest is only in hypotheses which assume that the
effect in each experimental arm is either that under the null hypothesis or the minimum
effect targeted under the alternative hypothesis (e.g. as it is when searching for optimal or
admissible designs) then a calculation of each of these quantities is available in the nstage
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package using the algorithms described by Royston et al. [83].
A further complication to the calculation is that under hypothesis Hm (0 < m < K),
the probabilities pjk of k experimental arms passing stage j have to be partitioned to
calculate the analogous probabilities for the effective and ineffective arms separately (since
ineffective and effective arms will result in different numbers of events occurring in each
stage). However, these two probabilities are not independent since all pairwise comparisons
use the same control arm. Calculation of the expected number of events therefore only
seems tractable under H0 or HK , that is, assuming all arms are ineffective or effective
respectively. This means that admissible designs which minimise (6.2) for some q can be
found but not those designs which are optimal under Hm for 0 < m < K. However, the
results above show that admissible designs are usually a superset of the set of optimal
designs and provide a greater choice of efficient designs to use in practice.
Additionally, when I 6= D, the number of control events required for the intermediate and
final analyses will not correspond to the same outcome. To ensure an average of a single
measure is taken, we only consider the number of I events occurring in the trial, eI . The
expected number of I events can be calculated using







(ej0 − e(j−1)0) + k(ej1 − e(j−1)1)
)
where ejk is the number of I events anticipated in the control (k = 0) or an experimental
arm (k = 1) by the end of stage j under θ = H0 or HK respectively. This measure will
be used in the next chapter where we apply the methods above to find admissible designs
for the STAMPEDE trial.
6.6 Extension of nstagebinopt
In Section 4.7, the nstagebinopt Stata program was introduced to allow users to find a set
of admissible designs for a trial with two arms, a prespecified number of stages and binary
intermediate and definitive outcomes. We have now extended this program to include the
methods above for finding admissible designs with more than one experimental arm, with
or without strong control of the FWER.
The following options have been added or amended in the program:
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Required
arms(#) # = K+ 1, the total number of arms in the study (including con-
trol arm). If more than two arms are specified, the program out-
puts designs which minimise the loss function defined in (6.2), oth-
erwise it outputs designs minimising qmax(N) + (1− q)E(N |H0).
aratio(numlist) list of allocation ratios A to search over. We recommend choosing
allocation ratios A ≤ 1.
Optional
fwer specify that the FWER is to be controlled in the strong sense at
the level specified in alpha().
Since sample sizes in a multi-arm trial can be decreased by allocating more patients to
control, a range of allocation ratios can now be searched over in nstagebinopt. Note that
this adds another parameter to the search procedure and so only a few reasonable values
of A should be specified to decrease computing time. For instance, if there are strong prior
notions that all K experimental arms are effective (and so a design which is admissible
for a larger value of q is likely to be chosen) then allocation ratios close to A = 1/
√
K are
likely to be the most efficient. Deviating slightly from the most optimal value does not
seem to greatly reduce efficiency and so the most practical allocation ratios (e.g. 2:1, 3:2
etc) in the vicinity of the optimal value could be selected.
Users also now have the option of controlling the maximum familywise error rate by
specifying the fwer option. Note that if I 6= D, there is currently not an option to control
the pairwise or familywise error rate under the global null hypothesis (i.e. under the null
for I and D in all arms) since this would not control these rates in the strong sense and
so is not recommended.
Examples of the syntax and output of nstagebinopt is shown below using similar design
parameters to the examples used in Section 4.7.4 on page 130 but with three arms and
maximum FWER of 2.5%. Allocation ratios A = 0.5 (2:1:1), 23 (3:2:2) and 1 (1:1:1) were
searched over.
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nstagebinopt, nstage(2) arms(3) alpha(0.025) power(0.9) theta0(0) theta1(0.2) ///
ctrlp(0.5) aratio(0.5 0.6667 1) fwer
--------------------------------------------------------------------------
q-range Stage Sig. Power Alloc. E(N|H0) E(N|H2) FWER
level ratio (SE)
--------------------------------------------------------------------------
[0.00,0.50] 1 0.27 0.95 0.67 258 430 0.0252
2 0.015 0.93 (0.0003)
--------------------------------------------------------------------------
[0.51,0.93] 1 0.24 0.97 0.67 279 409 0.0253
2 0.014 0.91 (0.0003)
--------------------------------------------------------------------------
[0.94,1.00] 1 0.23 0.99 0.67 338 405 0.0242
2 0.013 0.90 (0.0003)
--------------------------------------------------------------------------
Note: each design minimises the loss function (1-q)E(N|H0)+qE(N|H2) for values
of q specified in q-range. Hk is the hypothesis that k experimental
arms are effective.
nstagebinopt, nstage(2) arms(3) alpha(0.025) power(0.9) theta0(0 0) theta1(0.25 0.2) ///
ctrlp(0.5 0.5) ppv(0.9) aratio(0.5 0.6667 1) fwer
--------------------------------------------------------------------------
q-range Stage Sig. Power Alloc. E(N|H0) E(N|H2) FWER
level ratio
--------------------------------------------------------------------------
[0.00,0.12] 1 0.23 0.95 0.67 215 457 0.0250
2 .013145 0.94
--------------------------------------------------------------------------
[0.13,0.61] 1 0.21 0.97 0.67 219 428 0.0250
2 .013145 0.92
--------------------------------------------------------------------------
[0.62,1.00] 1 0.12 0.98 0.67 240 415 0.0250
2 .013145 0.91
--------------------------------------------------------------------------
Note: each design minimises the loss function (1-q)E(N|H0)+qE(N|H2) for values
of q specified in q-range. Hk is the hypothesis that k experimental
arms are effective.
nstagebinopt outputs the expected sample size measures used in the loss function, the
maximum type I error rate (or FWER if fwer is specified), stagewise operating charac-
teristics and allocation ratio of each admissible design. These design parameters can then
be entered into the nstagebin program to see each design in more detail, such as their
stagewise sample sizes and durations when a certain number of arms passes each stage.
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6.7 Discussion
In this chapter the methods for designing efficient two-arm multi-stage trials in Chapter 4
were extended to trials where more than one experimental arm is to be evaluated against
a control. Designs which minimise the expected sample size when k out of K experimental
arms are effective and the remaining K − k are ineffective, defined as Hk-optimal designs,
were introduced. These criteria seem more appropriate than those used by Wason and Jaki
[51] who only considered optimal designs for hypotheses in which at most one experimental
arm is effective. In practice, this is not likely to be the case.
In general, the H0-optimal design (i.e. the design that has the lowest ESS when no arms
are effective) tends to perform relatively poorly when all K arms are effective (i.e. under
HK). Likewise, the HK-optimal design can have a relatively large ESS under H0. This is
analogous to the null-optimal and minimax designs of Chapter 4 which have a relatively
large maximum and expected sample size under H0 respectively. On the other hand, the
optimal design which minimises the ESS when roughly half of the experimental arms are
effective performs consistently well over a wider range of hypotheses.
Admissible MAMS designs were also investigated and defined as the set of feasible designs
which minimised the weighted sum qE(N |HK) + (1 − q)E(N |H0) for some parameter
q ∈ [0, 1]. Maximum sample size was not used as a criteria as it is for two-arm trials since
it is less likely to be realised when evaluating more than one experimental arm [51]. H0-
and HK-optimal designs are always special cases of admissible designs, minimising the
loss function for q = 0 and q = 1 respectively. Other optimal designs are sometimes also
admissible but not always.
The parameter q could encompass the prior beliefs about the effectiveness of the arms
under study or the relative importance of the expected sample sizes under H0 and HK to
the investigators. Designs which minimise the loss function for a wider range of values of
q are likely to be more desirable as they are admissible for a wider range of prior beliefs or
scenarios. Hence it is important to find the admissible designs for all values of q so that
those which cover the broadest range of opinions can be found. In addition, admissible
designs for various numbers of stages should also be found since designs using more stages
will not always have greater efficiency (e.g. see the 6-arm designs in Figure 6.3 and 3-arm
designs in Figure 6.5).
The allocation ratios which minimised the ESS when none, one or all arms are effective
were investigated for H0-, H1- and HK-optimal designs. Under HK , all arms are likely
to reach the final stage of the study and so the optimal allocation ratio for HK-optimal
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designs is roughly equal to that for a fixed sample design (
√
K : 1). As the number of
effective arms decreases, the probability of all arms reaching the final stage is reduced and
so the optimal allocation tends be more balanced. The savings in ESS gained by using the
optimal allocation ratio over 1:1 are relatively small for designs with few arms but become
much greater when assessing more arms. However, there is a risk that the ESS under
hypotheses for which the design is not optimised will be higher than that for a 1:1 design.
Thus, we recommend thoroughly investigating the effect of using an unequal allocation
ratio under various scenarios before choosing one to use in practice.
Finally, the nstagebinopt Stata program was extended to implement the methods devel-
oped in this chapter for finding admissible MAMS designs with more than one experimental
arm. Development of a similar program for MAMS designs evaluating time to event out-
comes is in progress. In the next chapter, we apply the methodology in this chapter to find




In this chapter the methods developed throughout Chapters 3–6 are applied to real and
hypothetical MAMS trials. We first calculate the FWER of the 6-arm 4-stage STAMPEDE
trial and determine whether a more efficient design could have been used by comparing the
original design to sets of admissible designs with similar pairwise operating characteristics.
We then consider admissible designs of hypothetical 2- and 3-arm multi-stage phase 2/3
TB trials with binary outcomes and compare the savings in patient resources and gains in
power that they achieve over the conventional approach of evaluating each new regimen
in separate trials.
7.1 STAMPEDE
7.1.1 Rationale for the original design
The original design of the STAMPEDE trial involved the comparison of five experimental
treatments for prostate cancer against a control in a four-stage trial, the design of which
was shown in Table 1.1 on page 44. Below is a summary of the rationale for choosing each
of the design parameters, as given by Sydes et al. [80].
1. Number of stages: four stages (three interim analyses on failure-free survival (FFS)
and the final analysis on overall survival (OS)) were chosen for “pragmatic” reasons.
Firstly, the trial team did not want too many stages in the trial which would have
decreased the amount of data accumulating between analyses and thus increased
both bias and the administrative burden. Using four stages meant that at least
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100 control arm FFS events would occur between analyses. However, the reasons
for using no fewer than four stages is not mentioned by Sydes et al. [80] and in
particular it does not appear that four stages were chosen to increase efficiency
under a particular hypothesis.
2. Target differences: A target HR under H1 of 0.75 was chosen for the OS outcome be-
cause it was considered to translate into a worthwhile improvement in 5-year survival
of 10%. The same target effect was chosen for FFS despite it being reasonable to
observe larger effects on FFS than OS [132–134]. Nonetheless, this allows treatments
with more modest effects on FFS to be targeted with higher power.
3. Stagewise powers: A high level of power was required for each interim analysis
to reduce the risk of discarding treatments which are at least as effective as the
minimum effects targeted under H1. Therefore 95% power was chosen for stages 1–3
while 90% power was used for the final analysis to ensure the overall power for each
experimental arm was relatively high [83].
4. Stagewise significance levels: Large significance levels were used for the initial stages
to allow interim analyses to be conducted early in the trial and with high power.
Sydes et al. [80] acknowledge that this allows ineffective arms a high chance of
proceeding to the next stage of the study, however, by using high power, effective
arms are more importantly much less likely to be erroneously dropped. The authors
report that the overall pairwise type I error rate is 0.013. However, as we discussed
in Section 3.2.5, this is the type I error rate under the null hypothesis for I as well
as D. As the authors acknowledge, treatments often have a larger effect on FFS
than OS and so the actual type I error rate is likely to be higher than 0.013. The
maximum value that it can be is the final stage significance level, α4 = 0.025, as
pointed out in Section 3.2.5.
5. Event rates: Median survival times on FFS (2 years) and OS (4 years) were based
on published data.
6. Allocation ratio: Two patients were allocated to the control arm for one patient
allocated to each experimental arm to allow a more reliable estimate of the control
arm event rate to be made. Furthermore, using an allocation ratio which is biased
towards the control arm reduces the required sample size for a fixed power in a
multi-arm trial [78]. However, reducing A increases the FWER (see Section 5.4.1)
and also reduces the chance of a patient receiving an experimental treatment which
can negatively impact recruitment rates [137] particularly later in the trial if some
experimental arms have been dropped. Nevertheless, this has not seemed to be the
case in STAMPEDE which has seen recruitment rates increase during the trial.
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7.1.2 Familywise error rate of STAMPEDE
Several key characteristics were not explicitly calculated during the design of the STAM-
PEDE trial including the familywise error rate and expected number of events. It was
initially thought that the FWER would be relatively low because the pairwise type I error
rate was estimated to be 0.013. Indeed, under the global null hypothesis (i.e. assuming H0
is true for I and D in all arms) the FWER is estimated to be 0.053 using the simulation
procedure described in Chapter 5. However, the pairwise type I error rate could be as high
as 0.025 (the final stage significance level) depending on the effectiveness of each arm on
FFS and so the maximum FWER is estimated to be 0.103 using a Dunnett probability.
Although this means that the STAMPEDE trial cannot be said to control the FWER in
the strong sense, this may not have been the aim of the trial.
The expected number of I events in STAMPEDE is 880 under H0 (no arms effective on I)
and 1806 under H5 (all arms effective on I). In the section that follows, we will determine
whether designs with smaller expected numbers of events could have been used.
7.1.3 Admissible STAMPEDE designs
The stagewise operating characteristics of the STAMPEDE trial were unlikely to have
been chosen to minimise sample size requirements under a particular hypothesis since a
calculation of the expected number of events was unavailable at the time. More efficient
designs may therefore exist. To investigate this, we applied the methods outlined in
Chapter 6 to find sets of admissible 2-, 3-, 4- and 5-stage designs of STAMPEDE which
minimise the loss function qE(eI |H5) + (1 − q)E(eI |H0) for some q ∈ [0, 1], where eI is
the total number of I events observed during the trial. In particular, we were interested
in answering the following:
1. Could the trial have used fewer than four stages without reducing efficiency?
2. Could higher stagewise powers have been used in the intermediate stages to give
arms which are effective on FFS a stronger change of reaching the final analysis?
3. Could a different allocation ratio have resulted in a more efficient design?
To redesign the STAMPEDE trial, the same target hazard ratios, accrual rates and median
survival times as the original design were used. Multi-stage designs were deemed feasible
if they had similar pairwise operating characteristics to the original design, i.e. power
ω = 0.834 and maximum pairwise type I error rate αmax = 0.025. The allocation ratio
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of the original design was initially used (A = 0.5). To see whether changing the relative
size of the control arm would have increased efficiency, we also investigated designs using
allocation ratios between A = 0.3 and A = 0.7 in increments of 0.01 and A = 1. Designs
with 2, 3, 4, and 5 stages were considered with the latter three using values of r of 0, 1/3
and 2/3 in the stagewise α-functions for generating intermediate significance levels.
Admissible STAMPEDE designs with 2, 3, 4 or 5 stages and a 2:1 C:E allocation ratio
which minimise the loss function for q = 0 (H0-optimal), 0.5 and 1 (H5-optimal) are
presented in Table 7.1 along with the actual design of STAMPEDE. All designs presented
in the table have the same maximum FWER as the original STAMPEDE design (0.103).
The table shows that admissible designs exist which are more efficient in terms of E(eI)
under either H0 or H5 than the original STAMPEDE design at the expense of higher
E(eI) under the other hypothesis. Figure 7.1 plots the expected number of I events under
H0 and H5 of these admissible designs and shows that none of them are more efficient
than the original STAMPEDE design under both hypotheses. The 5-stage design which
is admissible for q ∈ [0.31, 0.51] seems more appealing than the original design as it has
approximately 100 fewer events expected under H5 in exchange for just 19 more events
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Figure 7.1: Expected number of I events under H0 and H5 of admissible multi-stage
STAMPEDE designs and the original design.
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Figure 7.1 also shows that the original STAMPEDE design roughly coincides with the
4-stage admissible design which minimises the loss function for q ∈ [0.18, 0.29]. The
actual STAMPEDE design is therefore focussed more on minimising the expected number
of events when all arms are ineffective (i.e. under H0), rather than when they are all
effective. This is perhaps appropriate since such a large trial will have ample resources
and so will not need to be focussed on limiting the maximum duration of the trial. Instead,
if all arms turn out to be ineffective then a larger proportion of resources can be saved
and directed to the evaluation of other treatments.
Using fewer than four stages in STAMPEDE would have substantially decreased the overall
workload required for the trial by reducing the number of interim analyses [85]. However,
Figure 7.1 shows that it would have also increased the expected numbers of events under
H0 and, for some designs, H5. For instance, in the closest 3-stage admissible design to
STAMPEDE, E(N |H0) is 43 events higher and E(N |H5) is 49 events higher. However,
if reducing E(eI |H5) was of greater importance then choosing a 3-stage design which is
admissible for a larger value of q may have justified the increase in E(N |H0).
Table 7.1 also shows that the pairwise and familywise type I error rates under HG tend to
be larger for designs which are admissible for similar values of q but which use fewer stages.
For instance, the FWER under HG of the 2-stage H5-optimal design is 0.092 whereas it
is 0.077 for the corresponding 3-stage design and 0.049 for the 4-stage design. This may
have been an issue in STAMPEDE if control of the FWER under HG (weak control) was
required.
Admissible designs of STAMPEDE using other allocation ratios were investigated but
there were no significant reductions in E(eI) under any hypothesis (data not shown).
Furthermore, using a 1:1 allocation ratio would have considerably reduced the efficiency
of the trial (data not shown) which is not surprising given the large number of arms in
the study.
7.2 Admissible multi-arm multi-stage TB trials
7.2.1 One experimental arm
In Table 3.3 on page 92, examples of several two-arm two-stage phase 2/3 (I 6= D) TB
trial designs were presented. Design parameters for the I outcome (culture status at 8
weeks) were based on the phase 2 trial by Dorman et al. [101] while those for the definitive,
phase 3 outcome (relapse or treatment failure) were based on those used in the REMox
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study [106]. The design characteristics of these two fixed-sample trials (which we refer to
as the ‘conventional’ approach) were shown in Table 3.1 on page 89. Conducting these two
trials separately, as done in practice, results in an overall power of just 68%, an expected
sample size under H0 of 348 and maximum sample size of 1442. By contrast, the seamless
phase 2/3 designs presented in Table 3.3 had over 80% power and a much lower maximum
sample size of 1312 but higher expected sample sizes under H0 (e.g. > 450 patients).
Adding an extra interim analysis to these two-stage designs reduced the expected sample
size but also reduced power.
In these examples the stagewise significance levels and powers were not chosen to give
overall type I error rates and powers corresponding to the conventional designs but were
instead chosen to explore the effect of the stagewise operating characteristics on bias. To
better determine the gains in efficiency that could be achieved by using a seamless two-arm
design over the conventional approach, we applied the methods of Chapter 4 to find sets
of admissible phase 2/3 TB trial designs for various numbers of stages. Designs had a
maximum type I error rate equal to that of the conventional approach of 2.5% but a more
conventional power of 80% which is considerably higher than the combined power of the
designs in Table 3.1.
A design was deemed to be admissible if it minimised the loss function
qmax(N) + (1− q)E(N |H0)
for some q ∈ [0, 1]. Admissible designs were found using the nstagebinopt program intro-
duced in Chapter 4. For practical reasons, only designs which recruited a minimum of 10%
of the maximum control arm sample size in each stage were considered. Design parame-
ters for the I (phase 2) and D (phase 3) outcomes were derived from the corresponding
fixed-sample designs in Table 3.1.
The stagewise operating characteristics and sample sizes of admissible two-arm phase 2/3
designs using 2, 3 or 4 stages are shown in Table 7.2. In Figure 7.2, the expected and
maximum sample sizes of these designs are plotted along with the analogous values for
the conventional approach.
Table 7.2 shows that all admissible designs have maximum sample sizes which are between
80 to 434 patients lower than when conducting phases 2 and 3 separately, despite having
12% more power. This is mainly due to phase 2 patients continuing follow-up and being
included in the analysis of the phase 3 outcome at the end of the seamless designs. Many
admissible designs even have a maximum sample size which is lower than that for the
standalone phase 3 trial (N = 1122). The two-stage designs have a larger ESS than the
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J r αj ωI ωD max(N) E(N |H0) q-range
2
- 0.05, 0.025 0.89 0.89 1270 434 [0.00,0.02]
- 0.06, 0.025 0.90 0.88 1228 435 [0.03,0.22]
- 0.19, 0.025 0.97 0.82 1032 491 [0.23,1.00]
3
1.00 0.35, 0.10, 0.025 0.92 0.91 1362 328 [0.00,0.03]
1.00 0.28, 0.08, 0.025 0.93 0.89 1270 331 [0.04,0.18]
1.00 0.27, 0.08, 0.025 0.95 0.86 1156 357 [0.19,0.19]
1.00 0.41, 0.11, 0.025 0.96 0.85 1122 365 [0.20,0.45]
0.25 0.28, 0.13, 0.025 0.98 0.82 1032 439 [0.46,0.52]
0.75 0.40, 0.13, 0.025 0.99 0.81 1008 466 [0.53,1.00]
4
0.75 0.37, 0.16, 0.07, 0.025 0.96 0.86 1156 332 [0.00,0.29]
1.00 0.50, 0.18, 0.07, 0.025 0.98 0.83 1062 372 [0.30,0.74]
0.50 0.17, 0.09, 0.05, 0.025 0.99 0.81 1008 533 [0.75,1.00]
Table 7.2: Admissible two-arm multi-stage phase 2/3 TB designs with 2.5% maximum
type I error rate and 80% power. Note: the conventional design has max(N) = 1442,
E(N |H0) = 348 and 68% power. Key: J = number of stages; r = power in α-function;
αj = stagewise significance levels; ωI = power in intermediate stages; ωD = power in final
stage; max(N) = maximum sample size; E(N |H0) = expected sample size under H0.
conventional approach since the latter uses a lower significance level for the phase 2 trial
than that used in the first stage of the two-stage designs. However, admissible designs exist
(e.g. 3- or 4-stage null-optimal designs) which have both lower expected and maximum
sample sizes than the conventional approach. Thus, there does not necessarily have to be
a sample size ‘penalty’ for using a multi-stage approach to design a seamless, phase 2/3
trial unlike when designing a trial which incorporates only a single phase of testing (for
instance, see the two-arm two-stage phase 2 TB trials in Table 3.2).
The conventional approach to trial design therefore appears to have only a few advantages
over a multi-stage design. Firstly, treatment effect estimates will be unbiased at the end
of each phase since a separate sample is used in each trial. However, the investigation in
Chapter 3 showed that bias on the definitive outcome in a multi-stage trial is negligible
when using an intermediate outcome for interim analyses. Secondly and perhaps more
importantly, conducting phase 2 and 3 trials separately allows a break between phases to
contemplate the findings of the phase 2 trial which may have an influence on the design of
a future phase 3 trial — something which is not possible in a seamless design. However,
this may not be a problem in a field such as TB as trial designs are quite well established


























Figure 7.2: Expected and maximum sample sizes of two-arm multi-stage admissible phase
2/3 TB designs and the conventional approach of conducting phases 2 and 3 in separate
trials.
and may also not be a problem in other areas discussed by Cuffe et al. [12].
7.2.2 Two experimental arms
Sometimes there may be more than one experimental regimen available for phase 2 testing
at any one time. This is currently the case in TB and is likely to remain so for the
next few years as several new drug classes become available for testing in combination
with each other and with the drugs that compose the current standard regimen [10].
Two conventional approaches to such a situation is to either test each new regimen in a
separate phase 2 trial with its own control arm or to test all new regimens in a single
multi-arm phase 2 trial against a common control. The latter would clearly require a
smaller sample size since it only requires one control arm, however, there may be barriers
to conducting such a trial due to commercial conflicts or difficulty in sourcing drugs from
different companies [78].
In this section we compare the efficiency of these two conventional approaches against
a MAMS approach which incorporates both phases of testing for all new experimental
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treatments into a single trial. We hypothesise that when more than one new regimen is to
be evaluated, the benefits of the MAMS design increases beyond that seen in the previous
section for a single treatment.
We assume that two new TB regimens are both ready for testing in conventional phase
2 trials with arms showing superiority on culture status at 8 weeks being continued to
phase 3. If both arms are effective, a single confirmatory 3-arm phase 3 trial is used with
strong control of the FWER achieved using a Bonferroni correction, as is commonly done
in practice. The phase 2 and phase 3 designs are again based on those by Dorman et
al. [101] and REMox [106] respectively, the designs of which are shown in Table 3.1 for
a single experimental arm. The following three approaches to treatment evaluation are
considered:
1. Each regimen is first tested in its own phase 2 trial. If the treatment effect of only
one regimen is significant at the 2.5% level then it is continued to a phase 3 trial,
also using a 2.5% significance level. If both treatments pass phase 2, a 3-arm phase 3
trial is conducted including both regimens and using a Bonferroni-adjusted pairwise
significance level of 1.25% to ensure the FWER is no higher than 2.5%, as done in
the actual 3-arm REMox study.
2. Both regimens are tested in a single 3-arm phase 2 trial with 2.5% pairwise signifi-
cance level. The same procedure to that in the first approach is then used for phase
3.
3. A 3-arm multi-stage approach is used, assessing the phase 2 outcome at the interme-
diate stages and the phase 3 outcome at the final stage should any arms reach that
point. A pairwise power of 80% is used and the FWER is controlled by applying a
more powerful Dunnett correction to the final stage significance level (αJ = 0.0135).
Approaches 1 and 2 are analogous to the current methods for TB treatment evaluation.
The required sample sizes for these two approaches are shown in Table 7.3 along with
their expected sample sizes under H0 and H2. Approach 2 is more efficient than approach
1 under both hypothesis as it requires only a single control arm in phase 2. In Figure 7.3,
the expected sample sizes of these two approaches are plotted along with those of the 2-,
3- and 4-stage phase 2/3 admissible designs which were found using nstagebinopt.
Figure 7.3 shows that all admissible designs are more efficient when both arms are effective
than the designs in approaches 1 and 2 despite again having more power. This is because
the admissible designs include patients recruited in the intermediate (phase 2) stages in
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2× 2-arm 3-arm
phase 2 trials phase 2 trial
Phase 2 sample size 640 480
2-arm phase 3 1122 1122
3-arm phase 3 2013 2013
Maximum sample size 2653 2493
E(N |H0) 696 535
E(N |H2) 2287 2116
Table 7.3: Required sample sizes of two conventional approaches for evaluating two new
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Figure 7.3: Expected and maximum sample sizes of 3-arm multi-stage admissible phase
2/3 TB designs and two conventional fixed-sample approaches for evaluating two new TB
regimens.
the analysis of the definitive outcome in the final stage and thus require smaller maximum
sample sizes. Most admissible designs are more efficient under H0 than approach 1, but
only the 3- and 4-stage H0-optimal designs outperform approach 2 when both arms are
ineffective. The gains in efficiency of the 4-stage design in particular arguably justify the
additional analyses that may be required over approach 2. It should be noted that the
admissible designs have 12% more power than the fixed sample approaches and so the
differences in expected sample sizes will be much greater than those observed here if all
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approaches had the same overall pairwise power.
Interestingly, there were only two 2-stage admissible designs while a much broader range
of 3-stage designs was available. The 3-stage designs also had considerably lower expected
sample sizes than the 2-stage designs particularly under H0. Only three 4-stage admissible
designs were available and these were slightly more efficient than the 3-stage designs.
These results show that the savings in sample size achieved by using a seamless MAMS
approach increase when testing more experimental arms compared to testing each new
treatment in separate phase 2 trials followed by a single phase 3 trials of all successful
treatments. The savings gained by a MAMS approach will be even greater if phase 3 trials
of each successful treatment were to be conducted separately. However, the differences
in sample size requirements between the MAMS and conventional approaches are roughly
the same as they are in the two-arm case when using a single phase 2 trial to test all new
regimens. By using a seamless MAMS design, not only will patient resources be saved
but so too will the duration of testing as the often lengthy gap between phases 2 and 3 is
removed.
Chapter 8
Summary and future research
Owing to the increasing pace of drug discovery there is often more than one new treatment
available for evaluating in clinical trials in many disease areas [14,139]. Traditional clinical
trial designs, whereby new treatments are assessed in separate fixed-sample trials, are still
routinely used in practice perhaps due to their simplicity. However, they are inadequate for
keeping pace with drug discovery [1]. A major reason is their inefficiency — by assessing
treatments in separate fixed-sample trials, multiple control arms are required and there
is little to no opportunity to stop trials prematurely if the experimental arm is showing
no or overwhelming benefit. Using such designs can therefore increase the cost of drug
development which limits the number of treatments that can be assessed at any one
time. Recent research in adaptive designs has led to a vast increase in the number of
novel approaches aimed at increasing the efficiency of treatment evaluation. However,
their uptake in practice has been slow for reasons such as conservatism, lack of expertise,
software and funding, and the often longer time needed for designing such trials [140].
A type of adaptive design which has been the focus of this thesis is the multi-arm multi-
stage (MAMS) design introduced by Royston et al. [77,83]. This design works by assessing
multiple new treatments against a common control in a single trial, stopping recruitment
to arms which perform poorly during the trial and allowing interim assessments to be
made on an outcome which is on the causal pathway to the primary outcome of the trial.
Thus far this approach has been used to design trials in prostate and ovarian cancer and
has significantly reduced the time taken to evaluate new therapies in this area compared
to traditional fixed-sample designs [78]. A major advantage of this design is its relative
simplicity as each stage of the trial can be considered as a conventional fixed-sample
multi-arm design with its own significance level and power. The design was initially only
developed for time to event outcomes such as failure-free (FFS) and overall survival (OS)
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and so extending it to other types of outcome measure such as binary, continuous and
categorical is required to fully exploit its potential and increase its uptake in other disease
areas.
The work in this thesis is aimed at partly resolving this issue by extending the design
to time to event outcomes which are observed during a limited follow-up period and
binary outcomes. Some important outstanding issues regarding the design of MAMS
trials were also addressed, such as providing a fast and accurate calculation of familywise
error rate and developing methods and software for finding efficient MAMS designs with
a prespecified type I error rate and power. Below, a more detailed summary of this thesis
is given and ideas for future research outlined.
8.1 Summary of thesis
Chapters 2 and 3 of this thesis focused on extending the MAMS design to outcomes other
than time to event endpoints such as FFS and OS. A major motivation for this work
stemmed from TB; an area in which many new and repurposed drugs are in clinical de-
velopment and may therefore benefit from novels trial designs to accelerate the evaluation
of these new treatments in future [10].
In phase 2 TB trials, an outcome which is increasingly being used is time to culture
conversion [100]. To use such an outcome in a MAMS trial, two extensions were made
to the design: 1) HRs > 1 were allowed to be targeted under H1 since events need to
be observed more quickly on an experimental arm for it to be superior to control, and
2) a limit was placed on the duration of patient follow-up (in the original MAMS design,
patients were assumed to be followed up until the definitive outcome had been observed
or the trial had ended). These extensions to the methodology were recently used to help
design the 5-arm 2-stage PanACEA phase 2 study (see Section 2.6).
An outcome which has traditionally been used in phase 2 TB trials and is still in use
today is a binary outcome of culture status at a single time point, often 8 weeks or 2
months [122]. In addition, phase 3 TB trials use a long-term binary outcome of relapse
or treatment failure 1–2 years after randomisation. To allow both phases of evaluation
to be incorporated into a single seamless trial we therefore extended the MAMS design
to binary I and D outcomes which are observed at fixed timepoints after randomisation.
We also assessed bias in these designs in a similar manner to the investigation for time to
event outcomes by Choodari-Oskooei et al. [114] and found that while bias was relatively
low in all designs which were explored, it was practically zero on D when using a different
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I outcome for interim comparisons. The work of Chapter 3 has been published in BMC
Medical Research Methodology [141].
An important point raised in Chapter 3 which has implications for existing and future
MAMS trials in which I 6= D (such as STAMPEDE) is that the maximum type I error
rate is higher than the value calculated by Royston et al. [83]. Their calculation of the type
I error rate, α, is made under the assumption that H0 is true for both I and D. However,
in Chapter 3 we showed that the actual α is higher than this value if the effect on I is
more beneficial than that under H0. Such a scenario is entirely plausible and has often
been shown to be the case with FFS and OS in cancer [132–134]. Moreover, the maximum
value that α can be is the final stage significance level of the trial, αJ . Therefore when
designing a MAMS trial in which I 6= D, one should set αJ equal to the desired type I
error rate in order to control it under any scenario (i.e. in the strong sense).
Another important addition we have made to the MAMS design is to provide an accurate
calculation of the familywise error rate (FWER). In many multi-arm trials, control of the
familywise rather than pairwise error rate is required, particularly if they are confirma-
tory [20]. In Chapter 5, a fast and accurate calculation of the FWER using simulation of
trial-level data was described and incorporated into the nstage family of commands which
now calculate FWER by default. The calculation was shown to be simplified somewhat by
treating the MAMS design as a multi-arm 1-stage trial with the same maximum pairwise
type I error rate and using a Dunnett probability [22] accounting for the between-arm
correlation. FWER control can then be achieved by finding stagewise operating char-
acteristics corresponding to the pairwise type I error rate which satisfies the Dunnett
probability.
Prior to the work in this thesis there was no method available for finding feasible MAMS
designs; that is, designs which have a prespecified overall type I error rate and power.
Instead, one simply had to take an educated guess when choosing the stagewise operating
characteristics (or use the values recommended by Royston et al. [83]) and then work
iteratively to ensure overall power was relatively high and that analyses were roughly
equally spaced for practical reasons. A major downside to this approach is that it is
unlikely that the resulting design would be the most efficient possible design to use. In
Chapter 4 we therefore introduced a search procedure for finding a large set of two-arm
multi-stage designs with the desired overall pairwise type I error rate and power. From
this, the set of admissible designs (i.e. those which minimised a weighted sum of the
expected sample size under H0 and maximum sample size) was then found. Such designs
are likely to be the most ideal choice in practice as each one is often the most efficient
under a particular range of treatment effects. The final choice of design will therefore
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depend on prior beliefs about the effectiveness of the treatment under study, the relative
importance of the maximum and expected sample sizes to the investigators or both.
In Chapter 6 we extended the methods in Chapter 4 to find optimal and admissible
multi-stage designs in which more than one experimental treatment is evaluated. In our
examples, we also combined the methods with those in Chapter 5 to control the FWER
in the strong sense. The results showed that designs which minimise the ESS assuming
either none or all of the experimental arms are effective tend not to perform well under the
opposing hypothesis. However, designs which are optimal when about half of the experi-
mental arms are effective are a safer choice in practice as they have a relatively low ESS
over a wider range of hypotheses. This is also true of admissible designs which minimise a
more balanced weighted sum of the expected sample sizes. We recommend searching for
admissible rather than optimal designs in practice since the former are computationally
easier to find and usually provide a wider range of designs to choose from.
In Chapters 4 and 6 we found that using three stages generally provides a decent trade-off
between efficiency and the number of interim analyses required, regardless of the number
of arms being studied or the required sample size. Additional gains in efficiency can be
achieved by using four stages but they are often quite small. The trial team would therefore
have to make a judgement about whether this warrants an extra interim analysis for which
a considerable amount of work is often required [85]. In Chapter 6 we also investigated
optimal allocation ratios of optimal and admissible designs and found them to be roughly
equal to those for the corresponding fixed-sample design when all arms are assumed to be
effective but tend to 1:1 as the number of effective arms decreases.
Finally in Chapter 7 the methods developed in Chapters 3–6 were applied to real and
hypothetical examples of MAMS trials. We first found sets of admissible designs for
the STAMPEDE trial and showed that there was no design which had a lower expected
number of events under both H0 (when all arms are ineffective) and H5 (when all arms
are effective). In particular, using a different allocation ratio would not have significantly
increased the efficiency of the trial and there were no designs which had similar properties
to STAMPEDE but used fewer stages which would have reduced the overall workload of
the trial by reducing the number of interim analyses.
We also found admissible designs for seamless phase 2/3 multi-stage TB trials evaluating
one or two new treatment regimens. These designs were shown to be considerably more
efficient than the conventional approach of separate phase 2 and 3 trials of each new
regimen and even possessed greater power. Incorporating phases 2 and 3 into a single trial
can achieve these large savings in time and patient resources for two reasons: 1) a seamless
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design eliminates the delay between the end of a successful phase 2 trial and the start of
phase 3 and 2) unlike the conventional approach, the seamless designs include phase 2
patients in the analysis of the phase 3 endpoint at the end of the trial, thus reducing the
maximum sample size.
8.2 Stata software
We have made several updates to the nstage program in Stata for facilitating the design
of MAMS trials with time to event outcomes. Firstly, the program has been extended to
allow HRs greater than 1 to be targeted under H1. Outcomes for which a higher event
rate indicates benefit (e.g. time to cure) can now be investigated in a MAMS design.
We have also developed a subroutine for calculating the FWER of a MAMS design and
incorporated it into the nstage command to make FWER calculation a default feature.
These updates along with several others are described in [142].
In Chapter 2 we introduced the nstagesurv command for designing MAMS trials with
time to event outcomes observed during a limited follow-up period. In Chapter 3, the
nstagebin command was developed for designing MAMS trials with binary intermediate
and definitive outcomes. Both programs function in a similar manner to the original
nstage program [84] in that users must specify the stagewise operating characteristics
they wish to use. The programs then output the pairwise operating characteristics, sample
sizes and stage end times of the design as well as the FWER using the same subroutine
as that recently implemented in nstage.
For reasons discussed in the previous section, manually choosing stagewise operating char-
acteristics is not an ideal way to design a MAMS trial. We therefore developed the
nstagebinopt program using the methods described in Chapters 4 and 6 for finding ad-
missible MAMS designs with binary outcomes. Using this program, the user simply has to
enter the pairwise or familywise error rate and power that they would like their design to
possess along with the number of arms, stages and other design parameters and the pro-
gram will output the stagewise operating characteristics of the admissible designs. Given
these stagewise parameters, the user can then use the nstagebin program to see each
admissible design in more detail and decide which to then use in practice. Development
of a similar program for time to event outcomes is in progress.
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8.3 Limitations of the MAMS design
The advantages of the MAMS design over more conventional approaches to treatment
evaluation have been discussed throughout this thesis, however, there are some potential
drawbacks that one should be aware of before using a MAMS design. Firstly, a MAMS
trial is likely to require more resources to run than a traditional single-stage study due to
the use of interim analyses. The effort needed to conduct an interim analysis is described
in detail by Sydes et al. [85]. Secondly, incorporating two phases of testing into a single
MAMS trial is also likely to require much more planning than the conventional approach
of separate phases since the phase 3 aspect of the study might have to be planned in
advance of any phase 2 results.
While a seamless MAMS design with different I and D outcomes can considerably reduce
sample size requirements over separate phase 2 and 3 trials, such savings are less likely
to be made in a MAMS trial incorporating only a single phase of testing. If only one
experimental arm is being tested then the maximum sample size of the trial will be at
least as high as the fixed-sample design with the same pairwise operating characteristics,
as demonstrated in Figure 4.2 on page 120. Furthermore, the increase in the maximum
sample size tends to be greater for designs using more stages. However, in all I = D
examples considered in Chapter 4 the maximum sample size of the two-stage minimax
design was the same as that of the fixed-sample trial. Therefore, the maximum sample
size of the trial does not necessarily have to be higher in a MAMS trial. In all I = D
examples considered in Chapter 4 the maximum sample size of the admissible designs
was between 0–25% higher than the fixed sample size. Similar increases in the maximum
sample size will be required for multi-stage trials of more than one experimental arm,
however, in a multi-arm trial the maximum sample size is less likely to be required due
to the increased chance of dropping an arm at an interim analysis. The larger maximum
sample sizes are therefore less likely to be of a issue.
A major concern in any study which allows stopping for lack-of-benefit is the possibility
of dropping an arm at an interim analysis when in fact a beneficial effect would have been
shown on the primary outcome at the end of the study [143]. This is more likely to occur in
studies using an intermediate outcome which differs to the definitve outcome particularly
if it has low sensitivity — that is, if the alternative hypothesis is true for D then it should
also be true for I. A similar scenario may also occur in a multi-stage trial of a time to
event outcome particularly if the first interim analyis occurs very early in the trial since
survival advantages may only become apparent later in follow-up. To guard against this
the first interim analysis should not occur too early in the trial.
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Finally, the MAMS design developed in Chapter 3 allows a non-inferiority outcome to
be used for interim assessments. However, the interpretation of a non-inferiority analysis
often differs to that of a superiority outcome and so an analysis which suggests dropping
an arm for futility may not convince investigators to do so. Consequently arms are less
likely to be dropped at an interim analysis compared to when using a superiority analysis
and so efficiency will be lost.
8.4 Future research
The methodology presented in Chapters 2 and 3 goes some way to making the MAMS de-
sign more applicable to other outcome measures and disease areas. However, further work
is needed to allow any type of outcome and, in particular, any combination of intermediate
and definitive outcomes (e.g. a binary intermediate and a continuous definitive outcome)
to be used in a MAMS trial. In addition, developing a single, unified Stata program for
designing a MAMS trial with any type of outcome will avoid the vast number of separate
nstage- programs that might otherwise be required.
In Chapters 3 and 7 we gave some examples of hypothetical MAMS designs in TB. In these
designs culture status at 8 weeks was used as the intermediate outcome for the definitive
outcome of long term relapse. Although Phillips et al. [100] have shown culture status
at a single time point to be a poor surrogate for relapse, this does not necessarily mean
that it will act as a poor intermediate outcome [78, 83]. High negative predictive value is
a more important attribute so that arms which are ineffective on I are also likely to be
ineffective on D. Moreover, I should have high sensitivity so that arms which are effective
on D are not erroneously dropped at interim analyses [83]. Further work based on that
by Barthel et al. [118], who assessed FFS as an intermediate outcome for OS, should aim
to determine the suitability of culture status at a single time point as an intermediate
outcome for relapse by redesigning and reanalysing past TB studies as MAMS trials. The
rates at which arms are correctly or incorrectly dropped at interim analyses should be
assessed along with determining whether culture status at an earlier time point than 8
weeks could potentially be used, thus increasing efficiency.
In the MAMS design developed in Chapter 2, we allowed event times to be assumed to
follow a Weibull distribution to more accurately calculate stage end times and sample
sizes and implemented the methodology in the nstagesurv program. This was shown
to be particularly useful in TB as it modelled time to culture conversion much more
accurately than an exponential distribution (see Figure 2.3 on page 66). The nstage
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program currently only allows an exponential distribution to be assumed, however, in
cancer it is quite plausible for FFS and OS times to be non-exponentially distributed (e.g.
see [112]). Allowing the use of more general survival distributions such as a Weibull or
piecewise exponential in this program will therefore more accurately estimate sample sizes
and durations and thus improve projected estimates of trial funding.
In Chapter 4 and 6 we alluded to the fact that a stopping guideline for overwhelming
efficacy is often applied to the definitive outcome of a MAMS trial. However, we ignored
this rule when searching for optimal and admissible designs as it is not thought to influence
the choice of these designs. Moreover, incorporating such a rule into the methodology
would have significantly increased its complexity by having to account for effects on both
I and D and also having to consider the various implications of an arm crossing the
efficacy boundary in MAMS trial. Further work should investigate the effect of this efficacy
boundary on expected sample size and optimal and admissible designs particularly when
at least one arm in the trial is effective, and produce guidance on how to proceed should
an arm cross this boundary.
A more general extension which could be made to the MAMS design is to allow more than
one intermediate outcome to be assessed at each interim analysis [144,145]. For example,
safety is often an important factor to assess in many trials and one may wish to evaluate it
alongside an intermediate efficacy outcome to allow arms to be dropped if they show harm
(unlike the efficacy outcome on which arms are dropped for lack-of-benefit). Alternatively,
it may also be useful to assess the D outcome at each interim analysis or incorporate it into
the analysis of I to increase power [73]. The impact of including an additional outcome
on the pairwise and familywise operating characteristics will need careful assessment and
software will need to be updated accordingly.
Much discussion has recently been made over adding arms to an ongoing MAMS design
such as the STAMPEDE trial which to date has added two new arms since it began [19,85].
The effect of adding arms on the FWER needs to be considered further as it is not
initially clear how much it will be inflated when arms are only added when existing arms
are dropped for lack-of-benefit. A related question is whether a sequentially rejective
procedure such as that described in [44] could be applied to the MAMS design. Such
a procedure relaxes future stopping rules if arms are dropped during the course of the
trial so that the power for the remaining comparisons is increased without inflating the
FWER. For instance, if a two-stage trial initially has two experimental arms and one arm
is dropped at the first analysis then one could use a significance level in the final analysis
which is higher than that proposed in the initial design.
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8.5 Conclusion
The MAMS design described by Royston et al. [77, 83] has demonstrated its ability to
accelerate the drug development process in oncology and could have a similar impact in
other disease areas. The work of this thesis has broadened the areas in which the MAMS
design could be used and has shown the savings in resources that could be made over
conventional approaches to treatment evaluation, particularly in TB. Methods have been
developed for facilitating the design of MAMS trials with focus on error rate control and
increasing efficiency. Stata software which is freely available in public repositories has
been created for implementing these procedures in practice, further supporting the uptake
of the MAMS design.
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Appendix A
Integration of the Weibull
distribution function
Below, the final term in equation (2.11) in Chapter 2 is calculated for the Weibull distribu-
tion by integrating the Taylor Series expansion of its distribution function F (t) = 1−e−λtγ .
First, note that the Taylor Series expansion of e−λtγ is
e−λt
γ









Fk(tj − t)dt =
∫ t∗
0

















































Calculation of the between-stage
correlation for binary outcomes




i whose (j, k)th
entries are the correlations between the treatment effects in stages j and k under H0 and
H1 respectively, are required. We begin with a general case where the binary outcomes
of interest in stages j and k are different. Suppose outcome X is the outcome of interest
in stage j and outcome Y is of interest in stage k with j < k and denote the observed
treatment effects by θˆj and θˆk respectively.







the standard deviation of θhi in its normal approximation is
σhi =
√
pihi (1− pihi )
AnCi
+
piCi (1− piCi )
nCi
Assuming success rates between treatment arms are independent, the correlation between
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Denote by XCm and Y
C
m the observed X and Y outcomes respectively for the mth patient
in the control arm (XCm, Y
C
m ∈ {0, 1}) where XCm is observed during or before stage j and
Y Cm is observed during or before stage k (j < k). The covariance between the control arm
event rates in stage j on the X outcome and stage k on the Y outcome is
Cov(pˆiCj , pˆi
C




































m )− E(XCl )E(Y Cm )
}
Assuming observations from different patients are independent implies
E(XCl Y
C
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}














(piC(j,k) − piCj piCk )
where piC(j,k) is the probability of a patient experiencing both the X and Y outcomes in
the control arm. A similar argument for the covariance of event rates between stages in






(pih(j,k) − pihj pihk ).
It follows that
ρh(j,k) =
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The values piC(j,k) and pi
h
(j,k) may be estimated from prior knowledge. Alternatively, if
estimates of the positive predictive value in each arm are available, that is, the probability
of a patient having a Y event given that they have had an X event, then from the definition
of conditional probability
piC(j,k) = P (Y
C
m = 1|XCm = 1)piCj
and
pih(j,k) = P (Y
h
m = 1|Xhm = 1)pihj .
If the outcomes of interest in stages j and k are the same then equation (B.1) simplifies.




































since underlying treatment effects are assumed to be constant throughout the trial. Note





The entries, ρh(j,k), below the main diagonal of R
h
i can now be calculated using (B.1) for the
correlations between the effects on the intermediate and final outcomes and using (B.2)
for the correlations between the effects on intermediate outcome in different stages. Since
each matrix is symmetric we set ρh(j,k) = ρ
h
(k,j) and all diagonal entries, i.e. the correlation
between treatment effects in the same stage, are ρh(j,j) = 1.
Appendix C
Characteristics of other two-arm
multi-stage I = D admissible
designs
The following figures plot expected sample sizes under H0 against maximum sample sizes
of admissible designs with the same I and D binary outcomes and pairwise operating
characteristics (α, ω) = (0.025, 0.8) and (0.05, 0.8), analogous to those plots shown in
Figure 4.2 on page 120. Minimum target treatment effects under H1 of (a) 0.2 and (b) 0.1
are explored.
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2-stage 3-stage 4-stage 5-stage
Figure C.1: Expected sample sizes under H0 versus maximum sample sizes of admissible
2-, 3-, 4- and 5-stage designs for α = 0.025, ω = 0.8 and target treatment effects of (a)
θ1 = 0.2 (left) and (b) θ1 = 0.1 (right). The vertical dashed lines represent the sample
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Figure C.2: Expected sample sizes under H0 versus maximum sample sizes of admissible
2-, 3-, 4- and 5-stage designs for α = 0.05, ω = 0.8 and target treatment effects of (a)
θ1 = 0.2 (left) and (b) θ1 = 0.1 (right). The vertical dashed lines represent the sample
size, N , of the corresponding fixed-sample design: (a) N = 142 and (b) N = 606.
Appendix D
Characteristics of other two-arm
multi-stage I 6= D admissible
designs
The following figures plot expected sample sizes under H0 for I against maximum sample
sizes of admissible designs with different I and D binary outcomes and pairwise operating
characteristics (α, ω) = (0.025, 0.8) and (0.05, 0.8), analogous to those plots shown in
Figure 4.5 on page 127. Minimum target treatment effects under H1 of (a) 0.2 and (b)
0.25 on the I outcome are explored.
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Figure D.1: Expected sample sizes under H0 versus maximum sample sizes of admissible
2-, 3- and 4-stage designs with I 6= D, α = 0.025, ω = 0.8 and minimum target treatment
effects on I (θI) of (a) 0.2 (left) and (b) 0.25 (right). The vertical dashed lines represent
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Figure D.2: Expected sample sizes under H0 versus maximum sample sizes of admissible
2-, 3- and 4-stage designs with I 6= D, α = 0.05, ω = 0.8 and minimum target treatment
effects on I (θI) of (a) 0.2 (left) and (b) 0.25 (right). The vertical dashed lines represent
the sample size of the corresponding fixed-sample design (N = 142).
Appendix E
Distribution of Zjk
Below is a proof that the test statistics, Zjk (j = 1, . . . , J ; k = 1, . . . ,K), generated using







and between-stage and between-arm correlation structure



















since E(xjk) = 0 for all j = 1, . . . , J and k = 0, . . . ,K.
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since V (xjk) = 1 for all j = 1, . . . , J and k = 0, . . . ,K.
3. Between-stage correlation


























Characteristics of other optimal
I = D MAMS designs
The following figures plot expected sample sizes under H0, . . . ,HK of optimal MAMS
designs with the same I and D binary outcomes, analogous to Figures 6.1 on page 160
and 6.2 on page 162. Designs with K = 2 and K = 5 experimental arms and operating
characteristics (FWER, ω) = (0.025, 0.8) and (0.05, 0.8) are investigated. All designs have
a minimum target treatment effect under H1 of 0.2.
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Figure F.1: Expected sample sizes of H0-, H1- and H2-optimal 3-arm multi-stage designs
with ω = 0.8, FWER = 0.025 (top) and 0.05 (bottom) when 0, 1 or 2 experimental arms
are effective.

















































Number of effective arms
FWER=0.05, w=0.8
Figure F.2: Expected sample sizes of H0-, H2- and H5-optimal 6-arm multi-stage designs
with ω = 0.8, FWER = 0.025 (top) and 0.05 (bottom) when 0, . . . , 5 experimental arms
are effective.
Appendix G
Characteristics of other admissible
I = D MAMS designs
The following figures plot expected sample sizes under H0 and HK of admissible MAMS
designs with the same I and D binary outcomes, analogous to Figure 6.3 on page 166.
Designs with K = 2 and K = 5 experimental arms and operating characteristics (FWER,
ω) = (0.025, 0.8) and (0.05, 0.8) are investigated. All designs have a minimum target
treatment effect under H1 of 0.2.
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Figure G.1: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm
(right figure) multi-stage admissible designs with FWER = 0.025, ω = 0.8, θ1 = 0.2 and
1:1 allocation ratio. The vertical dashed lines represent the size of the corresponding fixed-
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Figure G.2: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm
(right figure) multi-stage admissible designs with FWER = 0.05, ω = 0.8, θ1 = 0.2 and
1:1 allocation ratio. The vertical dashed lines represent the size of the corresponding fixed-
sample designs. Solid scatter points are also Hk-optimal designs for some k (0 < k < K).
Appendix H
Characteristics of other admissible
I 6= D MAMS designs
The following figures plot expected sample sizes under H0 and HK of admissible designs
with different I and D binary outcomes, analogous to those plots shown in Figure 6.5 on
page 168. Designs with K = 2 and K = 5 experimental arms and operating characteristics
(FWER, ω) = (0.025, 0.8) and (0.05, 0.8) are investigated. All designs have a minimum
target treatment effect under H1 of 0.2 on the I and D outcomes.
224















320 340 360 380 400 420
















800 850 900 950
ESS | 5 effective arms
6-arm
FWER=0.025, w=0.8
2-stage 3-stage 4-stage 5-stage
Figure H.1: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm
(right figure) multi-stage admissible designs with I 6= D, FWER = 0.025, ω = 0.8, 1:1
allocation ratio and minimum target treatment effects on I and D of θ1 = 0.2. The vertical
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Figure H.2: Expected sample sizes under H0 and HK of 3-arm (left figure) and 6-arm
(right figure) multi-stage admissible designs with I 6= D, FWER = 0.05, ω = 0.8, 1:1
allocation ratio and minimum target treatment effects on I and D of θ1 = 0.2. The
vertical dashed lines represent the size of the corresponding fixed-sample designs.
